CA2700573A1 - Cancer stem cell antigen vaccines and methods - Google Patents
Cancer stem cell antigen vaccines and methods Download PDFInfo
- Publication number
- CA2700573A1 CA2700573A1 CA2700573A CA2700573A CA2700573A1 CA 2700573 A1 CA2700573 A1 CA 2700573A1 CA 2700573 A CA2700573 A CA 2700573A CA 2700573 A CA2700573 A CA 2700573A CA 2700573 A1 CA2700573 A1 CA 2700573A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cancer stem
- stem cell
- cancer
- neural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 288
- 201000011510 cancer Diseases 0.000 title claims abstract description 186
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 152
- 102000036639 antigens Human genes 0.000 title claims abstract description 114
- 108091007433 antigens Proteins 0.000 title claims abstract description 114
- 239000000427 antigen Substances 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 75
- 229960005486 vaccine Drugs 0.000 title description 20
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 80
- 102100040120 Prominin-1 Human genes 0.000 claims description 79
- 230000001537 neural effect Effects 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 102000008730 Nestin Human genes 0.000 claims description 24
- 108010088225 Nestin Proteins 0.000 claims description 24
- 210000005055 nestin Anatomy 0.000 claims description 24
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 claims description 22
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 claims description 22
- -1 BCL-XL Proteins 0.000 claims description 20
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 20
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 20
- 108010002687 Survivin Proteins 0.000 claims description 20
- 102100032912 CD44 antigen Human genes 0.000 claims description 17
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 17
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 claims description 17
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 claims description 17
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 16
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 16
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 16
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 16
- 241000237858 Gastropoda Species 0.000 claims description 15
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 15
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims description 15
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 15
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 15
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 15
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims description 15
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 14
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 14
- 238000009566 cancer vaccine Methods 0.000 claims description 14
- 229940022399 cancer vaccine Drugs 0.000 claims description 14
- 206010018338 Glioma Diseases 0.000 claims description 13
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims description 12
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims description 12
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims description 12
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 claims description 12
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 210000005087 mononuclear cell Anatomy 0.000 claims description 11
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 10
- 102000012850 Patched-1 Receptor Human genes 0.000 claims description 10
- 102100021762 Phosphoserine phosphatase Human genes 0.000 claims description 10
- 102100034026 RNA-binding protein Musashi homolog 1 Human genes 0.000 claims description 10
- 101710129077 RNA-binding protein Musashi homolog 1 Proteins 0.000 claims description 10
- 108010076573 phosphoserine phosphatase Proteins 0.000 claims description 10
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 claims description 9
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 claims description 9
- 229940030156 cell vaccine Drugs 0.000 claims description 9
- 101150069931 Abcg2 gene Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 108091007065 BIRCs Proteins 0.000 claims description 7
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 claims description 7
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 7
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 101150025362 Msi1 gene Proteins 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 230000008774 maternal effect Effects 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 102000005445 Neuronal Apoptosis-Inhibitory Protein Human genes 0.000 claims 3
- 230000028993 immune response Effects 0.000 abstract description 8
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 201
- 230000014509 gene expression Effects 0.000 description 39
- 241000700159 Rattus Species 0.000 description 38
- 150000001413 amino acids Chemical group 0.000 description 33
- 210000004881 tumor cell Anatomy 0.000 description 32
- 239000002356 single layer Substances 0.000 description 26
- 239000002609 medium Substances 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 23
- 210000001178 neural stem cell Anatomy 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 208000005017 glioblastoma Diseases 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 19
- 239000012091 fetal bovine serum Substances 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 190000008236 carboplatin Chemical compound 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 229960004562 carboplatin Drugs 0.000 description 11
- 208000002409 gliosarcoma Diseases 0.000 description 11
- 210000004248 oligodendroglia Anatomy 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 8
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 8
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 229960004964 temozolomide Drugs 0.000 description 8
- 206010014967 Ependymoma Diseases 0.000 description 7
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 7
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 7
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 6
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 108010081750 Reticulin Proteins 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000005022 packaging material Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 201000010133 Oligodendroglioma Diseases 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000158 apoptosis inhibitor Substances 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 208000029824 high grade glioma Diseases 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 201000011614 malignant glioma Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 102000040104 IAP family Human genes 0.000 description 3
- 108091069885 IAP family Proteins 0.000 description 3
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 3
- 108010041191 Sirtuin 1 Proteins 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002502 anti-myelin effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000448 cultured tumor cell Anatomy 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010014968 Ependymoma malignant Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000037564 High-grade astrocytoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000001662 Subependymal Glioma Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 2
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000014534 anaplastic ependymoma Diseases 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 201000004057 myxopapillary ependymoma Diseases 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000030819 subependymoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000746366 Rattus norvegicus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000960939 Rattus norvegicus Interleukin-4 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 101001074046 Xenopus laevis Zinc finger protein GLI1 Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 102000044752 human PROM1 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 201000000393 papillary ependymoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001128—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001163—Phosphatases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464428—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
Abstract
Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein.
Description
CANCER STEM CELL ANTIGEN VACCINES AND ME'I'HODS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit ofpriority to U.S. Provisiottal Patent Application Serial No. 60/826,955, filed on September 26, 2006; the entire contents of which are incorporated herein.by reference.
BACKGROUND
Over the past 30 years, a wealth of inforination has been generated concerning the in vivo and in vitro properties o'fbrain tumors and rodent modcls of brain tumor. The 9L
gliosarcoma, which was generated from inbred Fisher rats, is a widely used syngencie rat model for brain tumors. Originally produced by N-methyl-nitrosourea mutagenesis in Fisher rats, the tumor was cloned and designated 9L gliosarcoma because of its dual appearance of a glioblastoma and a sarcoma (Benda et al., J.
Neurosurg.,,34:310=323, 1971; Schmidek et al., J. Neurosurg., 34:335-340, 1971). The tumor could be proliferated under in vivo and in vitro conditions, making it a useful candidate as a glioma tumor model. The 9L gliosarcoma model clinically mimics rapidly growing and fatal intracerebral tuinors, making it the most widely used rat brain tumor model.
Stem cells have been defined as multipotent, self-renewing cells with the potential to differentiate into multiple cell types. Systems have been developed to identify the first neural stem cells in a defined media, whereby striatal embryonic progenitors could be harvestcd and grown in culture as undifferentiated neurospheres (clonally derived aggregates of cells derived from a single stem cell) under the influence of the mitogens EGF and bFGF. Many of these cells expressed nestin (an intermediate filament found in neuroepithelial stem cells), but not markers for the more.differentiated principal cell types of the CNS---ncuronal and glial cells. However, when grown on coverslips treated with poly-.L-ornithine, a substrate that allows cellular adhesion, manyofthe cells within the neurospheres differentiated into neurons and astrocytes with discontinued nestzn expression. The isolated striatal cells fulfilled the critical features expected from neural stem cells: an unlimited capacity for self-renewal and capacity to differentiate into the principal mature neural cells (Potten.et al., Development, 110: 1001-1020, 1990; Lee et al., Nat. Neurosci., 8:723-729, 2005; Maric et al., J. Neurosci., 23:240-251, 2003;
Weissman et al., Annu. Rev. Cell. Dev. Biol., 17:387-403, 2001;Seaberg et al., Trends.Neurosci., 26:125-131, 2003; Reya et al., Nature, 414:105-111, 200i). Under similar circumstances "cancer stem cells" appear to have the same characteristics of self-renewal and multipotentey.
Malignant brain tumors carry a poor prognosis even in the midst of surgical, radio-, and chemotherapy. With the poor prognosis of brain tumors amidst the available therapeutic treatments, there exists a significant need for more effective therapies to treat such tulnors.
SUMMARY
This invention is based, inter alia, on the discovery that vaccines based on cancer stem cell antigens are exceptionally useful for therapy of cancer.
Immunization of aniinals with dendritic cells pulsed with antigens from isolated cancer stem cells provided a significant survival benefit as compared to irnmunization with dendritic cells pulsed with differentiated tumor cells. Cancer stem cells were found to express major histocompatibility (MHC), indicating that they can display antigens. Further, proteins differentially expresscd in cancer stem cells as compared to differentiated tumor cells were identified. These proteins can be useful in providing antigenic compositions for treatment of cancers (e.g., neural cancers such as gliomas).
Accordingly, this application provides methods and compositions for cancer vaccines that target cancer stem cells. Cancer steln cells are important in tumor maintenance, proliferation, and resistance to chemotherapy and radiation therapy. Thus, the new vaccines that target cancer stem cells provide for greater therapeutic and/or prophylactic effect, particularly in cancers that are resistant to conventional treatments.
In one aspect, this application provides methods of treating cancer (e.g., neural cancer) in a patient that include administering to the patient a composition that includes antigen presenting cells (e.g., dendritic cells) that present cancer stem cell antigens (e.g., neural stem cell antigens).
In another aspect, this application provides methods of treating cancer (e.g., neural cancer) in a patient that include the steps of: obtaining a population of antigen presenting cells (e.g., dendritic cells); contacting the antigen presenting cells with a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) under conditions such that the antigen presenting cells present cancer stem cell antigens (e.g., neural cancer stem cell antigens); and administering to a patient a composition that includes the antigen presenting cells.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit ofpriority to U.S. Provisiottal Patent Application Serial No. 60/826,955, filed on September 26, 2006; the entire contents of which are incorporated herein.by reference.
BACKGROUND
Over the past 30 years, a wealth of inforination has been generated concerning the in vivo and in vitro properties o'fbrain tumors and rodent modcls of brain tumor. The 9L
gliosarcoma, which was generated from inbred Fisher rats, is a widely used syngencie rat model for brain tumors. Originally produced by N-methyl-nitrosourea mutagenesis in Fisher rats, the tumor was cloned and designated 9L gliosarcoma because of its dual appearance of a glioblastoma and a sarcoma (Benda et al., J.
Neurosurg.,,34:310=323, 1971; Schmidek et al., J. Neurosurg., 34:335-340, 1971). The tumor could be proliferated under in vivo and in vitro conditions, making it a useful candidate as a glioma tumor model. The 9L gliosarcoma model clinically mimics rapidly growing and fatal intracerebral tuinors, making it the most widely used rat brain tumor model.
Stem cells have been defined as multipotent, self-renewing cells with the potential to differentiate into multiple cell types. Systems have been developed to identify the first neural stem cells in a defined media, whereby striatal embryonic progenitors could be harvestcd and grown in culture as undifferentiated neurospheres (clonally derived aggregates of cells derived from a single stem cell) under the influence of the mitogens EGF and bFGF. Many of these cells expressed nestin (an intermediate filament found in neuroepithelial stem cells), but not markers for the more.differentiated principal cell types of the CNS---ncuronal and glial cells. However, when grown on coverslips treated with poly-.L-ornithine, a substrate that allows cellular adhesion, manyofthe cells within the neurospheres differentiated into neurons and astrocytes with discontinued nestzn expression. The isolated striatal cells fulfilled the critical features expected from neural stem cells: an unlimited capacity for self-renewal and capacity to differentiate into the principal mature neural cells (Potten.et al., Development, 110: 1001-1020, 1990; Lee et al., Nat. Neurosci., 8:723-729, 2005; Maric et al., J. Neurosci., 23:240-251, 2003;
Weissman et al., Annu. Rev. Cell. Dev. Biol., 17:387-403, 2001;Seaberg et al., Trends.Neurosci., 26:125-131, 2003; Reya et al., Nature, 414:105-111, 200i). Under similar circumstances "cancer stem cells" appear to have the same characteristics of self-renewal and multipotentey.
Malignant brain tumors carry a poor prognosis even in the midst of surgical, radio-, and chemotherapy. With the poor prognosis of brain tumors amidst the available therapeutic treatments, there exists a significant need for more effective therapies to treat such tulnors.
SUMMARY
This invention is based, inter alia, on the discovery that vaccines based on cancer stem cell antigens are exceptionally useful for therapy of cancer.
Immunization of aniinals with dendritic cells pulsed with antigens from isolated cancer stem cells provided a significant survival benefit as compared to irnmunization with dendritic cells pulsed with differentiated tumor cells. Cancer stem cells were found to express major histocompatibility (MHC), indicating that they can display antigens. Further, proteins differentially expresscd in cancer stem cells as compared to differentiated tumor cells were identified. These proteins can be useful in providing antigenic compositions for treatment of cancers (e.g., neural cancers such as gliomas).
Accordingly, this application provides methods and compositions for cancer vaccines that target cancer stem cells. Cancer steln cells are important in tumor maintenance, proliferation, and resistance to chemotherapy and radiation therapy. Thus, the new vaccines that target cancer stem cells provide for greater therapeutic and/or prophylactic effect, particularly in cancers that are resistant to conventional treatments.
In one aspect, this application provides methods of treating cancer (e.g., neural cancer) in a patient that include administering to the patient a composition that includes antigen presenting cells (e.g., dendritic cells) that present cancer stem cell antigens (e.g., neural stem cell antigens).
In another aspect, this application provides methods of treating cancer (e.g., neural cancer) in a patient that include the steps of: obtaining a population of antigen presenting cells (e.g., dendritic cells); contacting the antigen presenting cells with a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) under conditions such that the antigen presenting cells present cancer stem cell antigens (e.g., neural cancer stem cell antigens); and administering to a patient a composition that includes the antigen presenting cells.
In a further aspect, this application provides methods of inducing or stimulating an immune response in a patient, and methods of generating antibodies specific for cancer stem cell antigens, that include administering to the patient a composition that includes antigen prescnting cells (e.g., dendritic cells) that present cancer stem cell antigens (e.g., neural stem cell antigens).
In another aspect, this application provides methods of inducing or stimulating an immune response in a patient, and methods of generating antibodies specific for cancer stem cell antigens, by obtaining a population of antigen presenting cells (e.g., dendritic cells); contacting the dendritic cells with a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) under conditions such that the antigen presenting cells present cancer stem cell antigens (e.g., neural cancer stem cell antigens);
and administering to a patient a composition that includes the antigen presenting cells.
In a further aspect, this application providcs methods of preparing a cancer vaccine (e.g., a neural cancer vaccine), that include the steps of: obtaining a population of antigen presenting cells (e.g., dendritic cells), and contacting the antigen presenting cells with a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) under conditions such that the antigen presenting cells present cancer stem cell antigens (e.g., neural cancer stem cell antigens), thus preparing a cancer vaccine. In some embodiments, the methods further include administering the vaccine to a patient.
In another aspect, this application provides methods of preparing a cell vaccine for treating a cancer (e.g., a neural cancer) by obtaining mononuclear cells from a subject;
culturing the mononuclear cells in vitro under conditions in which mononuclear cells differentiate into antigen presenting cells; isolating cancer stem cells (e.g., neural cancer stem cells) from the same or different subject; preparing a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) from the cancer stem cells; and culturing the antigen presenting cells in the presence of the cancer stem cell antigen composition, thus preparing a cell vaccine. In some embodiments, the methods further include administering the vaccine to a patient.
In some embodiments of any of the above aspects, the antigen presenting cells are autologous to the subject or patient. In some embodiments, the antigen presenting cells are allogencic to the subject or patient.
In some embodiments of any of the above aspects, the cancer stem cell antigen composition is a lysate of cancer stem cells (e.g., neural stem cells). In other embodiments, the cancer stem cell antigen composition is an acid eluate of cancer stem cells (e.g., neural cancer stem cells).
In some embodiments of any of the above aspects, the neural cancer stem cell antigen composition is obtained from a brain tumor {e.g., a glioma). In some embodiments of any of the above aspects, the cancer stem cells express CD 133. In some embodiments of any of the above aspects, the cancer stem cell antigen composition includes one or more isolated peptides of.CD 133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi l), maternal embryonic leucine zipper kinase (MELK), GLI 1, PTCH1, Bmi- 1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP 1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin. In some embodiments, the peptides are synthetic.
In another aspect, this application provides kits for preparing a cell vaccine for inducing an immune response or treating a cancer (e.g., a brain cancer) that.include one or more isolated peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msil), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
In a further aspect, this application provides compositions (e.g., immunomodulatory compositions) that include antigen presenting cells (e.g., dendritic cclls) that present cancer stem cell antigens (e.g., neural cancer stem cell antigens). In some embodiments, the cancer stem cell antigens include peptides of 4ne or:more of CD 133, CD90, CD44, CXCR4, Nestin, Musashi- I(Ntsi I), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCHI, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
In.some embodimcnts, the compositions are produced by methods described herein.
In another aspect, this application provides for the use of compositions (e.g., immunomodulatory eompositions) that include antigen presenting cells (e.g., dendritic cells) that present cancer stem cell antigens (e.g., neural caricer stem cell antigens) in the preparation of a medicament for modulating an immune response or treating cancer in a subject. In some embodiments, the cancer stem cell antigens include peptides of one or more of CD 133, CD90, CD44, CXCR4, Nestin, Ivtusashi-l (Msil), maternal embryonic leucine zipper kinase (MELK), GLI 1, PTCHI, Bmi-1, phosphoscrine phosphatase (PSP), Snail, OCT4, BCRPI, MGMT, Bcl-2, FLIP,.BCL-XL, XIAP, cIAPI, cIAP2, NAIP, or survivin. In certain embodiments, the compositions are prnduced by methods described herein.
This application also provides immunogenic compositions that include, or encode cancer stcm cell antigens, and methods of using the compositions. For examplc, preparations of cancer stem cell antigens, for use as cancer vaccines (e.g., peptide vaccines, DNA vaccines) are provided.
"Beneficial results" may include, but are in no way limited to, lessening or alleviating the severity of a disease condition, inhibiting the disease condition from worsening, improving symptoms of a disease condition, and prolonging a patient's life or life cxpectancy.
"Cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, head and neck cancer, and brain cancer; including, but not limited to, gliomas, glioblastomas, glioblastoma multifonne (GBM), oligodendrogliomas, primitive neuroectodermal tumors, low, mid and high grade astrocytomas, ependymomas (e.g., myxopapillary ependymoma papillary ependyinoma, subependymoma, anaplastic ependymoma), oligodendrogliomas, medulloblastomas, meningiomas, pituitary adenomas, neuroblastomas, and craniopharyngiomas.
"Conditions" and "disease conditions," as used herein may include, but are in no way limited to any form of neoplastic cell growth and proliferation, whether malignant or benign, pre-cancerous and cancerous cells and tissues; in particular, gliomas, glioblastomas, glioblastoma multiforme (GBM), oligodendrogliomas, primitive neuroectodermal tumors, low, mid and high grade astrocytomas, ependymomas (e.g., myxopapillary ependymoma papillary ependymoma, subependymoma, anaplastic ependymoma), oligodendrogliomas, medulloblastomas, meningiomas, pituitary adenomas, neuroblastomas, and craniopharyngiomas.
"Mammal" as used herein refers to any member. of the class Mammalia, including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are ititended to be included within the scope of this term. The terms "patient" and "subject" are used herein interchangeably, and cover mammals, including humans.
"Pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnorrnal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
"Stem-like" or "stem," as used herein refers to cells that are able to self renew from a single clozne, differentiate into terminal cell types, and be serially transplantable in immunodeficient animals.
"Treatment" and "treating," as used herein refer to both therapeutic treatment and prophylactic or preventative rneasures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder even if the treatment is ultimately unsuccessful. Those in need of treatment include those already diagnosed as having the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. For example, intumor (e.g., canccr) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents or by the subject's own immune system.
"Tumor," as used herein refers to all neaplastic.cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
Unless otherwise defined, all technical and scientific terms used herein have the same rneaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference herein in their entirety. In case of conflict, the present specification, including definitions, will control.
In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
In another aspect, this application provides methods of inducing or stimulating an immune response in a patient, and methods of generating antibodies specific for cancer stem cell antigens, by obtaining a population of antigen presenting cells (e.g., dendritic cells); contacting the dendritic cells with a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) under conditions such that the antigen presenting cells present cancer stem cell antigens (e.g., neural cancer stem cell antigens);
and administering to a patient a composition that includes the antigen presenting cells.
In a further aspect, this application providcs methods of preparing a cancer vaccine (e.g., a neural cancer vaccine), that include the steps of: obtaining a population of antigen presenting cells (e.g., dendritic cells), and contacting the antigen presenting cells with a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) under conditions such that the antigen presenting cells present cancer stem cell antigens (e.g., neural cancer stem cell antigens), thus preparing a cancer vaccine. In some embodiments, the methods further include administering the vaccine to a patient.
In another aspect, this application provides methods of preparing a cell vaccine for treating a cancer (e.g., a neural cancer) by obtaining mononuclear cells from a subject;
culturing the mononuclear cells in vitro under conditions in which mononuclear cells differentiate into antigen presenting cells; isolating cancer stem cells (e.g., neural cancer stem cells) from the same or different subject; preparing a cancer stem cell antigen composition (e.g., a neural cancer stem cell antigen composition) from the cancer stem cells; and culturing the antigen presenting cells in the presence of the cancer stem cell antigen composition, thus preparing a cell vaccine. In some embodiments, the methods further include administering the vaccine to a patient.
In some embodiments of any of the above aspects, the antigen presenting cells are autologous to the subject or patient. In some embodiments, the antigen presenting cells are allogencic to the subject or patient.
In some embodiments of any of the above aspects, the cancer stem cell antigen composition is a lysate of cancer stem cells (e.g., neural stem cells). In other embodiments, the cancer stem cell antigen composition is an acid eluate of cancer stem cells (e.g., neural cancer stem cells).
In some embodiments of any of the above aspects, the neural cancer stem cell antigen composition is obtained from a brain tumor {e.g., a glioma). In some embodiments of any of the above aspects, the cancer stem cells express CD 133. In some embodiments of any of the above aspects, the cancer stem cell antigen composition includes one or more isolated peptides of.CD 133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi l), maternal embryonic leucine zipper kinase (MELK), GLI 1, PTCH1, Bmi- 1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP 1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin. In some embodiments, the peptides are synthetic.
In another aspect, this application provides kits for preparing a cell vaccine for inducing an immune response or treating a cancer (e.g., a brain cancer) that.include one or more isolated peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msil), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
In a further aspect, this application provides compositions (e.g., immunomodulatory compositions) that include antigen presenting cells (e.g., dendritic cclls) that present cancer stem cell antigens (e.g., neural cancer stem cell antigens). In some embodiments, the cancer stem cell antigens include peptides of 4ne or:more of CD 133, CD90, CD44, CXCR4, Nestin, Musashi- I(Ntsi I), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCHI, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
In.some embodimcnts, the compositions are produced by methods described herein.
In another aspect, this application provides for the use of compositions (e.g., immunomodulatory eompositions) that include antigen presenting cells (e.g., dendritic cells) that present cancer stem cell antigens (e.g., neural caricer stem cell antigens) in the preparation of a medicament for modulating an immune response or treating cancer in a subject. In some embodiments, the cancer stem cell antigens include peptides of one or more of CD 133, CD90, CD44, CXCR4, Nestin, Ivtusashi-l (Msil), maternal embryonic leucine zipper kinase (MELK), GLI 1, PTCHI, Bmi-1, phosphoscrine phosphatase (PSP), Snail, OCT4, BCRPI, MGMT, Bcl-2, FLIP,.BCL-XL, XIAP, cIAPI, cIAP2, NAIP, or survivin. In certain embodiments, the compositions are prnduced by methods described herein.
This application also provides immunogenic compositions that include, or encode cancer stcm cell antigens, and methods of using the compositions. For examplc, preparations of cancer stem cell antigens, for use as cancer vaccines (e.g., peptide vaccines, DNA vaccines) are provided.
"Beneficial results" may include, but are in no way limited to, lessening or alleviating the severity of a disease condition, inhibiting the disease condition from worsening, improving symptoms of a disease condition, and prolonging a patient's life or life cxpectancy.
"Cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, head and neck cancer, and brain cancer; including, but not limited to, gliomas, glioblastomas, glioblastoma multifonne (GBM), oligodendrogliomas, primitive neuroectodermal tumors, low, mid and high grade astrocytomas, ependymomas (e.g., myxopapillary ependymoma papillary ependyinoma, subependymoma, anaplastic ependymoma), oligodendrogliomas, medulloblastomas, meningiomas, pituitary adenomas, neuroblastomas, and craniopharyngiomas.
"Conditions" and "disease conditions," as used herein may include, but are in no way limited to any form of neoplastic cell growth and proliferation, whether malignant or benign, pre-cancerous and cancerous cells and tissues; in particular, gliomas, glioblastomas, glioblastoma multiforme (GBM), oligodendrogliomas, primitive neuroectodermal tumors, low, mid and high grade astrocytomas, ependymomas (e.g., myxopapillary ependymoma papillary ependymoma, subependymoma, anaplastic ependymoma), oligodendrogliomas, medulloblastomas, meningiomas, pituitary adenomas, neuroblastomas, and craniopharyngiomas.
"Mammal" as used herein refers to any member. of the class Mammalia, including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are ititended to be included within the scope of this term. The terms "patient" and "subject" are used herein interchangeably, and cover mammals, including humans.
"Pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnorrnal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
"Stem-like" or "stem," as used herein refers to cells that are able to self renew from a single clozne, differentiate into terminal cell types, and be serially transplantable in immunodeficient animals.
"Treatment" and "treating," as used herein refer to both therapeutic treatment and prophylactic or preventative rneasures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder even if the treatment is ultimately unsuccessful. Those in need of treatment include those already diagnosed as having the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. For example, intumor (e.g., canccr) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents or by the subject's own immune system.
"Tumor," as used herein refers to all neaplastic.cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
Unless otherwise defined, all technical and scientific terms used herein have the same rneaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference herein in their entirety. In case of conflict, the present specification, including definitions, will control.
In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
BRIEF DESCRIPTION OF THE FIGURES
Figure I is a schematic diagram of an exemplary process for vaccination of a patient with tumor antigen-pulsed dendritic cells. Monocytes are isolated from a patient and used to generate immature dendritic cells. After excision of a tumor or.a portion of the tumor, brain tumor stem-like cells are isolated aind used to prepare antigens for vaccination. The dendritic cells are pulsed with the antigens derived from the brain tumor stem-like cells. The mature antigen-presenting dendritic cells are then used to vaccinate the patient, providing an increased immune response against the tumor or residual tumor cells.
Figure 2 is a schematic diagram depicting an exemplary method of isolarion and generation of tumor neurospheres.
Figures 3A-3F are a.set of histograms depicting FACS analysis of neurospheres differentiated for 2 weeks. Neurospheres differentiated for 2 weeks show (3B) 96% of cells positive for the astrocyte marker GFAP; (3C) 88% of cells positive for the NSC
marker nestin; (3D) 29% of cells positive for the neuronal marker MAP2; (3E) 0% of cells positive for the neuronal marker beta-tubulin Ill; (3F) 6% of cells positive for the oligodendrocyte marker myelin/oligodendroctye. The samples were compared to a negative control as shown (3A).
Figure 4A is a graph depicting volume of tumors induced by neurospheres (n =
4) and monolayer cells (n = 4) at day 18. Tumors induced by neurospheres were significantly larger (p < 0.02) than those from the monolayer group.
Figure 4B is a line chart depicting survival of rats with tumors induced by neurosphercs (n = 9) and monolayer cells (n = 9). On average, animals in the neurosphere group died at a significantly (p < 0.02) earlier time point compared to those in the monolayer group.
Figures 5A-5E are a set of micrographs of tumors formed by implantation of neurospheres. (5A) neurospheres formed high grade gliomas with necrosis as seen on H&E; (5B) large and well circumferential tumors grew as evidenced in non-stained sections; (5C) large and well circumferential tumors grew as evidenced in sections stained for the nuclear marker DAPI; (5D) & (5E) comparison of non-tumor area (5D) and tumor area (5E) stained for reticulin reveals the high levels of reticulin formed in tumor engulfed regions, showing the histological sarcomatous component of the gliosarcoma.
Scale bar =
3000 m (5A) Scale bar = 1250 m (5B, 5C); Scale bar = 250 m (5D, 5E).
Figure I is a schematic diagram of an exemplary process for vaccination of a patient with tumor antigen-pulsed dendritic cells. Monocytes are isolated from a patient and used to generate immature dendritic cells. After excision of a tumor or.a portion of the tumor, brain tumor stem-like cells are isolated aind used to prepare antigens for vaccination. The dendritic cells are pulsed with the antigens derived from the brain tumor stem-like cells. The mature antigen-presenting dendritic cells are then used to vaccinate the patient, providing an increased immune response against the tumor or residual tumor cells.
Figure 2 is a schematic diagram depicting an exemplary method of isolarion and generation of tumor neurospheres.
Figures 3A-3F are a.set of histograms depicting FACS analysis of neurospheres differentiated for 2 weeks. Neurospheres differentiated for 2 weeks show (3B) 96% of cells positive for the astrocyte marker GFAP; (3C) 88% of cells positive for the NSC
marker nestin; (3D) 29% of cells positive for the neuronal marker MAP2; (3E) 0% of cells positive for the neuronal marker beta-tubulin Ill; (3F) 6% of cells positive for the oligodendrocyte marker myelin/oligodendroctye. The samples were compared to a negative control as shown (3A).
Figure 4A is a graph depicting volume of tumors induced by neurospheres (n =
4) and monolayer cells (n = 4) at day 18. Tumors induced by neurospheres were significantly larger (p < 0.02) than those from the monolayer group.
Figure 4B is a line chart depicting survival of rats with tumors induced by neurosphercs (n = 9) and monolayer cells (n = 9). On average, animals in the neurosphere group died at a significantly (p < 0.02) earlier time point compared to those in the monolayer group.
Figures 5A-5E are a set of micrographs of tumors formed by implantation of neurospheres. (5A) neurospheres formed high grade gliomas with necrosis as seen on H&E; (5B) large and well circumferential tumors grew as evidenced in non-stained sections; (5C) large and well circumferential tumors grew as evidenced in sections stained for the nuclear marker DAPI; (5D) & (5E) comparison of non-tumor area (5D) and tumor area (5E) stained for reticulin reveals the high levels of reticulin formed in tumor engulfed regions, showing the histological sarcomatous component of the gliosarcoma.
Scale bar =
3000 m (5A) Scale bar = 1250 m (5B, 5C); Scale bar = 250 m (5D, 5E).
Figures 6A-6B are line graphs depicting chemoresistance of neurospheres and monolayer cells to the indicated concentrations of carboplatin (6A) and Temodar (6B).
Each value represents the mean of three independent trials. Neurospheres were significantly more resistant (p < 0.05) to both chemotherapeutic agents as compared to monolayer cells.
Figure 7 is a bar graph depicting proliferation rates of neurospheres and monolayer cells in serum-containing media for 2 days. The WST-1 proliferation assay was used to measure absorbance, which directly correlates to the cell number. The monolayer cells proliferated at a significantly (p > 0.05) greater rate than the neurosphere cells.
Figures 8A-8C are micrographs depicting primary culture of adult human glioblastoma cells. (SA) Neurosphere-like tumor cells were found in glioblastoma primary cell culture in F-12/DMEM 10% FBS medium. Scale bar = 200 m. (8B) Neurosphere derived from a single isolated CD133' cell cultured in serum free medium with EGFIFGF.
Scale bar = 200 m. (8C) CD133 expression on a neurosphere derived from a single isolated CD133+ cell in serum free medium with EGF/FGF. Staining indicates CD
expression. Scale bar = 50 m.
Figures 9A-9C are histograms depicting CD133 protein expression on primary cultured tumor cells. Tumor cells were cultured in F-12/DMEM 10% FBS medium for 3-4 passages and stained with specific mAb to CD133 and isotype control-matched mAb.
Results are given as the percentage of CD133 positive cells in the total population. ln the histograms, the thick lines represent staining with CD133 mAb, and the thin lines represent the isotype control-matched mAb. (9A) tumor cells from patient No. 1049; (9B) tumor cells from patient No. 377; (9C) tumor cells from patient No. 66.
Figures l0A-l OD are line graphs depicting drug sensitivity of CD133 positive cancer stem cells derived from patient No. 66. Tumor cells of No.66 were cultured in FBS/F-12/DMEM medium for 4 passages. Both CD133 positive and negative tumor cells were collected by FACS sorting. 1 x 10 cells/well were plated in 96-well plate and treated with the indicated concentrations of VP- 16, Taxol, temozolomide, and carboplatin for 48 hours in FBSIF-12/ DMEM medium. * indicates p < 0.05 compared to autologous negative cells. Data are representative of two independent experiments. (l 0A) VP 16;
(lOB) Taxol; (lOC) temozolomide; (l OD) carboplatin.
Figures 11 A-11 C are a set of line graphs depicting drug sensitivity of CD133 positive cancer stem cells derived from patient Nos. 377 and 1049. Tumor cells of patient No.377 and No. 1049 were cultured in FBS/F-12IDMEM medium for 3 passages. Both CD133 positive and negative tumor cells were collected by FACS sorting. 1 x cells/well were plated in 96-well plate and treated with the indicated concentrations of carboplatin (I IA and 11C) or VP-16 (11B) for 48 hours in FBS/F-12/DMAEM
medium. *
indicates p < 0.05 compared to autologous CD133 negative cells. Data are representative of two independent experiments.
Figure 12 is a bar graph depicting CD133 mRNA expression in primary (1',) and recurrent (R) tumor tissue. Total RNA was extracted from both primary and recurrent tumor tissue derived from five patients, and CD133 mRNA expression was measured by real-ti.me qPCR. The relative CD133 mRNA level of recurrent tumor was presented as the fold increase compared to that of autologous primary tumor tissue. Data are representative of two independent experiments.
Figure 13 is a line graph depicting survival of 9L tumor-bearing rats vaccinated with dendritic cells pulsed with antigens from 9L adherent cells (9L-AC), 9L
daughter cells (9L-DC), 9L neurospheres (9L-NS), and dendritic cells alone (CONTROL).
Kaplan-Meier survival curve showed that the 9L-DC group had significantly longer survival than the other groups (p = 0.0015).
Figure 14 is a bar graph depicting IFNy production of splenocytes harvested from tumor bearing rats that were re-stimulated and by either re-exposure to a 9L
tumor cell target (Target) or to no target (NO Target). The re-stimulated splenocytes from NS
vaccinated rats released high level of IFNy when re-exposed to NS, whereas splenocytes from rats vaccinated with AC or DtC had no detectable IFNy in response to re-exposure to AC or DC.
Figures 15A and 15B are a pair of micrographs of tumor slices from rats vaccinated with dendritic cells pulsed with daughter cells (17A) and neurospheres (l 7B) and stained with anti-CD4 antibody. Greater infiltration of CD4+ cells was observed in the tumors of rats vaccinated with neurosphere-pulsed dendritic cells. (Magnification x40).
Figure 16 is a structural diagram ofCD133 depicting extracellular, intracellular, and transmembrane regions of CD 133.
Figures 17A and 17B are cell plots and histograms depicting expression of isotype control (17A) and MHC class I expression (17B) in human cancer stem cells.
Figures 18A and 18B are cell plots and histograms depicting expression of isotype control (18A) and M.HC class I expression (18B) in human neural stem cells.
Each value represents the mean of three independent trials. Neurospheres were significantly more resistant (p < 0.05) to both chemotherapeutic agents as compared to monolayer cells.
Figure 7 is a bar graph depicting proliferation rates of neurospheres and monolayer cells in serum-containing media for 2 days. The WST-1 proliferation assay was used to measure absorbance, which directly correlates to the cell number. The monolayer cells proliferated at a significantly (p > 0.05) greater rate than the neurosphere cells.
Figures 8A-8C are micrographs depicting primary culture of adult human glioblastoma cells. (SA) Neurosphere-like tumor cells were found in glioblastoma primary cell culture in F-12/DMEM 10% FBS medium. Scale bar = 200 m. (8B) Neurosphere derived from a single isolated CD133' cell cultured in serum free medium with EGFIFGF.
Scale bar = 200 m. (8C) CD133 expression on a neurosphere derived from a single isolated CD133+ cell in serum free medium with EGF/FGF. Staining indicates CD
expression. Scale bar = 50 m.
Figures 9A-9C are histograms depicting CD133 protein expression on primary cultured tumor cells. Tumor cells were cultured in F-12/DMEM 10% FBS medium for 3-4 passages and stained with specific mAb to CD133 and isotype control-matched mAb.
Results are given as the percentage of CD133 positive cells in the total population. ln the histograms, the thick lines represent staining with CD133 mAb, and the thin lines represent the isotype control-matched mAb. (9A) tumor cells from patient No. 1049; (9B) tumor cells from patient No. 377; (9C) tumor cells from patient No. 66.
Figures l0A-l OD are line graphs depicting drug sensitivity of CD133 positive cancer stem cells derived from patient No. 66. Tumor cells of No.66 were cultured in FBS/F-12/DMEM medium for 4 passages. Both CD133 positive and negative tumor cells were collected by FACS sorting. 1 x 10 cells/well were plated in 96-well plate and treated with the indicated concentrations of VP- 16, Taxol, temozolomide, and carboplatin for 48 hours in FBSIF-12/ DMEM medium. * indicates p < 0.05 compared to autologous negative cells. Data are representative of two independent experiments. (l 0A) VP 16;
(lOB) Taxol; (lOC) temozolomide; (l OD) carboplatin.
Figures 11 A-11 C are a set of line graphs depicting drug sensitivity of CD133 positive cancer stem cells derived from patient Nos. 377 and 1049. Tumor cells of patient No.377 and No. 1049 were cultured in FBS/F-12IDMEM medium for 3 passages. Both CD133 positive and negative tumor cells were collected by FACS sorting. 1 x cells/well were plated in 96-well plate and treated with the indicated concentrations of carboplatin (I IA and 11C) or VP-16 (11B) for 48 hours in FBS/F-12/DMAEM
medium. *
indicates p < 0.05 compared to autologous CD133 negative cells. Data are representative of two independent experiments.
Figure 12 is a bar graph depicting CD133 mRNA expression in primary (1',) and recurrent (R) tumor tissue. Total RNA was extracted from both primary and recurrent tumor tissue derived from five patients, and CD133 mRNA expression was measured by real-ti.me qPCR. The relative CD133 mRNA level of recurrent tumor was presented as the fold increase compared to that of autologous primary tumor tissue. Data are representative of two independent experiments.
Figure 13 is a line graph depicting survival of 9L tumor-bearing rats vaccinated with dendritic cells pulsed with antigens from 9L adherent cells (9L-AC), 9L
daughter cells (9L-DC), 9L neurospheres (9L-NS), and dendritic cells alone (CONTROL).
Kaplan-Meier survival curve showed that the 9L-DC group had significantly longer survival than the other groups (p = 0.0015).
Figure 14 is a bar graph depicting IFNy production of splenocytes harvested from tumor bearing rats that were re-stimulated and by either re-exposure to a 9L
tumor cell target (Target) or to no target (NO Target). The re-stimulated splenocytes from NS
vaccinated rats released high level of IFNy when re-exposed to NS, whereas splenocytes from rats vaccinated with AC or DtC had no detectable IFNy in response to re-exposure to AC or DC.
Figures 15A and 15B are a pair of micrographs of tumor slices from rats vaccinated with dendritic cells pulsed with daughter cells (17A) and neurospheres (l 7B) and stained with anti-CD4 antibody. Greater infiltration of CD4+ cells was observed in the tumors of rats vaccinated with neurosphere-pulsed dendritic cells. (Magnification x40).
Figure 16 is a structural diagram ofCD133 depicting extracellular, intracellular, and transmembrane regions of CD 133.
Figures 17A and 17B are cell plots and histograms depicting expression of isotype control (17A) and MHC class I expression (17B) in human cancer stem cells.
Figures 18A and 18B are cell plots and histograms depicting expression of isotype control (18A) and M.HC class I expression (18B) in human neural stem cells.
DETAILED DESCRIPTION
The present application describes compositions useful as vaccines for treating cancer (e.g., neural cancers, e.g., gliomas) that include dendritic cells pulsed with antigens obtained from cancer stem ceils (e.g., neurospheres); methods of producing vaccines that include dendritic cells pulsed with antigens obtained from cancer stem cells;
methods of treating cancer with vaccines that include dendritic cells pulsed with antigens obtained from cancer stem cells; and kits for treating cancer that include dendritic cells pulsed with antigens obtained from cancer stem cells.
Greater tumor infiltration of cytotoxic T-cells was observed in animals vaccinated against cancer stem cell antigens, and a stronger response against tumor cells was observed in T cells isolated from aiiimals vaccinated with cancer stem cell antigens, than in responses in which antigens were not prepared from stem cell enriched cell populations.
Cancer stem cells obtained from brain tumors were capable of self: renewal and proliferation, and could recapitulate the tumor when injected into rats.
Isolated cancer stem cells formed more aggressive tumors as comparedto differentiated tumor cells in vitro, and the cancer stem cells showed a higher resistance to chemotherapeutic agents.
Similarly, CD133-positive cancer stem cells were obtained from human tumors.
These cells were similarly resistant to chemotherapeutic agents and CD133-positive cells were found at a higher level in patients in whom tumors had recurred following resection.
Vaccination Methods Described herein are methods of vaccinating a subject, e.g., to treat cancer (e.g., neural cancer, e.g., gliomas) with antigen-presenting cells ("APC"), e.g., dendritic cells ("DC"), that include antigens from cancer stem cells, e.g., presented on the surface of the antigen-presenting cells. Dendritic cells (e.g., autologous or allogeneic dendritic cells) are contacted with cancer stem cell antigens as a cell lysate, acid elution, cell extract, partially purified antigens, purified antigens, isolated antigens, partially purified peptides, purified peptides, isolated peptides, synthetic peptides, or a combination of two or more of the above. The antigen-presenting cells are then administered to a subject in need of cancer vaccination (e.g., a subject diagnosed with or at risk for cancer) to treat the cancer. Figure 1 is a schematic diagram of an exemplary process for vaccination of a patient with cancer stem cell antigen-pulsed dendritic cells.
Cancer Stem Cells The "cancer stem cell" hypothesis proposes that only a small portion of a tumor is represented by the "cancer stem cell," which allows the tumor to proliferate and self renew, and eventually differentiate into the phenotypically diverse and heterogeneous tumor cell population (Bjerkvig et al., Nat. Rev. Cancer, 5:899-904, 2005).
Cancer stem cells can be isolated from any type of cancers, e.g., leukemias (Bonnet and Dick, Nat.
Med., 3:730-737, 1997), breast cancers (Al-Hajj et al., Proc. Nati. Acad. Sci.
USA, 100:3983-88, 2003), colon cancers (O'Brien et al., Nature, 445:106-110, 2007), and brain cancers (Singh et al., Nature, 432:396-401, 2004; Hemmati et al., Proc. Nati.
Acad. Sci.
USA, 100:15178-83,2003; Singh et al., Cancer Res., 63:5821-28, 2003; Sanai et al., N.
Engl. J. Med., 353:811-822, 2005; Tunici et al., Mol. Cancer, 3:25, 2004).
Cancer stem cells are characterized by their ability to self-renew and proliferate, and recapitulate through differentiation the tumor from which it is isolated. Additionally, neural cancer stem cells form clonally derived neurospheres in culture.
Cancer stem cells can be isolated by dissociating tuinor cells and culturing them under conditions that promote proliferation of stem cells (e.g., conditions that inhibit differentiation of the stem cells). Methods and conditions for isolating stem cells are known in the art. Exemplary methods and conditions can be found in U.S. Patent No.
5,589,376, U.S. Patent No. 5,643,741, U.S. Patent No. 5,650,299, U.S. Patent No.
5,824,489, U.S. Patent No. 5,849,553, U.S. Patent No. 5,928,947, U.S. Patent No.
5,981,708, U.S. Patent No. 6,337,184, U.S. Patent No. 6,645,763, U.S. Patent No.
6,800,790, U.S. Patent No. 6,875,607, U.S. Patent No. 6,984,522, U.S. Patent No.
7,109,03, U.S. Patent No. 7,115,267, and U.S. Patent No. 7,115,360.
Additionally, cancer stem cells can be identified or isolated (e.g., isolated from non-stem tumor cells) on the basis of expression (e.g., nucleic acid or protein expression) of molecular markers, e.g., molecular markers described in the U.S. patents referred to in the above paragraph. Exemplary molecular markers include CD133, Bmi-1, Notch, Sonic hedgehog, and Wnt. Additionally, exemplary molecular markers of neural cancer stem cells include CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi 1), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRPI, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAPI, cIAP2, NAIP, and survivin.
Isolation or identification of cancer stem cells can be performed by standard means, e.g., cell sorting (e.g., fluorescence activated cell sorting (FACS) ormagnetie cell sorting (MACS)).
Anti ens Antigenic peptides useful for loading DCs for vaccination are peptides that stimulate a T cell mediated immune response (e.g., a cytotoxic T cell response) by presentation to T cells on MHC molecules. Useful aritigenic peptides and proteins include those derived from cancer stem cells (e.g., neural cancer stem cells, CD133+
tumor cells, or neurospheres derived from tumors). In some embodiments, the cancer stem cell antigens are presented as a lysate of the cancer stem cells. In other embodiments, the cancer stem cell antigens are obtained by acid elution of peptides presented on MHC
molecules of the cancer stem cells. In an exemplary method, cancer stem cells are washed with an isotonic solution (e.g., Hank's buffered saline solution) to remove media components. The cells are then treated with acid (e.g., citrate phosphate buffer, pH 3.2) to dissociate peptides from surface MHCs; and the cells removed from the solution containing the soluble peptides. The acid-eluted cancer stem cell peptide antigens can be further purified (e.g., on a Cl 8 column) and frozen for storage prior to use.
Specific antigens that can be used in the methods described herein include portions of the amino acid sequences of CD 133, CD90, CD44, CXCTt4, -Nestin, .Musashi-1 (Msi 1), maternal. embryonic leucine zipper kinase (MELK), GLI1, PTCHI, Bmi-1,phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bel-2, FLIP, BCL-XL, XIAP, clAPl, cIAP2, NAIP, and survivin that binti to MHC molecules and are presented to'I' cells.
Peptides that bind to MHC class I molecules are generally 8-10 amino acids in length.
Peptides that bind to MHC class II molecules are generally 13 arnino acids or longer (e.g., 13-17 amino acids long).
CD133 is a 120 kDa, tive-traiYsmembrane domain glycoprotein expressed on neural and hematopoietic stem and progenitor cells (Yin et al., Blood, 90:5002-12, 1997).. Table I provides an amino acid sequence of CD133 (also available in GenBank under accession number NP 006008.1, GI:5174387): The structure.of CD133 includes an extraceliular N-terminus, two short intracellular loops, two large. extracellular. loops,.
andan intracellular C-terminus (FIG. 18). Exemplary CD133:T cell epitopes include 8-10 or 13-20 contiguous amino acid residues of amino acid.residues 325-350 of SEQ ID NO:53. An alternately spliced version of CD 13 3 is described in Yu et al., J. Biol. Chem., 277:207I
1-1 b, 2002..
CD90 is a cell surface.glycoprotein found on T cells and neurons. Table l provides an amino acid sequence of CD90 (also available in GenBank under accession number NP 006279.2, GI:19923362).
CD44 is a cell surface glycoprotein that may be involved in matrix adhesion.
Table 1 provides an amino acid sequence of CD44 (also available in GenBank.under accession number NP_000601.3, GI:48255935). Several isoforms of CD44 are produced, primarily by alternative splicing (see Marhaba et al:, J. Mol. Histol., 35:211-31,, 2004; Zoeller, Cancer Immunol. Immunother., 53:567-79, 2004).
CXCR4 is a chemokine receptor that has been found to be expressed in breast cancers (Muller et al., Nature, 410:50-56, 2001). Table 1 provides an amino acid sequence of CXCR4 (also available in GenBank under accession number NP 001008540.1, GI:56790927). An altemative spliced variant is available in GenBank under accession number NP 003458.1, GI:4503175.
Nestin is an intermediate filament protein expressedin ncural progenitor cells (Dahistrand et al., J. Cell Sci.,103:589-597; 1992). Table 1 provides an amino acid sequence ofNestin (also available in GenBank under accession nurnber NP
006608.1, GI:38176300).
Musashi-1 (Msil) is an RNA-binding protein expressed in neural progenitor cells (Good et al., Genomics, 52:382-384,1998; Siddall et al., Proc. Nat. Acad.
Sci.. USA, 103:84-8407, 2006; Okano etal., Exp. Cell Res., 306:349-356, 2005). Table I
provides an amino acid sequence of Musashi-1 (also available in GenBank under accession number NP 002433.1, GI:4505255).
Maternal embryonic.leucine zipper kinase (MELK) is a protein kinase expressed in multiple cancers (Gray et al., Cancer Res., 65:9751-61, 2005). Table 1 provides an amino acid sequence of MELK (also available in GenBank under accession number NP_055606.1, GI:7661974).
GLI l is a zinc-finger transcription factor upregulated in cancers, including gliomas (Kinzler et a1., Science, 236:70-73, 1987; Kinzler et al., Nature, 332:371-374,1988;
Kasper et al., Eur: J. Cancer, 42:437-445, 2006). Table. I provides an amino acid sequence of GLI1 (also available in GenBank under accession number NP 005260.1, GI:4885279).
PTCH1 is a transmembrane protein that is believed to function as a tumor suppressor (Katoh et al., Cancer Biol. Thor., 4:1050-54, 2005). Table 1 provides an amino acid sequence of PTCH l(also available in GenBank under accession number NP 000255.2, GI:134254446). Five isofonns of PTCH1 are produced by alternative splicing (Nagao et al., Gcnomics, 85:462-71, 2005).
Bmi-1 is a polycomb ring finger protein involved in proliferation of progenitor cells (Lessard et al., Nature, 423:255-260, 2003;.Park et al., Nature, 423:302-305, 2003;
Molofsky et al., Nature, 425:962-967, 2003). Bmi-1 can play a role in the malignant transformation of the HOX A9/MEIS-induced murine leukemia model (Lessard et al., Nature, 423:255-260, 2003) as well as in turnors of neural origin (van "Lohuizen et al., Nature, 353:353-355, 1991). Table I provides an arnino acid sequence of Bmi-1 (also available in GenBank under accession number NP00517I .4, GI:27883842).
Exemplary Bmi-I T cell epitopes include TLQDIVYKL (SEQ ID NO:86), CLPSPSTPV (SEQ ID
NO:87), VRYLETSKY (SEQ ID NO:88), KRYLRCPAA (SEQ ID NO:89), YEEEPLKDY (SEQ ID NO:90), and KEEVNDKRY (SEQ ID NO:91) (Stecle et al., Br. J.
Cancer 95:1202-11, 2006).
Phosphoserine phosphatase (PSP) is an enzyme that catalyzes the hydrolysis of phosphoserine. Table I provides an amino acid sequence ofPSP (also available in GenBank under accession number NP 004568.2, GI:46249388).
Snail is a zinc-finger transcription factor and anti-apoptotic protein (Vega et al., Genes Dev., 18:1131-1143, 2004). Table 1 provides an amino acid sequenee of Snail (also available in GenBank under accession numbcr NP 005976.2, GI:1876574I).
OCT4 is a POU homeodomain-containing transcription factor expressed in pluripotent cells (Nichols et al., Cell, 95:379-391, 1998). Table I provides an amino acid sequence of OCT4 (also available in GenBank under accession number NP_002692.2, GI:42560248). An alternate isoform of OCT4 is available in GenBank under accession number NP 976034.3, GI:116235491.
BCRP 1 is an ATP-binding cassette (ABC) transporter protein involved in multidrug resistance of tumors (Doyle et al., Proc. Nat. Acad. Sci. USA, 95:1566570, 1998). Table I provides an amino acid sequence of BCRP 1(also available in GenBank under accession number NP 004818.2, GI:62526033).
MGMT is an O-6-methylguanine-DNA mcthyltransferase DNA -mismatch repair protein that can provide resistance to some methylating and chloroethylating agents, such as temozolomide (Rabik et al., Cancer Treat. Rev., 32:261-276, 2006; Cai et al., Cancer Res., 65:3319-27, 2005). Table 1 provides an amino acid sequence of MGMT (also available in GenBank under accession number NP 002403.1, GI:4505177).
BCL-2 is a mitochondrial anti-apoptotic protein correlated with chemotherapy resistant cancers and decreased overall survival (Campos et al., Blood, 81:3091-3096, 1993). Table I provides an amino acid sequence of BCL-2 (also available in GenBank under accession number NP_000624.2, GI:72198189). An alternatively spliced isoform of BCL-2 is available in GenBank under accession number NP 000648:2, GI:72198346.
FLIP is an anti-apoptotic protein (Irmler. et al., Nature, 388:190-195, 1997).
Table I provides an amino acid sequence of FLIP (also available in GenBank under accession number NP003870.3, GI:21361769).
BCL-XL is an anti-apoptotic protein related to BCL-2, which may be involved in chemoresistance (Boise et al., Cell, 74:597-608, 1993; Andreeffet al., Leukemia, 13:1881-92, 1999). Table I provides an amino acid sequence of BCL-XL (also available in GenBank under accession number NP 612815.1, GI:20336335). BxemplaryT cell epitopes of BCL-XL include Bcl-xLI 18-126(TAYQSFEQV; SEQ ID N4:92), Bcl-xL173-182 (YLNDFILBPWI; SEQ ID NO:93), and Bcl-xLl 69-178 (WMATYLNDHL;
SEQ ID NO:94) (Andersen et al., J. Immunol., 175:2709-14, 2005).
XIAP is a member of the inhibitor of apoptosis protein (IAP) family (Deveraux et al., Nature, 388:300-304, 1997). Table 1 provides an amino acid sequence of XIAP (also available in GenBank under accession number NP_001158.2, GI:32528299).
cIAPI is a meinber of the IAP family of apoptosis inhibitors (Rothe et al., Cell, 83:
1243-1252, 1995; Liston et al., Nature, 379:349-353, 1996). Table I provides an amino acid sequence of cIAPl (also available in GenBank under accession number NP
00i 157. I, GI:4502141).
cIAP2 is a member of the .IAP family of apoptosis inhibitors (Liston et al., Nature, 379:349-353, 1996). Table 1 provides an amino acid sequence of cIAP2 (also available in GenBank under accession number NP_031490.1, GI:6680696).
NAIP is a member of the TAP family of apoptosis inhibitors (Roy et al., Cell, 80:167-178, 1995). Table I provides an amino acid sequence of NAIP (also available in GenBank under accession number NP 004527.2, GI:119393878). An alternatively spliced isoform of NAIP is available in GenBank under accession number NP 075043.1, GI:119393876.
Survivin is a meinber of the IAP family of apoptosis inhibitors (Li et al., Nature, 396:580-584, 1998). Table 1 provides an amino acid sequence of NAIP (also avai!able in GenBank under accession number NP 001159.2, GI:59859878). Alternatively spliced isoforms of survivin have been identified (see Wheatley et al., Int. Rev.
Cytol., 247:35-88, 2005; Noton et al., J. Biol. Chem., 281:1286-95, 2006; and Taubertet al., Oncogene, 24:5258-61, 2005). Sequences of exemplary alternative isoforms are available in GenBank under accessionnunibers NP 001012270.1, GI:59859880, and NP_001012271.1, G1:59859882. Exemplary T cell epitopes of survivin include Sur2O-28 (STFKNWPFL; SEQ ID NO:95), Sur96-104. (LTLGEFLKL; SEQ ID NO:96), Sur133-141 (RAIEQLAAM; SEQ ID NO:97), and Surl26-135 (ETAKKVRftAI; SEQ ID NO:98) (Bachinsky etal., Cancer Immun., 5:6, 2005).. Other exemplary T cell epitopes of survivin include Sur92-101 (QFEELTLGEF; SEQ ID NO:99), Sur54-62 (LAQCFFCFK; SEQ ID
NO:100), Surl 12-120 (KIAKETNNK; SEQ ID NO:101), Sur53-62 (DLAQCFFCFK; SEQ
ID NO:102), Surl 12-121 (KIAKETNNKK; SEQ. ID NO:103), Sur.l'8-28 (RISTFKNWPFL; SEQ ID NO:104), Sur$6-96 (FLSVKKQFEEL; SEQ ID NO:; 105), and the modified peptides Sur92T2 (QTEELTLGEF; SEQ ID NO:106), Sur93T2 (FTELTLGEF; SEQ ID NO:107), Sur93S2 (FSELTLGEF; SEQ ID NO:108), Sur38Y9 (MAEAGFIHY; SEQ ID NO:109), Sur47Yl 0(PTENEPDLAY; SEQ ID NO:110), Sur5K9 (TLPPAWQPK; SEQ ID NO:111), Sur54L2 (LLQCFFCFK; SEQ ID NO:112), and SurT8K10 (RISTFKNWI'K; SEQ 1D. N(3:113) (Reker et al., Canccr Biol. Ther., 3:173-179, 2004): Other exemplary T cell epitopes of survivin include ELTLGEFLKL
(SEQ ID
NO:114) and TLPPAWQPFL (SEQ ID NO:115) (Schmitz et al., Cancer Res. 60:4845-4849, 2000). Additional survivin cpitopes are described in Siegel et al., Br.
J. Haernatol., 122:911-914,2003.
Table 1. Sequences of Hur,ian Antigens Antigen Amino acid sequence CD133 r1ALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATNYETQDSHKAGPIGILFELVHI
FLYWQPRDFPEDTLRKFLQKAYESKIDYDKPE'i'VILGLKIVYYEFIGIILCCVLGLLFIIL
MPLVG'1'FFCMCRCCNKCGGEMHQRQKENGPFLRKCFAISLLVICIIISIGIFYGFVANHQV
RTRIKRSRKLADSNFKDLRTLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGGILDR
LRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLHQQSTQLSSSLTSVKTSLRSSLNDP
I,CLVHPSSETCNSTRLSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQGYQSLND
IPDRVQRQTTTVt7AGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESYIHRNLPTL
EEYDSYWttrLGGLVICSLLTLIVIFYYLGLLCGVCGYDI2IIATPTTRGCVSNTGGVFLMVGVG
LSFLFCWILMIIVVLTFVFGANVEKLICEPYTSKELFRVLDTPYLLNEDWEYYLSGKLFNK
SKMKLTFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESLKVNLNIFLL
GAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKANSLPPGNLR[QSLK
RDAQTIKTIHQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASLDFAQNFITNNTS
SVIIEETKKYGRTIIGYFEHYLQWIEFSISEKVASCKPVATALDTAVDVFLCSYIIDPLNL
HNPVMTSPSQH (SEQ ID NO:53) CD9O MNLAISIALLLTVLQVSRGQKVTSLTACLVDQSLRLDCRHEN'1'SSSPIQYEFSLTRETKKH
VLFGTVGVPEHTYRSRTNFTSKYNMKVLYLSAFTSKDEGTYTCALHHSGHSPPISSQNVTV
LRDKLVKCEGISLLAQNTSWLLLLLLSLSLLQATDFMSL (SEQ ID NO:54) Antigen Anzino acid sequence CD44 rIDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTLP
TMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNAS
APPEEDCT'SVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNP'1'DDDVSSGSS
SERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRTPATTLMSTSATATETATKRQETWDW
FSWLFLPSESKNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDEDFIS
STISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTTRMTDVDRNGTTAYEGNWNPEAHPP
LIHHEHHEEEETPHSTSTIQATPSSTTEETA`1'QKEQWFGNRWHEGYRQTPKEDSHSTTGTA
AASAHTSHPMQGRTTPSPEDSSWTDFFNPISHPMGRGHQAGRRMDMDSSHSITLQPTANPN
TGLVEDLDRTGPLSMTTQQSNSQSFSTSHEGLEEDKDHPTTSTLTSSNRNDVTGGRRDPNH
SEGSTTLLEGYTSITYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNRSLSGDQDTFH
PSGGSHTTHGSESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIAVN
SRRRCGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRN
LQNVDMKIGV (SEQ ID NO:55) LVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNFLCKAVHVIYTV
NLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKWYVGVWIPALLLTIPDFIFANVSE
ADDRYICDRFYPNDLWVWFQFQHIMVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKT
TVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAFFHCCLNPIL
YAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHSS (SEQ ID
N0:56) Nestin MEGCMGEESFQMWELNRRLEAYLARVKALEEQNELLSAELGGLRAQSADTS6+TRAHADDELA
ALRALVDQRWREKHAAEVARDNLAEELEGVAGRCQQLRLARERTTEEVARNRRAVEAEKCA
RAWLSSQVAELERELEALRVAHEEERVGLNAQAACAPRCPAPPRGPPAPAPEVEELARRLG
EAWRGAVRGYQERVAHMETSLGQARERLGRAVQGAREGRLELQQLQAERGGLLERRAALEQ
RLEGRWQERLRATEKFQLAVEALEQEKQGLQSQIAQVLEGRQQLAHLKMSLSLEVA'I'YRTL
LEAENSRLQTPGGGSKTSLSFQDPKLELQF'PRTPEGRRLGSLLPVLSPTSLPSPLPATLET
PVPAFLKNQEFLQARTPTLASTPIPPTPQAPSPAVDAEIRAQDAPLSLLQTQGGRKQAPEP
LRAEARVAIPASVLPGPEEPGGQRQEASTGQSPEDHASLAPPLSPDHSSLEAKDGESGGSR
VFSICRGEGEGQIWGLVEKETAIEGKWSSLQQEIWEEEDLNRKEIQDSQVPLEKETLKSL
GEEIQESLKTLENQSHETLERENQECPRSLEEDLETLKSLEKENKELLKDVEWRPLEKEA
VGQLKPTGKEDTQTLQSLQKENQELMKSLEGNLETFLFPGTENQELVSSLQENLESLTALE
KENQEPLRSPEVGDEEALRPLTKENQEPLRSLEDENKEAFRSLEKENQEPLKTLEEEDQSI
VRPLETENHKSLRSLEEQDQETLRTLEKETQQRRRSLGEQDQMTLRPPEKVDLEPLKSLDQ
EIARPLENENQEFLKSLKEESVEAVKSLETEILESLKSAGQENLETLKSPETQAPLWTPEE
INQGAMNPLEKEIQEPLESVEVNQETFRLLEEENQESLRSLGAWNLENLRSPEEVDKESQR
NLEEEENLGKGEYQESLRSLEEEGQELPQSADVQRWEDTVEKDQELAQESPPGMAGVENED
EAELNLREQDGFTGKEEWEQGELNATEEVWIPGEGHPESPEPKEQRGLVEGASVKGGAEG
LQDPEGQSQQVGAPGLQAPQGLPEAIEPLVEDDVAPGGDQASPEVMLGSEPAMGESAAGAE
PGPGQGVGGLGDPGHLTREEVMEPPLEEESLEAKRVQGLEGPRKDLEEAGGLGTEFSELPG
KSRDPWEPPREGREESEAEAPRGAEEAFPAETLGHTGSDAPSPWPLGSEEAEEDVPPVLVS
PSPTYTPILEDAPGPQPQAEGSQEASWGVQGRAEALGKVESEQEELGSGEIPEGPQEEGEE
SREESEEDELGETLPDSTPLGFYLRSPTSPRWDPTGEQRPPPQGETGKEGWDPAVLASEGL
EAPPSEKEEGEEGEEECGRDSDLSEEFEDLGTEAPFLPGVPGEVAEPLGQVPQLLLDPAAW
DRDGESDGFADEEESGEEGEEDQEEGREPGAGRWGPGSSVGSLQALSSSQRGEFLESDSVS
VSVPWDDSLRGAVAGAPKTALETESQDSAEPSGSEEESDPVSLEREDKVPGPLEIPSGMED
AGPGADIIGVNGQGPNLEGKSQHVNGGVMNGLEQSEEVGQGMPLVSEGDRGSPFQEEEGSA
LKTSWAGAPVHLGQGQFLKFTQREGDRESWSSGED (SEQ ID N0:57) Antigen Amino acid sequence Msil METDAPQPGLASPDSPHDPCKMFIGGLSWQTTQEGLREYFGQFGEVKECLVMRDPLTKRSR
GFGFVTFMDQAGVDKVLAQSRHELDSKTIDPKVAFPRRAQPKMV'T'RTKKIFVGGLSVNTTV
EDVKQYFEQFGKVDDAMLMFDKTTNRHRGFGFVTFESEDIVEKVCEIHFHEINNKMVECKK
AQPKEVMSPTGSARGRSRVMPYGMDAFMLGIGMLGYPGFQATTYASRSYTGLAPGYTYQFP
EFRVERTPLPSAPVLPELTAIPLTAYGPMAAAAA.AAAVVRGTGSHPWTMAPPPGSTPSRTG
GFLGTTSPGPMAELYGAANQDSGVSSYISAASPAPSTGFGHSLGGPLIATAFTNGYH
(SEQ ID NO:58) MELK MKDYDELLKYYELHETIGTGGFAKVKI,ACHILTGEMVAIKxMDKNTLGSDLPRIKTEIEAL
KNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAY
VHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGK
SYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQML
QVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCV'I'ELSVHHRNNRQTMEDLI
SLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGQASATPFTDIKSNNWSLEDVTASDKN
YVAGL,IDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTPANKLKNKENVY
TPKSAVKNEEYFMI'PEPKTPVNKNQHKREILTTPNRYTTPSKARNQCLKETPIKIPVNSTG
'I'DKLMTGVISPERRCRSVELDLNQAHMEE'.PPKRKGAKVFGSLERGLDKVITVLTRSKRKGS
ARDGPRRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHVDFVQKGYTLKCQTQSDFGKVTMQ
FELEVCQLQKPDVVGIRRQRLKGDAWVYKRLVEDILSSCKV (SEQ ID NO:59) GLII MFNSMTPPPISSYGEPCCLRPLPSQGAPSVGTEGLSGPPFCHQANLMSGPHSYGPARETNS
CTEGPLFSSPRSAVKLTKKRALSISPLSDASLDLQTVIRTSPSSLVAFINSRCTSPGGSYG
HLSIGTMSPSLGFPAQMNHQKGPSPSFGVQPCGPHDSARGGMIPHPQSRGPFPTCQLKSEL
DMLVGKCREEPLEGDMSSPNSTGIQDPLLGMLDGREDLEREEKREPESVYETDCRWDGCSQ
EFDSQEQLVHHINSEHIHGERKEFVCHWGGCSRELRPFKAQYMLVVHMRRHTGEKPHKCTF
EGCRKSYSRLENLKTHLRSHTGEKPYMCEHEGCSKAFSNASDRAKHQNRTHSNEKPYVCKL
PGCTKRYTDPSSLRKHVKTVHGPDAHVTKRHRGDGPLPRAPSISTVEPKREREGGPIREES
RLTVPEGAMKPQPSPGAQSSCSSDHSPAGSAANTDSGVEMTGNAGGS'T'EDLSSLDEGPCIA
GTGLSTLRRLENLRLDQLHQLRPIGTRGLKLPSLSHTGTTVSRRVGPPVSLERRSSSSSSI
SSAYTVSRRSSLASPFPPGSPPENGASSLPGLMPAQHYLLRARYASARGGGTSPTAASSLD
RIGGLPMPPWRSRAEYPGYNPNAGVTRRASDPAQAADRPAPARVQRFKSLGCVHTPPTVAG
GGQNFDPYLPTSVYSPQPPSITENAAMDARGLQEEPEVGTSMVGSGLNPYMDFPPTDTLGY
GGPEGAAAEPYGARGPGSLPLGPGPPTNYGPNPCPQQASYPDPTQETWGEFPSHSGLYPGP
KALGGTYSQCPRLEHYGQVQVKPEQGCPVGSDSTGLAPCLNAHPSEGPPHPQPLFSITYPQP
SPPQYLQSGPYTQPPPDYLPSEPRPCLDFDSPTHSTGQLKAQLVCNYVQSQQELLWEGGGR
EDAPAQEPSYQSPKFLGGSQVSPSRAKAPVNTYGPGFGPNLPNHKSGSYPTPSPCHENFW
GANRASHRAAP:PPRLLPPLPTCYGPLKVGGTNPSCGHPEVGRLGGGPALYPPPEGQVCNPL
DSLDLDNTQLDFVAILDEPQGLSPPPSHDQRGSSGHTPPPSGPPNMAVGNMSVLLRSLPGE
TEFLNSSA (SEQ ID NO:60) Antigen Anvino acid sequence LEQISKGKATGRKAPLWLRAKFQRLLFKLGCYIQKNCGKFLWGLLIFGAFAVGLKAANLE
TNVEELWVEVGGRVSRELNYTRQKIGEEAMFNPQLMIQTPKEEGANVLTTEALLQHLDSAL
QASRVHVYMYNRQWKLEHLCYKSGELITETGYMDQIIEYLYPCLIITPLDCFWEGAKLQSG
TAYLLGKPPLRWTNFDPLEFLEELKKINYQVDSWEEMLNKA.EVGHGYMDRPCLNPADPDCP
ATAPNKNSTKPLDMALVLNGGCHGLSRKYMHWQEELIVGGTVKNSTGKLVSAHALQTMFQL
MTPKQMYEHFKGYEYVSHINWNEDKAAAILEAWQRTYVEVVHQSVAQNSTQKVLSFTTTTL
DDILKSFSDVSVIRVASGYLLMLAYACLTMLRWDCSKSQGAVGLAGVLLVALSVAAGLGLC
SLIGISFNAA`NPQVLPFLALGVGVDDVFLLAHAFSETGQNKRIPFEDRTGECLKRTGASVA
LTSISNVTAFFMAALIPIPALRAFSLQAAVVVVFNFAMVLLIFPAILSMDLYRREDRRLDI
FCCFTSPCVSRVIQVEPQAYTDTHDNTRYSPPPPYSSHSFAHETQITMQSTVQLRTEYDPH
THVYYTTAEPRSEISVQPVTVTQDTLSCQSPESTSSTRDLLSQFSDSSLHCLEPPCTKWTL
.SSFAEKHYAPFLLKPKAKVVVIFLFLGLLGVSLYGTTRVRDGLDLTDIVPRETREYDFIAA
QFKYFSFYNMYTV''rQKADYPNIQHLLYDLHRSFSNVKYVMLEENKQLPKMWLHYFRDWLQG
LQDAFDSDWETGKIMPNNYKNGSDDGVLAYKLLVQTGSRDKPIDISQLTKQRLVDADGIIN
PSAFYIYLTAWVSNDPVAYAASQANIRPHRPEWVHDKADYMPETRLRIPAAEPIEYAQFPF
YLNGLRDTSDFVEAIEKVRTICSNYTSLGLSSYPNGYPFLFWEQYIGLRHWLLLFISVVLA
CTFLVCAVFLLNPWTAGIIVMVLALMTVELFGMMGLIGIKLSAVPWILIASVGIGVEFTV
HVALAFLTAIGDKNRRAVLALEHMFAPVLDGAVSTLLGVLMLAGSEFDFIVRYFFAVLAIL
TILGVLNGLVLLPVLLSFFGPYPEVSPANGLNRLPTPSPEPPPSVVRFAMPPGHTHSGSDS
SDSEYSSQTTVSGLSEELRHYEAQQGAGGPAHQVIVEATENPVFAHSTVVH'PESRHHPPSN
PRQQPHLDSGSLPPGRQGQQPRRDPPREGLWPPPYRPRRDAFEISTEGHSGPSNRARWGPR
GARSHNPRNPASTAMGSSVPGYCQPITTVTASASVTVAVHPPPVPGPGRNPRGGLCPGYPE
TDHGLFEDPHVPFHVRCERRDSKVEVIELQDVECEERPRGSSSN (SEQ ID NO:61) Bmi-1 MHR`1".CRIKITELNPHLMCVLCGGYFIDATTIIECLHSFCKTCIVRYLETSKYCPICDVQVH
KTRPLLNIRSDKTLQDIVYKLVPGLFKNEMKRRRDFYAAHPSADAANGSNEDKGEVADEDK
RIITDDEIISLSIEFFDQNRLDRKVNKDKEKSKEEVNDKRYLRCPAAMTVMHLRKFLRSKM
DIPNTFQIDVMYEEEPLKDYYTLMDIAYIYTWRRNGPLPLKYRVRPTCKRMKISHQRDGLT
NAGELESDSGSDKANSPAGGIPSTSSCLPSPSTPVQSPHPQFPHISSTMNGTSNSPSGNHQ
SSFANRPRKSSVNGSSATSSG (SEQ ID NO:62) PSP MVSHSELRKLFYSADAVCF'DVDSTVIREEGIDELAKICGVEDAVSEMTRRAMGGAVPFKAA
LTERLALIQPSREQVQRLIAEQPPHLTPGIRELVSRLQERNVQVFLISGGFRSIVEHVASK
LNIPATNVFANRLKFYFNGEYAGFDETQP'I'AESGGKGKVIKLLKE,KFHFKKIIMIGDGATD
MEACPPADAFIGFGGNVIRQQVKDNAKWYITDFVELLGELEE (SEQ ID NO:63) Snail MPRSFLVRKPSDPNRKPNYSELQDSNPEFTFQQPYDQAHLLAAIPPPEILNPTASLPMLIW
DSVLAPQAQPIAWASLRLQESPRVAELTSLSDEDSGKGSQPPSPPSPAPSSFSSTSVSSLE
AEAYAAFPGLGQVPKQLAQLSEAKDLQARKAFNCKYCNKEYLSLGALKMHIRSHTLPCVCG
TCGKAFSRPWLLQGHVRTHTGEKPFSCPHCSRAFADRSNLRAHLQTHSDVKKYQCQACART
FSRMSLLHKHQESGCSGCPR (SEQ ID NO:64) PCPPPYEFCGGMAYCGPQVGVGLVPQGGLETSQPEGEAGVGVESNSDGASPEPCTVTPGAV
KLEKEKLEQNPEESQDIKALQKELEQFAKLLKQKRITLGYTQADVGL'I'LGVLFGKVFSQTT
ICRFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLVQARKRKRTSIENRVRGN
LENLFLQCPKPTLQQISHIAQQLGLEKDVVRVWFCNRRQKGKRSSSDYAQREDFEAAGSPF
SGGPVSFPLAPGPHFGTPGYGSPHFTALYSSVPFPEGEAFPPVSVTTLGSPMHSN (SEQ
ID NO:65) Antigen Aniino acid sequence j3CRP) MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVEK
EILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCNSG
YWQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVrQELGLDKVADSKVGTQFI
RGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIFSIHQ
PRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIINGDSTAV
ALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKKITVFKE
ISY'1'TSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTWLGLVIGAIYFGLKNDSTGIQNRA
GVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLPMRMLPSII
FTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSWSVATLLMTICFVFMM
IFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGNNPCNYATCTG
EEYI,VKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS (SEQ ID N0:66) MGMT MDKDCEMKR`PTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQ
CTAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKWKFGEVISYQQLAALAG
NPKAARAVGGAMRGNPVPILIPCHRWCSSGAVGNYSGGLAVKEWLLAHEGHRLGKPGLGG
SSGI,AGAWT,KGAGATSGSPPAGRN (SEQ ID NO:77) SRDPVARTSPLQTPAAPGAAAGPALSPVPPWHLTLRQAGDDFSRRYRRDFAEMSSQLHLT
PFTARGRFA`IWEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNR
HLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK (SEQ
ID NO:78) FLIP MSAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYR
VRRFDLLKRILKMDRKAVETHLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGR
GKISKEKSFLDLWELEKLNLVAPDQLDLLF.KCLKNIHRIDLKTKIQKYKQSVQGAGTSYR
NVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFLPQSIPEERY
KMKSKPLGICLIIDCIGNE'I'ELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMPEHRDY
DSFVCVLVSRGGSQSVYGVDQTHSGLPLHHIRRMFMGDSCPYLAGKPKMFFIQNYWSEGQ
LENSSLLEVDGPAMKNVEFKAQKRGLCTVHREADFFWSLCTADMSLLEQSHSSPSLYLQCL
SQKLRQERKRPLLDLHIELNGYMYDWNSRVSAKEKYYVWLQHTLRKKLILSYT (SEQ ID
N0:79) BCL-XL MSQSNRELWDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLAD
SPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQS
FEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQ
ENGGWDTFVELYGNNAAAESRKGQERFNRWFL`I'GMTVAGVV'LLGSLFSRK (SEQ ID
N0:80) XIAP MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTV
RCFSCtIAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLG
SRDHFALDRPSETHADYLLRTGQWDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRE
LASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAV
SSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGG
GLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRI
DDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESS
QTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVI
TFKQKIFMS (SEQ ID NO:81) Antigen Amino acid sequence cIAP 1 MHKTASQRLFPGPSYQNIKSIMEDSTILSDIqTNSNKQKMICYDFSCELYRMSTYSTFPAGVP
VSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKLGDSPIQKHKQLYPSCSFIQNLVSASLG
STSKNTSPMRNSFAHSLSPTLEHSSLFSGSYSSLSPNPLNSRAVEDISSSRTNPYSYAMST
EEARFLTYHMWPLTFLSPSELARAGFYYIGPGDRVACFACGGKLSNWEPKDDAMSEHRRHF
PNCPFLENSLETLRFSISNLSMQTHAARMRTFMYWPSSVPVQPEQLASAGFYYVGRNDDVK
CFCCDGGLRCWESGDDPWVEHAKWFPRCEFLIRMKGQEFVDEIQGRYPHLLEQLLSTSDTT
GEENADPPIIHFGPGESSSEDAVNMNTPVVKSALEMGFNRDLVKQTVQSKILTTGENYKTV
NDIVSALLNAEDEKREEEKEKQAEEMASDDLSLIRINRMALFQQLTCVLPILDNLLKANVI
NKQEHDIIKQKTQIPLQARELIDTILVKGNiAANIFKNCLKEIDSTLYKNLFVDKNNII{YIP
TEDVSGLSLEEQLRRLQEERTCKVCMDKEVSVVFIPCGHLWCQECAPSLRKCPICRGIIK
GTVRTFLS (SEQ ID NO:82) cjAP2 MVQDSAFLAKLMKSADTI'ELKYDFSCELYRLSTYSAFPRGVPVSERSLARAGFYYTGANDK
VKCFCCGLMLDNWKQGDSPMEKHRKLYPSCNFVQTLNPANSLEASPRPSLPSTAMSTMPLS
FASSENTGYFSGSYSSFPSDPVNFRANQDCPALSTSPYHFAMNTEKARLLTYETWPLSFLS
PAKI'.,AKAGFYYIGPGDRVACFACDGKLSNWERKDDAMSEHQRHFPSCPFLKDLGQSASRYT
VSNLSMQ"I'HAARIRTFSNWPSSALVHSQELASAGF`IYTGHSDDVKCFCCDGGLRCWESGDD
PWVEHAKWFPRCEYLLRIKGQEFVSQVQAGYPIiLLEQLLSTSDSPEDENADAAIVHFGPGE
SSEDVVMMSTPVVKAALEMGFSRSLVRQTVQRQILATGENYRTVSDLVIGLLDAEDEMREE
QMEQAAEEEESDDLALIRKNKMVLFQHLTCVTPMLYCLLSARAITEQECNAVKQKPHTLQA
STLIDTVLAKGNTAATSFRNSLREIDPALYRDIFVQQDIRSLPTDDIAALPMEEQLRKLQE
ERI+iCKVCMDREVSIVFIPCGHLWCKDCAPSLRKCPICRGTIKGTVRTFLS (SEQ ID
NO:83) NAIP MA`i'QQKASDERISQFDHNLLPELSALLGI:,DAVQLAKELEEEEQKERAKMQKGYNSQMRSEA
KRLKTFVTYEPYSSWIPQEMAAAGFYFTGVKSGIQCFCCSLILFGAGLTRLPIEDHKRFHP
DCGFLLNKDVGNIAKYDIRVKNLKSRLRGGKMRYQEEEARLASFRNWPFYVQGISPCVLSE
AGFVFTGKQIYIVQCFSCGGCLGNWEEGDDPWKEHAKWFPKCEFLRSKKSSEEITQYIQSYK
GFVDITGEHFVNSWVQRELPMASAYCNDSIFAYEELRLDSFKDWPRESAVGVAALAKAGLF
YTGIKDIVQCFSCGGCLEKWQEGDDPLDDHTRCFPNCPFLQNMKSSAEVTPDLQSRGELCE
LLETTSESNLEDSIAVGPIVPEMAQGEAQWFQEAKNLNEQLRAAYTSASFRHMSLLDISSD
LATDHLLGCDLSIASKI-TISKPVQEPLVLPEVFGNLNSVMCVEGEAGSGKTVLLKKIAFLWA
SGCCPLLNRFQLVFYLSLSSTRPDEGLASIICDQLLEKEGSVTEMCVRNIIQQLKNQVLFL
LDDYKEICSIPQVIGKLIQKNIiLSRTCLLIAVRTNRARDIRRYLETILEIKAFPFYNTVCI
LRKLFSHNMTRLRKFMVYFGKNQSLQKIQKTPLFVAAICAHWFQYPFDPSFDDVAVFKSYM
ERLSLRNKATAEILKATVSSCGELALKGFFSCCFEr`NDDDLAEAGVDEDEDLTMCLMSKFT
AQRLRPFYRFLSPAFQEFLAGMRLIELLDSDRQEHQDLGLYHLKQINSPMMTVSAYNNFLN
YVSSLPSTKAGPKIVSHLLHLVDNKESLENISENDDYLKHQPEISLQMQLLRGLWQICPQA
YF.SMVSEHLLVLALKTAYQSNITVAACSPFVLQFLQGRTLTLGALNLQYFFDHPESLSLLRS
IHFPIRGNKTSPRAHFSVLETCFDKSQVPTIDQDYASAFEPMNEWERNLAEKEDNVKSYMD
MQRRASPDLSTGYWKLSPKQYKIPCLEVDVNDIDWGQDMLEILMTVFSASQRIELHLNHS
RGFIESIRPALELSKASVI'KCSISKLELSAAEQELLLTLPSLESLEVSGTIQSQDQIFPNL
DKFLCLKELSVDLEGNINVFSVIPEEFPNFHHMEKLLIQISAEYDPSKLVKLIQNSPNLHV
FHLKCNFFSDFGSLMTMLVSCKKLTEIKFSDSFFQAVPFVASLPNFISLKILNLEGQQFPD
EETSEKFAYILGSLSNLEELILPTGDGIYRVAKLIIQQCQQLHCLRVLSFFKTLNDDSWE
IAKVAISGGFQKLENLKLSINHKITEEGYRNFFQALDNMPNLQELDISRHFTECIKAQATT
VKSLSQCVLRLPRLIRLNMLSWLLDADDIALLNVMKERHPQSKYLTILQKWILPFSPIIQK
(SEQ ID NO:84) Survivin MGAPTLPPAWQPFLKDHRISTFKN6dPF'LEGCACTPERMAEAGFIHCPTENEPDLAQCFFCF
KELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKK
EFEETAEKVRRAIEQLAAMD (SEQ ID NO:85) T cell epitopes can be identified by a number of different methods. Naturally processed MHC epitopes can be identified by mass spectrophotometric analysis ofpeptides cluted from antigen-loaded APC (e.g., APC that have taken up antigen, or that have been engineered to produce the protein intracellularly). After incubation at 37 C, cells are lysed. in detergent and the MHC protein is purified (e.g., by affinity chromatography). Treatment of the purified MHC with a suitable chemical medium (e.g., under acidic conditions) results in the elution of peptides from the MHC. This pool of peptides is separated and the profile compared with peptides from control APC
treated in the same way. The peaks -unique to the protein expressing/fed cells are analyzed (for example by mass spectrometry) and the peptide fragments identified. This protoco) identifies peptides generated from a particular antigen by antigen processing.
Alternatively, epitopes can be identified by screening a synthetic library of peptides that overlapand span the length of the antigen in an in vitro assay. For example, peptides that are 9 amino acids in length and which overlap by 5 amino acids may be used. The peptides are tested in an antigen presentation system that includes antigen presenting cells and T cells. T cell activation in the presence of APCs presenting the peptide can be measured (e.g., by measuring T cell proliferation or cytokine production) and compared to controls, to determine whether a particular cpitope is recognized by the T
cells:
T cell epitopes can be predicted in silico; e.g., usirig the methods described in Parker et al., J. Immuno1:,152:163, 1994 and Rammensee et al., Immunogenet., 50:213-219, 1999.
Antigenic peptides can be obtained by chemical synthesis using a commercially available automated peptide synthesizer. Synthetic peptides can be precipitated and further purified, for example by high perfonnance liquid chromatography (HPLC).
Alternatively, isolated peptides can be obtained by purification and/or recombinant methods using-host cell and.vector expression systems.
Preparation of Antijzen Presentinp, Cells Antigen presenting cells (APC), such as DCs, suitable for administration to subjects (e.g., glioma patients) can be isolated or obtained from any tissue in which such cells are found, or may be otherwise cultured and provided using standard techniques.
Methods of preparing antigen presenting cells are well-known to those of skill in the art.
Mature dendritic cells are typically idenfiified as having the following cell surface marker phenotype: MAC3", CD80t, CD86'-, CD40"', CD54+, MHC Class I and MHC Class II, and are capable of FITC-dextran uptake.
APCs (e.g., DCs) can be found, by way of example, in the bone marrow or PBMCs of a mammal, in the spleen of a mammal or in the skin of a mammal (i.e., Langerhan's cells, which possess certain qualities similar to that of DC, may be found in the skin). For instance, bone marrow can be harvested from a mammal and cultured in a medium that promotes the growth of DCs. GM-CSF, IL-4 and/or other cytokines (e.g., TNF-a), growth factors and supplements may be included in this medium.
After a suitable amount of time in culture in medium containing appropriate cytokines (e.g., time suitable to expand and differentiate the DCs into mature DCs, e.g., 2, 4, 6, 8, 10, 12, or 15 days), clusters of DCs are cultured in the presence of a sufficient number of antigens of interest (e.g., in the presence of eancer stem cell lysate, acid eluted peptides of cancer stem cells, peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1(Msi1), maternal embryonic leucine zipper kinase (MELK), GLII, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, clAP 1, c1AP2, NAIP, or survivin, or a combination of two or more of the above antigens) and harvested for use in a cancer vaccine. For example, peptide antigens can be added to the culture medium at a concentration of about 1.0 to 50, e.g., 5, 10, 15, 20, or 30 glml (per antigen).
Alternately, or in combination, antigens can be transgenically expressed in DCs, e.g., by transfection of nucleie acids encoding one or more of the antigens or portions of antigens.
In one exemplary method, APCs are isolated from a subject (e.g., a human) according to the following exemplary procedure. Mononuclear cells are isolated from blood using leukapheresis (e.g., using a COBE Spectra Apheresis System). The mononuclear cells are allowed to become adherent by incubation in tissue culture flasks for 2 hours at 37 C. Nonadherent cells are removed by washing. Adherent cells are cultured in medium supplemented with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4) for five days. On day five, TNF-a is added to the culture medium for another 3-4 days. On day 8 or 9, cells are harvested and washed, and incubated with peptide antigens for 16-20 hours on a tissue rotator. Peptide antigens are added to the cultures at a concentration of- 10 g/ml (per antigen).
Various other niethods can be used to isolate the APCs, as would be recognized by one of skill in the art. DCs occur in low numbers in all tissues in which they reside, making isolation and enrichment of DCs a requirement. Any of a number of procedures entailing repetitive density gradient separation, fluorescence activated.cell sorting techniques, positive selection, negative selection or a combination thereof are routinely used to obtain enriched populations or isolated DCs. Guidance on such methods for isolating DCs can be found in O'Doherty et al., J. Exp. Med., 178:1067-78, 1993; Young and Steinman, J. Exp. Med., 171:1315-32, 1990; Freudenthal and Steinman, Proc.
Nat.
Acad. Sci. USA, 57:7698-7702, 1990; Macatonia et al., 67:285-289, 1989;
Markowicz and Engleman, J. Clin. Invest., 85:955-961, 1990; Mehta-Damani et al., J.
Immunol., 153:996-1003, 1994; and Thomas et al., J. Immunol., 151:6840-6852, 1993. One method for isolating DCs from human peripheral blood is described in U.S. Patent No.
5,643,786.
Methods of producing DCs from embryonic stem cells are described in U.S.
Patent No.
7,247,480.
Administration of Cancer Vaccines The APC-based cancer vaccine may be delivered to a recipient by any suitable delivery route, which can include injection, infusion, inoculation, direct surgical delivery, or any combination thereof. In some embodiments, the cancer vaccine is administered to a human in the deltoid region or axillary region. In some embodimeiits, the vaccine is administered to a subject locally to the site of a tumor, within the tumor, or to an area from which a tumor has been surgically resected.
An appropriate carrier for administering the ceils may be selected by one of skill in the art by routine techniques. For example, the phartnaceutical carrier can be a buffered saline solution, e.g., cell culture media.
The quantity of APC appropriate for administration to a patient as a cancer vaccine to effc,~ct the methods of the present invention and the most convenient route of such administration may be based upon a variety of factors, as may the formulation of the vaccine itself. Some of these factors include the physical characteristics of the patient (e.g.., age, weight, and sex), the physical characteristics of the. tumor (e.g., location, size, rate of growth, and accessibility), and the extent to which other therapeutic methodologies (e.g., chemotherapy, and beam radiation therapy) are being implemented in connection with an overall treatment regimen. Notwithstanding the variety of factors one should consider in implementing the methods of the present invention to treat a disease condition, a mammal can be administered with from about 105 to about 109 APC (e.g., 107 APC) in from about 0.05 mL to about 5 mL solution (e.g., saline) in a single administration.
Additional administrations can be carried out, depending upon the above-described and other factors, such as the severity of tumor pathology. In one embodiment, from about_one to about five administrations of about 106 APC is performed at two-week intervals.
DC vaccination can be accompanied by other treatments. For example, a patient receiving DC vaccination may also be receiving chemotherapy, radiation, and/or surgical therapy concurrently. Methods of treating cancer using DC vaccination in conjunction with chemotherapy are described in Wheeler et al., U.S. Pat. Pub. No.
2007/0020297. In some embodiments, a patient receiving DC vaccination has already received chemotherapy, radiation, and/or surgical treatment for the cancer. In one embodiment, a patient receiving DC vaccination is treated with a COX-2 inhibitor, as described in Yu and Akasaki, WO 2005/037995.
Pharmaceutical Comgositions In various embodiments, the present invention provides pharmaceutical compositions including a pharmaceutically acceptable excipient along with a therapeutically effective amount of the inventive vaccine comprising dendritic cells pulsed with cancer stem cell antigens as described herein. " Pharmaceutieally acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous:
In various embodiments, the pharmaceutical compositions according to the invention may be formulated for delivery via any route of administration.
"Route of administration" may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, transmucosal, transdermal, or parenteral.
"Parenteral" refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac,,intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders.
The pharmaceutical compositions according to the.invention can also contain any pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof. Each component of the carrier must be "pharmaceutieally acceptable"
in that it must be compatible with the other ingredients of the forrnulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
The pharmaceutical compositions according to the invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration. One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, for instance, by monitoring a subject's response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed. 20th edition, Williams & Wilkins PA; USA) (2000).
Kits Kits to treat cancer are also contemplated. The kits are useful for practicing the inventive method of treating cancer with a vaccine comprising dendritic cells pulsed with cancer stem cell antigens as described herein. The kit is an assemblage of materials or components, including at least one of the inventive compositions. Thus, in some embodiments the kit contains a composition including a vaccine comprising dendritic cells pulsed with cancer stem cell antigens as described herein.
The exact nature of the components configured in the inventive kit depends on its intended purpose. For example, some embodiments are configured for the purpose of treating a particular cancer. In one embodiment, the kit is configured forthe purpose of treating brain tumors. In one particular embodiment, the brain tumor is a glioma. In another embodiment, the brain tumor is GBM. In one embodiment, the kit is configured particularly for the purpose of treating mammalian subjects. In another embodiment, the kit is configured particularly for the purpose of treating human subjects. In further embodiments, the kit is configured for veterinary applications, treating subjects such as, but not limited to, farm animals, domestic animals, and labaratory animals.
Instructions for use may be included in the kit. "Instructions for use"
typically include a tangible expression dcscribing the technique to be employed in using the components of the kit to effect a desired outcome, such as induction nf an immune response against a tumor, to treat a cancer. For example, the instructions may comprise instructions to administer a vaccine comprising dendritic cells pulsed with cancer stern cell antigens to the patient. ' Optionally, the kit also contains other useful components, such as, diluents, buffers, pharmaceutically acceptable carriers, syringes, catheters, applicators, pipetting or measuring tools, or other useful paraphernalia as will be readily recognized by those of skill in the art.
The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form;
they can be provided at room, refrigerated or frozen temperatures. 'I'he components are typically contained in suitable packaging material(s). As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as inventive compositions and the like. The packaging material is.
constructed by well known methods, preferably to provide a sterile, contaminant-free environment. The packaging materials employed in the kit are those customarily utilized in cancer treatments or in vaccinations. As used herein, the term "package"
refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the individual kit components. Thus, for example, a package can be a glass vial used to contain suitable quantities of an inventive composition containing for example, a vaccine comprising de,-ndritie cells pulsed with cancer stem cell antigens as described herein. The packaging material generally has an external label which indicates the contents and/or purpose of the kit and/or its components.
EXAMPLES
The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that spccific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One: skilled in the art.rnay develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.
Example 1. 'The 9L Gliosarcoma Cell Line Contains Self-Renewin ells To determine if a population of self-renewing stem cells exist within the phenotypically heterogeneous 9L gliosarcoma tumor, the cells were.grown as monolayers in the presence of 10% FBS and subsequently grew them in serum free media containing mitogens. A schematic diagram of culturing of tumorstem cells is presented in Fig. 2. 9L
gliosarcomas were resuspended in Dulbecco's modified Eagle's medium/F-12 medium containing 10% fetal bovine serum (FBS) and plated at a density of 1 x 106 live cells per 75 cm2 flask. The cells attached and grew as mondlayers and were passaged upon confluency. Spheres were derived by placing the 9L gliosarcomas cells grown as monolayers into a defined serum-free NSC medium (Reynolds et al., J.
Neurosci;, 12:
4565-74,1992; Reynolds et al., Science, 255:1707-10, 1992) consisting of Dulbecco's modified Eagle's rnediurn/F-12 medium supplemented with 20 ng/mL of both epidermal growth factor (EGF; Peprotech, Rock.y. Hill, NJ) and basic fibroblast growth factor (bFGF;
Peprotech, Rocky Hill, NJ). Cells were fed every 2 days by adding fresh NSC
media supplemented with growth factors. After primary spheres forined and reached 10-200 cells per sphere, the cells were harvested, dissociated into single cells using trypsin and EDTA
(GIBCO BRL) and mechanical pipetting, strained through a cell strainer, and plated at a clonal density of 1,000 cells/mL in neurosphere-conditioned medium to generate clonally dcrived subspheres (Geschwind et al., Neuron, 29:325-339, 2001; Groszer etal., Science, 294: 2186-89, 2001). The cells were fed every 2 days by adding fresh NSC media supplemented with mitogens. Cells and subsequent spheres were observed daily.for 18 days, and passaged into fresh media. Subspheres ranging from approximately 15 cells to cells were evident after 18 days and displayed the self-renewing and proliferative 35 capacity of the 9L spheres.
Subtle differences were observed in surface adhesion properties between the two cell populations when using different coating solutions. fit was found that poly-L-lysine proved less effective in binding toneurospheres than did.laminin. Even affter 2 days, only a small portion of the cells adhered (- 5%). However, when neurospheres were allowed to adhere to chamber slides coated with laminin, nearly all the cells (- 70%) adhered within the first 3 hours. As a consequence, poly-L-lysine was not used as an adhesive substrate in further studies. A similar trend was observed when comparing adhesion of monolayers to chamber slides coated with either poly-L-lysine or laminin-cellular morphology was more apparent in monolayers grown on laminin coated chamber slides within a 6 hour time period. Furthermore, a distinct morphololocal characteristic was apparent in the ditl'erentiated neurospheres, where arms of differentiated cells originating from one neurosphere homed to arms formed by another nearby neurosphere (FIG. 8A).
These examples of extracellular adhesion and cellular homing can be used to distinguish cancer stem-like cells (CSLCs) from non-CSLCs within a tumor.
Example 2. 9L Neurospheres Express NSC Markers and Can Generate Both Neuronal and Glial Cells in Culture To determine the expression of markers for stem cells, neurospheres were immunostained for NSC markers. nestin and Sox2. Neurospheres were.also stained for the lineage markers for astrocytes, OFAP, neurons, beta-tubulin III and MAP2, and oligodendrocytes, myclin/oligodendrocyte. Cells in the outer region of the neurosphere labeled for nestin, while cells throughout the neurospliere were labeled for Sox2. A large number of cells within the tumor spheres were also found to be positive for the lineage marker GFAP, while relatively few cells expressed the neuronal lineage markers 0-tubulin III, MAP2, and myelin/oligodendrocyte.
To test whether spheres have multipotent capabilities and produce progenies of different lineages, spheres were seeded into chamber slides (Lab-TekII, Nalge Nunc Internat7onal) for differentiation assay. The cells were grown for 14 days in medium devoid of growth factors bFGF and EGF but permissive for differentiation, and processed for immunocytochemistry as described below. The medium included Dulbecco's modified Eagle's medium/F-12 medium containing 10% fetal bovine serum (FBS).
To examine the expression ofNSC markers and lineage.markers,.immuncyto- and immunohistochemical staining was performed. For staining of differentiated spheres, spheres and 9L monolayers, cells growing in chamber slides were fixed with 4%
paraformaldehyde for 15 minutes at 4 C, treated with 5% NHS (normal horse serum)/0.1 % Triton-X, and then stained with the following antibodies: rabbit anti-riestin (1:200, Chemicon), rabbit anti-Sox2 (1:1,000, Chemicon), rabbit anti-MAP2 (I:I,000, Sigma), mouse anti-R-tubulin III (1:200, Chemicon), rabbit anti-GFAP (1:1000, Chemicon), mouse.anti-myelin/oligodendrocyte (1:1,000, Chemicon). The primary antibodies were detectcxi'with Cy3 or.:FITC-conjugated anti-mouse or anti-rabbit IgG
antibody (1:200, Jackson Immuno Research). 'I'he cells were counterstained with 4',6-diamidino-2-ph.enylindole (DAPI; Vector I:;aboiatoriess) to identifyall nuclei. The stained sections were examined and photographed using a QED cell scannerprograrn and Nikon Eclipse TE2000-E microscope, and analyzed using Image J(NIH). For iinmunostaining of spheres, the spheres where allowed to adhere to precoated (with laminin) chamber slides for 3 hours before fixation, while monolayers were allowed to adhere overnight in non-fixed chamber. slides.
Cells stained positive for the NSC markers.nestin and Sox2, as well as the lineage markers for astrocytes, GFAP, neurons, MAP2, and oligodendrocytes, myelin/oligodendrocyte. However, no cells were labeled with the neuronal marker beta-tubulin III. FACS analysis showed similar results to those derived via immunocytochemistry, which showed differentiated cells labeledfor nestin (88%;
FIG.
3C),Sox2 (24%), GFAP (96 /6; FIG. 3B), MAP2 (29%; FIG. 3D), and myelin/oligodendrocyte (6%; FIG. 3F), but not for (i-tubulin III (0%; FIG.
3E). For FACS
analysis, cells were fixed with 4% paraformaldehyde for 15 minutes at 4 C, treated with 5% NHS (normal horse serum)/0.1/o TritonT"'-X, and then stained with the following antibodies: rabbit anti-nestin (1:1,000, Chemicon), rabbit anti-Sox2 (1:1,000, Chemicon), rabbit anti-MAP2 (1:1,000, Sigma), mouse anti-p-tubulin IIi (1:500, Chemicon), rabbit anti-GFAP (1:1000, Chernicon), and mouse anti-myelin/oligoderxdrocyte (1:1,000, Chemicon). The primary antibodies were detected with FTI'C-conjugatcd atiti-mouse or anti-rabbit IgG antibody (1:200, Jackson Immuno Research) using 10d cells in a FACSVantageTM fluorescence activated cell. sorter (Becton Dickinson). "I'hese results indicate that these cancer stem-like cells (CSLCs), unlike normal stem cells, differentiate into aberrant cells that are positive for multiple differentiation markers, notably GFAP and MAP2. Such a dual nature is apparent in the majority of cells differentiated from neurospheres. Furthermore, many cells still remained highly positive for nestin and Sox2.
The expression pattern of the differentiated progeny was similar in profile to that of primary cultured tumor cells from which thespheres had originally been isolated and predominantly differentiated into GFAP and MAP2 positive cells that recapitulated the parental tumor phenotype. Additionally, the level of labeling for the NSC
markers nestin and Sox2 still remained high, even after 14 days of differentiation. The staining pattern for the monolayer population was similar to neurospheres differentiated for 14 days, except for the expression of Sox2, which was greater in neurospheres differentiated for 14 days.
These results reveal that 9L spheres are multipotent for the three neural cell types and differentiate into cells found in the original tumor from which they were obtained.
Example 3. The Aizuressiveness of 9L Cells in vivo is Reliant on the Neurosphere Cancer Stem-Like Cells To detennine if 9L cells grown as monolayer or neurospheres differ in their ability to grow as a tumor after implantation 5,000 cells from both populations of cells were injected into rats and survival and tumor volume were assayed.
Fisher F344 rats 6-8 weeks old (Harlan Sprague-Dawley, Indianapolis, IN) were anesthetized with i.p: ketamine and xylazine, and stereotactically implanted in the right striatum (from bregma in mm: anterior-posterior +1 mm; medial-lateral -3 mm;
dorsal-ventral -5 mm) with either isolated 9L sphere cells containing the luciferase gene (5,000 cells) or non-sphere-forming monolayer cells containing the luciferase gene (5,000 õells) in 4 L of 1.2% methylcellulose/PBS (Rehemtulla et al., Neoplasia, 2:491-495, 2000).
Rats were portioned to either the tumor volume group (n =10) or the survival group (n =
18), with control rats (n = 6) receiving 4 L of 1.2% methylcelluloselPBS only.
Because half of each group consisted of either animals implanted with spheres or monolayers, tumor aggression could be detennined. Animals in the tumor volume group were sacrificed 18 days after tumor implantation. Tumor volume was assessed by using the formula for an ellipsoid, (length x width x height)/2 (Advani et al., Cancer Res., 59:2055-58, 1999), with the height and the width of the tumor being approximately equal because of the well-defined circumference of the tumors generated by the 9L
gliosarcoma (see Sibenaller et al., Neurosurg. Focus, 19:E1, 2005). A significantly (P <
0.02) greater tumor volume was observed in the rats implanted with neurosphere cells as compared to rats implanted with monolayer cells (FIG. 4A).
Animals in the survival group were followed for survival and euthanized via asphyxiation when terminal neurological signs developed (e.g., inability to aeccss food, water, seizure activity, weakness, and paralysis) or if animals exceeded a survival period of 40 days. Following euthanization, brains were harvested and frozen in 2-methylbutane (Sigma), cooled to -20 C, and stored at -80 C until sectioning. For H&E
staining, 20 m coronal brain sections described above were mounted on slide and stained with Harris hematoxylin for 2 minutes and then counterstained with alcoholic eosin.
Reticulin stains were performed on 12 m coronal brain sections.
Similar to the results seen in the tumor size groups, rats implanted with neurospheres on average had shorter survival times than rats implanted with monolayer cells (FIG. 4B). Six rats in the neurosphere goup had large tumors that lead to terminal neurologcal symptoms, whereas 3 showed evidence of small tumors after 40 days of survival as seen by H&E staining of brain sections. In contrast, only 4 rats had tumors large enough to create terminal neurological symptoms in the monolayer group, whereas 5 showed evidence of small tumor or engraftment after 40 days of survival as determined by H&E staining. Furthermore, the rats in the monolayer group which developed terminal neurological signs of tumor did so at a later time (36 days compared to 29 days in the neurosphere group), which was significant when analyzed using the Kaplan-Meicr test (P
< 0.02).
To determine the establishment of tumor in vivo, 150 mg/kg of the luciferase substrate D-luciferin (Biosynth, International, Inc., Naperville, IL) was administered i.p. to animals in the survival group, and luciferase scans were taken 15 minutes later. Luciferase scans generated at 14 days post implantation demonstrated a greater proportion of animals with tumor burden in the neurosphere group compared to the monolayer group,.
even though a higher expression level of luciferase in vitro was observed in monolayer cells as compared to neurosphere cells.
'To determine if the 9L neurospheres could recapitulate the 9L sarcoma in vivo, histological analysis of the tumors was performed. The tumor-cell-implanted rat brains were cut with a cryostat into 20 m coronal sections and fixed in 4%
paraformaldehyde, washed with PBS, and air dried. To characterize the brain tissue by immunohistochemistry, free-floating sections were blocked with 5% NHS (normal horse serum) for 30 minutes at room temperature and then stained with the following antibodies:
rabbit anti-nestin (1:200, Chemicon), rabbit anti-Sox2 (1:1,000, Chemicon), rabbit anti-MAP2 (1:1,000, Sigma), mouse anti-(3-tubulin 111 (1:200, Chemicon), rabbit anti-GFAP
(1:1000, Chemicon), mouse anti-myelin/oligodendrocyte (1:1000; Chemicon). The primary antibodies were detected as in Example 1. The cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories) to identify all nuclei. The stained sections were examined and photographed using the Zeiss Axiovision 3.1 program in conjunction with Zeiss AxioskopT"" 2 microscope, and analyzed using Image J
(NIH).
Tumors from the neurosphere cell population were large and well-circumferential, and showed cells positive for the NSC marker nestin, as well as cells positive for the lineage markers GFAP, 0-tubulin III, and myelin/oligodendrocytes. Most of the labeling within the tumor volume was directed against GFAP, and a lesser degrce of labeling was observed for (i-tubulin III, myelin/oligodendrocyte, and nestin. A significant portion (>
75%) of the tumor volume stained positive for reticulin, consistent with a sarcomatous component. Additionally, H&E staining revealed a high grade glioma with necrosis consistent with a glioblastoma, displaying the dual naturc of the gliosarcoma.
Neurospheres formed high grade gliomas with necrosis as seen on H&E (FIG. 5A).
The tumors were large and well circwnferential as evidenced in non-stained sections (FIG. 5B) and stained for the nuclear marker DAPI (FIG. 5D). A comparison of non-tumor area (FIG. 5D) with tumor area (FIG. 5E) stained for reticulin revealed high levels of reticulin in tumor engulfed regions, showing the histological sarcomatous component of the gliosarcoma. The staining pattems suggest that 9L neurospheres recapitulated the original tumor by differentiating into both neural and glial lineages in vivo.
Example 4. Proliferation Rate and Drug Sensitivityof 9L Neurospheres To compare the differential proliferation rates and resistance to chemotherapeutic agents, 2,000 healthy 9L sphere and monolayer cells were exposed to either Dulbecco's modified Eagle's medium/F-12 medium containing 10% fetal bovine serum (FBS), or 100 M stock solution of Temozolamide or Carboplatin dissolved in PBS at concentrations of 1,000 M, 500 M, 250 M, and 125 M for 2 days. The viability of the cells was scored by measurement of the absorption of formazan dye (the amount of formazan dye formed directly correlates to the number of metabolically active cells) using the cellular proliferation assay WST-1 (Roche Molecular Biochemicals, Mannheim, Germany).
Formazan was measured with the use of a microplate reader (Tecan) and spectrophotometer set at a wavelength of 440 nm and a reference wavelength of 890 nm.
Cellular viability was determined by exposing cells to WST-] for 4 hours, and calculating the percentage of viable cells. Proliferation was also assessed by using manual cell counting after 7 days in culture, with an initial cellular concentration of 100,000 cells/mL
in a 25 mmZ flask.
The neurospheres demonstrated significantly (P < 0.05) greater resistance to temozolamide (FIG. 6B) and carboplatin (FIG. 6A) when compared to the 9L cells grown as a monolayer under the same conditions. When the celis were not treated with the chemotherapeutic agents and simply grown in medium, there was a significantly (P < 0.05) greater increase in cell number in the monolayer group by a factor of 1.48 when using the WST-1 proliferation assay when the cells were not treated with the chemotherapeutic agents. The results of the proliferation assays are depicted in FIG. 7, which is a bar graph that shows a greater increase in cells in the monolayer group. A similar trend in the untreated cells was also observed using the manual cell count metliod, which showed a greater increase in monolayers by a factor of 1.35. This example demonstrates that neurosphere cells have a.greater resistance to chemotherapeutic agents.
Example 5. Isolation of Human CD133-Positive Cancer Stem Cells Glioblastoina specimens were obtained froin patients (with inforned consent) via the Brain Tumor Registry and were reviewed and released by a pathologist in the operating room. Independent pathologists classified the tumors by type and grade in accordance with the WHO histological grading of central nervous system tumors. IRB
certified technicians processed the glioma tissues under sterile conditions in a laminar flow hood.
Tumor cells were cultured in the following complete medium:.I3am's F-12/DMEM
with high glucose (Irvine scientific, Santa Ana, CA), 10 mM HEPES (Invitrogen, Carlsbad, CA), 0.1 mg/ml Gentamicin (Invitrogen) and 10% heat-inactivated FBS (Irvine Scientific, Santa Ana, CA). The cultured cells were maintained for 3-4 passages. Floating neurosphere-like cells wcre obtained that were capable of forming new spheres.
in medium containing FBS for 3-4 passages.
Three adult glioblastoma primary tumor cell lines (Nos. 1049, 377, and 66) were derived by the above method and analyzed by FACS for CD133 expression. Tumor cells were collected and stained with anti-CD133 antibody (mouse monoclonal IgG1; 1:
10;
Milteny Biotec) or IgG I isotype control antibody(BD Pharmingen, San Diego, CA).
After PE-anti-mouse IgGI (BD Pharmingen) staining for 30 minutes, CD133 staining was analyzed by flow cytometry using a FACSCaliburTm fluorescence activated cell sorter (Becton Dickinson, San Jose, CA). CD133 expression was observed in 10:2% (No.
66;
FIG. 9C), 27% (No. 1049, FIG. 9A) and 69.7% (No. 377; FIG. 9B) of the total population examined.
To investigate the capacity of self-renewal and clonogenic potential of CD133+
cell, a single isolated CD133 positive cancer stem cell was isolated by DAKOcytomationT'" (DAKO, Carpinteria, CA) sorting and cultured in a defined serum-free NSC medium (Kabos et al., Exp. Neurol., 178:288-293, 2002) containing 20 ng/ml of basic fibroblast growth factor (bFGF, Peprotcch, Rocky Hill, NJ), 20 ng/ml of epidermal growth factor (EGF, Peprotech) and 20 ng/ml leukemia inhibitory factor (LIF, Chemicon, Temecula, CA). Single isolated CD133 positive cancer stem cells were able to form neurospheres (FIG. 8A), and were demonstrated to have the capacity for self-renewal and clonogenic potential (FIG. $B), and sustained expression of CD133 in serum-free medium containing EGF/FGF (FIG. $C).
Example b Human CD133 Positive Tumor Cells Express Markers Associated With Neural Precursors To determine the expression of other genes in CD 133 positive cells, CD 133 positive cells and CD133 negative cells were obtained by FACS sorting as described in Example 5 and real-time PCR was used to analyze some markers associated with neural precursors in.these two populations. 'Total RNA was extracted from the isolated CD133 positive and CD133 negative cells using an RNA4PCRTM kit (Ambion, Austin, TX) according to the manufacturer's protocol. For eDNA synthesis, -l g total RNA
was reverse-transcribed into cDNA using Oligo dT primer and iScriptT'" cDNA
synthesis kit reverse transcriptase. cDNA was stored at -20 C. Gene expression was quantified by real-time quantitative RT-PCR using QuantiTect''"' SYBR Green dye (Qiagen, Valencia, CA). DNA amplification was carried out using IcyclerT"" (BIO-RAD, Hercules, CA), and the detection was perfonned by measuring the binding of the fluorescence dye SYBR
Green I to double-stranded DNA. All the primer sets were obtained from Qiagen (see Table l).
Table 2. Oiieonucleotide primers sequences used for SYBR Green real=time PCR
Gene Fortivard Reverse Beta- 5'-TTCTACAATGAGCTGCGTGTG-3' 5'-GGGGTG'1"I'GAAGG'I'CTCAAA-3' actin (SEQ ID NO:1) (SEQ ID NO:2) CD133 5'-GCATTGGCATCTI'CTATGGTT-3' 5'-CGCCTTGTCCTI'GGTAG'fGT-3' (SEQ ID NO:3) (SEQ ID NO:4) MSIl 5'-GAGACTGACGCGCCCCAGCC-3' 5'-CGCCTGGTCCAT'GAAAGTGACG-3' (SEQ ID NO:5) (SEQ IDNO:6) MELK 51-CTI'GGATCAGAGGCAGATGI'T"TGGAG-3' 5'-GTTG"rAATCTTGCATGATCCAGG-3' (SEQ ID NO:7) (SEQ ID NO:8) PSP 3-GGCGGGGCAGTGCCITTCAAA-3' 5'=TG'ITGGCTGCGTCTCATCAAAACC-3' (SEQ ID NO:9) (SEQ ID N0:10) CD90 5'=CGC1'CTCCTGCTAACAGTCTT-3' 5'-CAGGCTGAACTCGTACTGGA-3' .(SEQ IDNO:11) (SEQ,ID NO:12) NESTIN 5-ATCGCT'CAGGTCCTGGAA-3' 5'-AAGCTGAGGGAAGTCTTGGA-3' (SEQ ID NO:13) (SEQ ID NO:14) CD44 5'-AGAAGG'TGTGGGCAGAAGAA-3' S'-AAATGCACCA'I'TTCCTGAGA-3' (SEQ ID NO: 15) (SEQ ID NO: 16) GLII 5'-AGGGAGGAAAGCAGACTGAC-3' 5'-CCAGTCATTTCCACACCACf-3' (SEQ ID NO: 17) (SEQ ID NO: 18) CXCR4 5'-GATCAGCATCGACTCCTTCA-3' 5'-GGCfCCAAGGAAAGCATAGA-3' (SEQ ID N0:19) (SEQ ID NO:20) Bmi-1 5'-GGAGACCAGCAAGTATTGTCCTT'I'TG-3' 5'-CATTGCI'GCTGGGCATCGTAAG-3' (SEQ ID NO:21) (SEQ ID NO:22) PTCHI 5'-CGCCTATGCCTGTCTAACCATGC=3' 5'-AAATGGCAAAACCTGAGTTG-3' (SEQ ID NO:23) (SEQ ID NO:24) Snail 5'-ACCACTATGCCGCGCTCTT-3' 5'-GGTCGTAGGGCTGCI'GGAA-3' (SEQ ID NO:25) (SEQ ID NO:26) SIRT1 5'-ACTTGTACGACGAAGACGAC-3' 5'-CAGAAGGTTATC'I'CGGTACC-3' (SEQ ID N0:27) (SEQ ID NO:28) Survivin 5'-TGCCTGGCAGCCCTITC-3' 5'-CCTCCAAGAAGGGCCAGTI'C-3' (SEQ ID NO:29) (SEQ ID NO:30) CIAP1 5'-CAGCCTGAGCAGCTTGCAA-3' 5'-CAAGCCACCA'I'CACAACAAAA-3' (SEQ ID NO:31) (SEQ ID NO:32) CIAP2 5'-TCCGTCAAGTI'CAAGCCAGTT-3' 5'-TCTCCTGGGCTGTCTGATGTG-3' (SEQ ID NO:33) (SEQ ID NO:34) NAIP 5'-GCITCACAGCGCATCGAA-3' 5'-GCTGGGCGGATGCITfC-3' (SF..Q ID NO:35) (SEQ ID NO:36) XIAP 5'-AGTGGTAGTCCfG'I'TTCAGCATCA-3' 5'-CCGCACGGTATCTCCfTCA-3' (SEQ ID N0:37) (SEQ ID NO:38) BCL-2 5'-CATGCTGGGGCCGTACAG-3' 5'-GAACCGGCACCTGCACAC-3' (SEQ ID N0:39) (SEQ ID N0:40) BCL-XL 5'= CGCATI`GTTCCCATAGAGTfCCA-3' 5'-CCTGA:A'I'GACCACCTAGAGCCTT-3' (SEQ ID NO:41) (SEQ ID NO:42) FLIP 5'-CATCCACAGAATAGACCTGAAGACAA-3' 5'-(SEQ ID NO:43) GCTTGGAGAACA CfCCI'GTAACTfG-3' (SEQ ID NO:44) BAX 5'-TGG AGCTGCAGAGGATGATTG-3' 5'-GAAGTI'GCCGTCAGAAAACATG-3' (SEQ ID NO:45) (SEQ ID NO:46) BCRP-1 5' TGGCTGTCATGGCTFCAGTA-3' 51-GCCACGTGA'C'TCITCCACAA-3' (SEQ ID NO:47) (SEQ ID NO:48) MGMT 5'-C'I'.GGCI'GAATGCCTACTI CC=3' 5'- CAACC1TCAGCAGCITCCAT-3' (SEQ Il) NO:49) (SEQ ID NO:50) OCT4 5'-CCTGAAGCAGAAGAGGATCA-3' 5'-CCGCAGCT'I'ACACATGITCT-3' (SEQ ID NO:51) (SEQ ID NO:52) Quantification of target genemRNA as compared to an internal control (beta-actin) was performed by following a. C=1= method. An amplification plot that had been the plot of tluorescence signal vs. cyele number was drawn. The difference (ACT) between the mean values in the duplicated samples of target gene and those of beta-actin were calculated by Microsoft Excel and the relative quantified value (RQV) was expressed as 2-cT. The relative expression of each gene was compared to autologous CD133 negative cells. The.results ofthe QT-PCT analysis are presented in Table 3.
Table 3. Relative Expression of Genes in CD133+ Cancer Stem Cells No. 66 No. 377 No. 1049 Gene name CD133- CD133+ CD133- CD133+ CD133- CD133+
CD90 1 15.6 0.66 1 12.8~0.94 1 13.5:E 0.75 CD44 1 5.70.48 1 2.5~0:22 1 2:8+0.19 337,8t 251.53= 264.9t CXCR4 1 l 1 29.2 22.1 22.9 Nestin 1 21:4 1.25 1 23.2 1.65 1 22.1 + 1.54 MSI . 1 84 t 7.6 1 75.4 + 7.03 1 53.5 f 6:2 467.7 ~ 514.6 MELK 1 1351195.8 1 ~~ 1 40:5 45.6 GLI-1 .1 46 3.8 1 4314.5 1 49~5.9 PTCH 1 164:1.48 1 13.5 0.85 1 14.3t1:24 MGMT 1 32.4t2:5 1 34.7 2.9 1 56.3+4:2 BCRPI 1 .6:5 0.43 1 4r3 0.25 1 4.8 Ø24 SIRTl 1 4:9 034 1 4.2 0.26 1 5.4 0.29 FLIP 1 294 25.5 1 157.6t 1 145.6 14.2 13.7 BCL-2 1 13.9 0.95 1 4.9 0.54 1 3.8t0.54 BCL-XL 1 5.6~0.39 1 3.2 0.16 1 2.5t0.14 cIAPl 1 39.0 4- 3.5 1 4.3 0.53 1 5.6 0.65 cIAP2 1 3 0.25 1 1.9t0.12 1 1.7 0.14 XIAP 1 21.9 2:2 1 9.7 0.68 1 10.3 0.91 NAIP 1 12.1 0.75 1 6.4 0.43 1 4.5 f 0.62 Survivin 1 1.6-10.08 1 2.3 0.18 1 2.4~0.18 BAX 1 0.33 0.03 1 0.49 0.06 1 0.21 ~ 0.05 CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi 1), and maternal embryonic leucine zipper kinase (MELK) mRNA expression on CD 133 positive cancer stem cells was upregulated by an average of 15.6, 5.7, 337.8, 2.14, 84, and 1351 fold, respectively, compared to the levels found on autologous CD133 negative tumor cells. mRNA
levels for GLI1 and PTCH1 were upregulated an average of 46 and 16 times, respectively, in CD133 positive cells, as compared to CD133 negative cells. Furthermore, Bmi-1, phosphoserine phosphatasc (PSP), SI-IH, OCT4 and Snail mRNA were expressed in CD133 positive cells derived from the three cell lines; none of the five genes were detectable on CD133 negative cells. Additionally, anti-apoptotic genes were also upregulated (see Example 8).
Example 7. CD133 Positive Cancer Stem Cells Are Resistant to Chemotherapeutic Aeents To detennine whether CD133 positive cancer stem cells were resistant to chemotherapeutic agents, the WST-1 Cell Proliferation Assay was used to examine the drug sensitivity of CD 133 positive cells and CD 133 negative cells (both collected by FACS sorting from the three glioblastoma patients' primary cultured tumor cells as described above). CD133 positive and negative cells were exposed to conventional chemotherapeutic agents, temozolomide, carboplatin, VP- 16 or taxol at various concentrations, for up to 48 hours in 10% FBS/F-12/DMEM culture medium.
Temozolomide was supplied by the Schering-Plough Research Institute (Kenilworth, NJ) and was dissolved in DMSO (Sigma Chemical Co., St Louis, MO) at 100 mM stock solution. Carboplatin, etoposide (VP-16) and paclitaxel (Taxol) were obtained from Sigma-Aldrich (St. Louis, MO). CD133 positive cells isolated from No. 66 showed dramatic drug resistance to the above four agents including temozolomide (FIG.
I OC), carboplatin (FIG. lOD), VP- 16 (FIG. l0A), and Taxol (FIG, lOB) as compared to autologous CD133:negative cells. CD133 positive cells isolated from No. 377 showed significant resistance to carboplatin at all concentrations tested (FIG. 11A) and. to V'P-1.6 at 200 M (FIG.11B). CD133 positive cells isolated from No. 1049 showed significant resistance to carboplatin at 200 M compared to autologous CD.133 negative cells (FIG.
1 i C). This example demonstrates increased drug resistance of CD 133 positive cancer stem cells as compared to autologous CD133 negative cells.
Example $ Anti-Apontotic Genes Are Upregulated in CD133 Positive Cancer Stem Cells Real-time PCR of FACs-sorted CD139 positive and CD133 negative cells was used to investigate the relative expression of multi-drug resistance genes and genes related to inhibiting cell apoptosis between these two populations. BCRP1 has been demonstrated to play an important role in the drug resistance of normal stem cells and tumor stem cells (Zhou et al., Nat. Med., 7:1028-34, 2001; Hirschmann-Jax et al., Proc. Natl.
Acad. Sci.
USA, 101: 14228-33, 2004). Higher expression of BCRP 1(6.5 fold) was found in positive cells as compared to that of autologous CD133 negative cells.
Furthermore, anti-apoptotic genes, such as FLIP, BCL-2, and BCL-XL, were found at significantly higtier levels (294,139and:5.6 times higher) in CD133 positive cells than in CD133 negative cells. Also, inhibitorof apoptosis protein (IAPs) familymernbers; XIAP, cIAPl, cIAP2, NACP, and survivin were found at higher expression levels on CD133 positive cells 21.9, 39.04, 3.03, 12.1, 6.73, and 1.6 times higher, respectively, than in CD133 negative cells. It has been demonstrated that SIRT1 deacetylates the DNA repair factor Ku70, causing it to sequester the pro-apoptotic factor, Bax, away.from mitochondria, thereby inhibiting stress-induced apoptotic cell death (Cohen et al., Science, 305:390-392, 2004). SIRT1 deacetylase mRNA.expression was increased 4.92 times in CD133 positive cells.
The pro-apoptotic gene BAX was decreased 3 times in CD133 positive cells as compared to autologous CD 133 negative cells. 'Ifius, gene cxpression differences were observed in CD133 positive cells as compared to CD133 negative cells.
Example 9. Recurrent.Glioblastomas Express.Hig_her LevelsofCD133 Malignant glioma is a highly recurrent tumor even after surgery, chemotherapy, radiation and immunotherapy. To address the potential role of CD133 positive tumor cells in glioblastoma recurrence, the CD133 expression upon first and second resection of tumor tissue from the same patient were compared. We obtained primary tumor tissue from five pathological confirmed grade IV astrocytoma (GBM) patients, and thenre-operated following radiation, chemotherapy, and/or immunotherapy to obtain rccurrent tumor tissue. RNA extraction and RT-PCR was performed for CD133 as described above.
For all tested patients, CD133 expression was significantly higher in recurrent tumor tissue (relative expression -2.5-19.1) than that in autologous primary tumor tissue (relative expression -l)(FIG. 12). This example implicates a resistant CD133 positive tumor population in tumor recurrence.
Example 10lmmuni7.ation With Cancer Stem Cell Antigens Increased Survival A dendritic cell vaccine was.generated using antigens from neurospheres, daughter cells, and monolayer cells. Immature dendritic cells were generated from the bone marrow of 6-12-week-old Fisher F344 rats as previously described (Talmor et al., Eur.
J.
Immunol., 28:811-817, 1998). Briefly, bone marrow was harvested from the femoral and tibial marrow cavities and cultured in RPMI 1640 media supplemented with.10%
fetal bovine serum (Gemini Biotechnologies, Calabasas, CA), 1%
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 50 ng/ml recombinant rat GM-CSF and 100 ng/ml recombinant rat IL-4 (R & D Systems, Minneapolis, MN). Cultures were fed every 2 days by removing 75% of the media and replacing it with fresh media containing cytokines (this washed away most of the lymphocytes and granulocytes). To determine the percentage of immature dendritic cells generated and cultured from the bone marrow of Fisher rats after 1 week of exposure to GM-CSF and IL-4, FACS analysis was run on cells immunostained with antibodies for CD86 (costimulatory marker B7-1; DC marker), CD80 (costimulatory marker B7-2; DC marker), CD3 (T cell marker), or MHC II (DC marker). The dendritic cell populations obtained were positive for CD86, CD80, and MHC II, while negative for CD3.
Soluble peptides were generated for dendritic cell pulsing by cell lysis. 9L
neurospheres, daughter cells, and monolayer (adherent) cells were processed in the laboratory to produce a single cell suspension. The cells were then lysed by 4 to 5 freeze cycles (on liquid nitrogen) and thaw cycles (room temperature). Lysis was monitored by tight microscopy, and larger particles were removed by centrifugation (10 minutes at 600x g). The supernatants were passed through a 0.2 m filter, and protein concentrafion was determined by BioRad protein assay and aliquots frozen at -80 C until use.
To establish intracranial tumors, adult Fisher F344 rats were stereotactically inoculated in the right corpus striatum (from bregma in mm: anterior-posterior +1 mm;
medial-lateral -3 mm; dorsal-ventral -5 mm) with 25,000 9L-luciferase tumor cells as described above. For vaccination of the rats, freshly cultured immature dendritic cells were cocultured overnight for 24 hours with 80-100 g of cell lysate one day prior to the vaccination at days 7, 14, and 21 post-operatively. Vaccinations were given subcutaneously in the flanks on days 7, 14, and 21 with 50,000 DCs pulsed with antigens from either 9L neurospheres (NS), daughter cells (DtC), monolayer (adherent) cells (AC), or saline control. The animals were followed for survival and euthanized when terminal neurological signs developed, for example, inability to access food, water, seizure activity, weakness, and paralysis.
Tumor bearing rats injected with three successive vaccines (once per week) of dendritic cells pulsed with control, AC , DtC, or NS antigens, had median survival dates of 26.5, 32, 29 and 50 days, respcctively (FIG. 13). Kaplan-Meier analysis showed that rats treated with 9L neurosphere lysate-pulsed DC had significantly longer survival time than each of the other groups (p = 0.0015).
Example 11. DCs Pulsed With Cancer Stem Cell Antip-ens Induced a Strong Cvtotoxic T
Cell Resnonse Against 9L Tumor Cells To determine whether the relative protective effect of NS-DC vaccination on survival. is due to tumor-specific immuriity, a cytotoxic T lymphocyte (CTL) assay was performed. Spleens were removed on day 28 post-intracranial 9L-luciferase tumor cells implantation from groups of rats treated with either control or 9L peptide-pulsed dendritic cells. Splenocytes were isolated and re-stimulated in vitro, as described (Wunderlich et al., "Assays for T-cell function," In: Coligan et al., eds., Current Protocols in Immunology, New York, NY, John Wiley & Sons, Inc;1997:3.11.1-3.11.20; Ehtesham et al., J.
Immunother., 26:107-116, 2003) with either irradiated (10,000 rads) 9L
adherent cells (AC), daughter cells (DtC) or neurospheres (NS). The effector: target (E:T) ratio was 6:1.
Re-stimulated cells were cultured in RPMI-1640 with 10% fetal bovine serum, 1%
penicillin-streptomycin, and 1% HEPES in 6-Well flat-bottom plates in a humidified 37 C, 5% COz incubator. Cells were incubated for 11 days with addition of IL-2 (300 units/mL) every 3 days. After 11 days of re-stimulation, the.cells were re-exposed to their initial target (i.e., irradiated 9L AC, DtC, or NS). 24 hours later, culture media was harvested from the remaining cells and used for IFNy protein quantification by ELISA
(Ehtesham et al., J. Immunother., 26:107-116, 2003). Re-stimulated splenocytes from rats treated with NS pulsed DCs showed significantly higher IFNy release in response to exposure to tumor cell targets than re-stimulated splenocytes from rats treated with AC or DtC
(FIG. 14), indicating that a higher cytotoxic T cell response was obtained in the NS-DC
vaccinated rats. These data were also confirmed by PCR for IFNy levels (dat:a not shown).
The higher IFNy response in the NS-DC vaccinated group corresponds to the higher survival rate observed in the same group. These data show that a cancer stem cell antigen vaccine targets tumor cells more potently than vaccines based on tumor antigens from daughter cells, or cell populations that are not.enriched for cancer stem cells.
Example 12. Intracranial T-Cell Infiltration Is Associated With .Prolonged Survival A representative number of brains from DC-DtC and DC-NS vaccinated rats were carefully removed and post-fixed in 4% paraformaldehyde. Coronal sections of 20 m were cut on a cryostat and blocked with normal horse serum for I hour. Slides were then incubated with anti-CD4 (clone OX-38 monoclonal antibody diluted in 1:200 in PBS) for 2 hours at room temperature, followed by. a 20 minute incubation at room temperature with the linking antibody (BioGenex biotinylated anti-mouse immunoglobulin). After washing in PBS, the labeled moiety (BioGenex Horse Radish Peroxidase-conjugated streptavidin) was added for 20 minutes at room temperature. DAB (3,3'-diaminobenzidine) was used as the chromogen. For analysis of CD8 expression, slides were incubated overnight with Anti-CD8 alpha Chain, clone OX-8 antibody (Chemicon).
Immunohistochemical assessment of brain sections from rats vaccinated with dendritic cells pulsed with NS vaccinated showed that there was a robust infiltration of CD4+ (FIG. 15B) and CD8 + lymphocytes that was not observed in the brain sections obtained from rats vaccinated with dendritic cells pulsed with daughter cell antigens (FIG.
15A). This infiltration of T cells correlates with increased survival of rats vaccinated with NS pulsed DCs.
Example 13. Cancer Stem Cells Express MHC. Unlike Normal Stem Cells Five glioblastoma multiforme (GBM) cancer stem cells (CSC) were generated by the methods described in Yuan et al. (Oncogene, 23:9392-9400, 2004). Briefly, tumor specimens were obtained within half an hour of surgical resection from five adult GBM
patients, as approved by the Institutional Review Boards at the Cedars-Sinai Medical Center. Tumor tissue was washed, minced, and enTymatically dissociated (Reynolds et al., Science,.255:1707-10,1992). Tumor cells were.resuspended in DMEM/F12 medium containing 10% fetal bovine serum (FBS) as growth medium and plated at a density of 2x 106 live cells per 75 emZ flask. The cells attached and grew as a monolayer in flasks.
All the five monolayer growing adult GBM cells were switched into a defined serum-free NSC medium (Reynolds et al., Science, 255:1707-10,1992) containing 20 ng/ml of basic fibroblast growth factor (bFGF, Peprotech, Rocky Hill, NJ) and 20 ng/ml of epidermal growth factor (EGF, Peprotech). Normal human fetal neural stem cells (NSC) were cultured in the same defined serum-free medium as for cancer stem celis. CSC
and NSC
cells were stained by FITC-HLA-A,B,C antibody and isotype control antibody (BD
Bioscience, San Diego, CA) and analy-ced by flow cytometry. Representative CSC
and NSC results were shown in the FIGs. 17A-17B and 18A-18B, respectively.
HLA expression was seen in 5 of 5 cancer stem cells from different patients.
CSCs expressed high levels of HLA-A,B,C, however, NSC did not expression MHC class I
(HLA-A,B,C) antigens on the surface. This unexpected result indicates that specific cancer stem cell antigens on cancer stem cells can be targeted using vaccines that generate T cells that recognize and kill cancer stem cell antigens in the context of MHC. Therefore cancer stem cells will be targeted, whereas normal stem cells will not.
Example 14. Isolation of CD133 T Cell Epitopes A nucleic acid encoding a portion of CD133 extracellular domain 1(amino acid residues 116-270 of SEQ ID NO:53) is used in cloning and expression on the surface of DC. DC are transfected with CD133-1 cDNA constract or empty vector (mock) for hours. The successful transfection of DC-CD133 cells is identified either by anti-CD133 monoclonal antibody using flow cytometry. or by EGFP cloned vector under fluorescent microscopy.
Antigen presenting cells with CD133 receptor are stimulated by CD133 T cell epitopes. Overlapping peptides ofS-10 amino acids of residues 325-350 of SEQ
ID
NO:53 are produced as.MHC class I epitopes. Similarly, overlapping peptides of.13-20 amino acid of residues 325-350 are produced as .MHC class 11 epitopes.
Stimulated APC
using the peptide epitopes lead to enhanced production of CD8 T celis targetcd to CD133 molecular on stem/progenitor cells in brain tumors.
OTHER EMBODIMENTS
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the. scope of the following claims.
The present application describes compositions useful as vaccines for treating cancer (e.g., neural cancers, e.g., gliomas) that include dendritic cells pulsed with antigens obtained from cancer stem ceils (e.g., neurospheres); methods of producing vaccines that include dendritic cells pulsed with antigens obtained from cancer stem cells;
methods of treating cancer with vaccines that include dendritic cells pulsed with antigens obtained from cancer stem cells; and kits for treating cancer that include dendritic cells pulsed with antigens obtained from cancer stem cells.
Greater tumor infiltration of cytotoxic T-cells was observed in animals vaccinated against cancer stem cell antigens, and a stronger response against tumor cells was observed in T cells isolated from aiiimals vaccinated with cancer stem cell antigens, than in responses in which antigens were not prepared from stem cell enriched cell populations.
Cancer stem cells obtained from brain tumors were capable of self: renewal and proliferation, and could recapitulate the tumor when injected into rats.
Isolated cancer stem cells formed more aggressive tumors as comparedto differentiated tumor cells in vitro, and the cancer stem cells showed a higher resistance to chemotherapeutic agents.
Similarly, CD133-positive cancer stem cells were obtained from human tumors.
These cells were similarly resistant to chemotherapeutic agents and CD133-positive cells were found at a higher level in patients in whom tumors had recurred following resection.
Vaccination Methods Described herein are methods of vaccinating a subject, e.g., to treat cancer (e.g., neural cancer, e.g., gliomas) with antigen-presenting cells ("APC"), e.g., dendritic cells ("DC"), that include antigens from cancer stem cells, e.g., presented on the surface of the antigen-presenting cells. Dendritic cells (e.g., autologous or allogeneic dendritic cells) are contacted with cancer stem cell antigens as a cell lysate, acid elution, cell extract, partially purified antigens, purified antigens, isolated antigens, partially purified peptides, purified peptides, isolated peptides, synthetic peptides, or a combination of two or more of the above. The antigen-presenting cells are then administered to a subject in need of cancer vaccination (e.g., a subject diagnosed with or at risk for cancer) to treat the cancer. Figure 1 is a schematic diagram of an exemplary process for vaccination of a patient with cancer stem cell antigen-pulsed dendritic cells.
Cancer Stem Cells The "cancer stem cell" hypothesis proposes that only a small portion of a tumor is represented by the "cancer stem cell," which allows the tumor to proliferate and self renew, and eventually differentiate into the phenotypically diverse and heterogeneous tumor cell population (Bjerkvig et al., Nat. Rev. Cancer, 5:899-904, 2005).
Cancer stem cells can be isolated from any type of cancers, e.g., leukemias (Bonnet and Dick, Nat.
Med., 3:730-737, 1997), breast cancers (Al-Hajj et al., Proc. Nati. Acad. Sci.
USA, 100:3983-88, 2003), colon cancers (O'Brien et al., Nature, 445:106-110, 2007), and brain cancers (Singh et al., Nature, 432:396-401, 2004; Hemmati et al., Proc. Nati.
Acad. Sci.
USA, 100:15178-83,2003; Singh et al., Cancer Res., 63:5821-28, 2003; Sanai et al., N.
Engl. J. Med., 353:811-822, 2005; Tunici et al., Mol. Cancer, 3:25, 2004).
Cancer stem cells are characterized by their ability to self-renew and proliferate, and recapitulate through differentiation the tumor from which it is isolated. Additionally, neural cancer stem cells form clonally derived neurospheres in culture.
Cancer stem cells can be isolated by dissociating tuinor cells and culturing them under conditions that promote proliferation of stem cells (e.g., conditions that inhibit differentiation of the stem cells). Methods and conditions for isolating stem cells are known in the art. Exemplary methods and conditions can be found in U.S. Patent No.
5,589,376, U.S. Patent No. 5,643,741, U.S. Patent No. 5,650,299, U.S. Patent No.
5,824,489, U.S. Patent No. 5,849,553, U.S. Patent No. 5,928,947, U.S. Patent No.
5,981,708, U.S. Patent No. 6,337,184, U.S. Patent No. 6,645,763, U.S. Patent No.
6,800,790, U.S. Patent No. 6,875,607, U.S. Patent No. 6,984,522, U.S. Patent No.
7,109,03, U.S. Patent No. 7,115,267, and U.S. Patent No. 7,115,360.
Additionally, cancer stem cells can be identified or isolated (e.g., isolated from non-stem tumor cells) on the basis of expression (e.g., nucleic acid or protein expression) of molecular markers, e.g., molecular markers described in the U.S. patents referred to in the above paragraph. Exemplary molecular markers include CD133, Bmi-1, Notch, Sonic hedgehog, and Wnt. Additionally, exemplary molecular markers of neural cancer stem cells include CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi 1), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRPI, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAPI, cIAP2, NAIP, and survivin.
Isolation or identification of cancer stem cells can be performed by standard means, e.g., cell sorting (e.g., fluorescence activated cell sorting (FACS) ormagnetie cell sorting (MACS)).
Anti ens Antigenic peptides useful for loading DCs for vaccination are peptides that stimulate a T cell mediated immune response (e.g., a cytotoxic T cell response) by presentation to T cells on MHC molecules. Useful aritigenic peptides and proteins include those derived from cancer stem cells (e.g., neural cancer stem cells, CD133+
tumor cells, or neurospheres derived from tumors). In some embodiments, the cancer stem cell antigens are presented as a lysate of the cancer stem cells. In other embodiments, the cancer stem cell antigens are obtained by acid elution of peptides presented on MHC
molecules of the cancer stem cells. In an exemplary method, cancer stem cells are washed with an isotonic solution (e.g., Hank's buffered saline solution) to remove media components. The cells are then treated with acid (e.g., citrate phosphate buffer, pH 3.2) to dissociate peptides from surface MHCs; and the cells removed from the solution containing the soluble peptides. The acid-eluted cancer stem cell peptide antigens can be further purified (e.g., on a Cl 8 column) and frozen for storage prior to use.
Specific antigens that can be used in the methods described herein include portions of the amino acid sequences of CD 133, CD90, CD44, CXCTt4, -Nestin, .Musashi-1 (Msi 1), maternal. embryonic leucine zipper kinase (MELK), GLI1, PTCHI, Bmi-1,phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bel-2, FLIP, BCL-XL, XIAP, clAPl, cIAP2, NAIP, and survivin that binti to MHC molecules and are presented to'I' cells.
Peptides that bind to MHC class I molecules are generally 8-10 amino acids in length.
Peptides that bind to MHC class II molecules are generally 13 arnino acids or longer (e.g., 13-17 amino acids long).
CD133 is a 120 kDa, tive-traiYsmembrane domain glycoprotein expressed on neural and hematopoietic stem and progenitor cells (Yin et al., Blood, 90:5002-12, 1997).. Table I provides an amino acid sequence of CD133 (also available in GenBank under accession number NP 006008.1, GI:5174387): The structure.of CD133 includes an extraceliular N-terminus, two short intracellular loops, two large. extracellular. loops,.
andan intracellular C-terminus (FIG. 18). Exemplary CD133:T cell epitopes include 8-10 or 13-20 contiguous amino acid residues of amino acid.residues 325-350 of SEQ ID NO:53. An alternately spliced version of CD 13 3 is described in Yu et al., J. Biol. Chem., 277:207I
1-1 b, 2002..
CD90 is a cell surface.glycoprotein found on T cells and neurons. Table l provides an amino acid sequence of CD90 (also available in GenBank under accession number NP 006279.2, GI:19923362).
CD44 is a cell surface glycoprotein that may be involved in matrix adhesion.
Table 1 provides an amino acid sequence of CD44 (also available in GenBank.under accession number NP_000601.3, GI:48255935). Several isoforms of CD44 are produced, primarily by alternative splicing (see Marhaba et al:, J. Mol. Histol., 35:211-31,, 2004; Zoeller, Cancer Immunol. Immunother., 53:567-79, 2004).
CXCR4 is a chemokine receptor that has been found to be expressed in breast cancers (Muller et al., Nature, 410:50-56, 2001). Table 1 provides an amino acid sequence of CXCR4 (also available in GenBank under accession number NP 001008540.1, GI:56790927). An altemative spliced variant is available in GenBank under accession number NP 003458.1, GI:4503175.
Nestin is an intermediate filament protein expressedin ncural progenitor cells (Dahistrand et al., J. Cell Sci.,103:589-597; 1992). Table 1 provides an amino acid sequence ofNestin (also available in GenBank under accession nurnber NP
006608.1, GI:38176300).
Musashi-1 (Msil) is an RNA-binding protein expressed in neural progenitor cells (Good et al., Genomics, 52:382-384,1998; Siddall et al., Proc. Nat. Acad.
Sci.. USA, 103:84-8407, 2006; Okano etal., Exp. Cell Res., 306:349-356, 2005). Table I
provides an amino acid sequence of Musashi-1 (also available in GenBank under accession number NP 002433.1, GI:4505255).
Maternal embryonic.leucine zipper kinase (MELK) is a protein kinase expressed in multiple cancers (Gray et al., Cancer Res., 65:9751-61, 2005). Table 1 provides an amino acid sequence of MELK (also available in GenBank under accession number NP_055606.1, GI:7661974).
GLI l is a zinc-finger transcription factor upregulated in cancers, including gliomas (Kinzler et a1., Science, 236:70-73, 1987; Kinzler et al., Nature, 332:371-374,1988;
Kasper et al., Eur: J. Cancer, 42:437-445, 2006). Table. I provides an amino acid sequence of GLI1 (also available in GenBank under accession number NP 005260.1, GI:4885279).
PTCH1 is a transmembrane protein that is believed to function as a tumor suppressor (Katoh et al., Cancer Biol. Thor., 4:1050-54, 2005). Table 1 provides an amino acid sequence of PTCH l(also available in GenBank under accession number NP 000255.2, GI:134254446). Five isofonns of PTCH1 are produced by alternative splicing (Nagao et al., Gcnomics, 85:462-71, 2005).
Bmi-1 is a polycomb ring finger protein involved in proliferation of progenitor cells (Lessard et al., Nature, 423:255-260, 2003;.Park et al., Nature, 423:302-305, 2003;
Molofsky et al., Nature, 425:962-967, 2003). Bmi-1 can play a role in the malignant transformation of the HOX A9/MEIS-induced murine leukemia model (Lessard et al., Nature, 423:255-260, 2003) as well as in turnors of neural origin (van "Lohuizen et al., Nature, 353:353-355, 1991). Table I provides an arnino acid sequence of Bmi-1 (also available in GenBank under accession number NP00517I .4, GI:27883842).
Exemplary Bmi-I T cell epitopes include TLQDIVYKL (SEQ ID NO:86), CLPSPSTPV (SEQ ID
NO:87), VRYLETSKY (SEQ ID NO:88), KRYLRCPAA (SEQ ID NO:89), YEEEPLKDY (SEQ ID NO:90), and KEEVNDKRY (SEQ ID NO:91) (Stecle et al., Br. J.
Cancer 95:1202-11, 2006).
Phosphoserine phosphatase (PSP) is an enzyme that catalyzes the hydrolysis of phosphoserine. Table I provides an amino acid sequence ofPSP (also available in GenBank under accession number NP 004568.2, GI:46249388).
Snail is a zinc-finger transcription factor and anti-apoptotic protein (Vega et al., Genes Dev., 18:1131-1143, 2004). Table 1 provides an amino acid sequenee of Snail (also available in GenBank under accession numbcr NP 005976.2, GI:1876574I).
OCT4 is a POU homeodomain-containing transcription factor expressed in pluripotent cells (Nichols et al., Cell, 95:379-391, 1998). Table I provides an amino acid sequence of OCT4 (also available in GenBank under accession number NP_002692.2, GI:42560248). An alternate isoform of OCT4 is available in GenBank under accession number NP 976034.3, GI:116235491.
BCRP 1 is an ATP-binding cassette (ABC) transporter protein involved in multidrug resistance of tumors (Doyle et al., Proc. Nat. Acad. Sci. USA, 95:1566570, 1998). Table I provides an amino acid sequence of BCRP 1(also available in GenBank under accession number NP 004818.2, GI:62526033).
MGMT is an O-6-methylguanine-DNA mcthyltransferase DNA -mismatch repair protein that can provide resistance to some methylating and chloroethylating agents, such as temozolomide (Rabik et al., Cancer Treat. Rev., 32:261-276, 2006; Cai et al., Cancer Res., 65:3319-27, 2005). Table 1 provides an amino acid sequence of MGMT (also available in GenBank under accession number NP 002403.1, GI:4505177).
BCL-2 is a mitochondrial anti-apoptotic protein correlated with chemotherapy resistant cancers and decreased overall survival (Campos et al., Blood, 81:3091-3096, 1993). Table I provides an amino acid sequence of BCL-2 (also available in GenBank under accession number NP_000624.2, GI:72198189). An alternatively spliced isoform of BCL-2 is available in GenBank under accession number NP 000648:2, GI:72198346.
FLIP is an anti-apoptotic protein (Irmler. et al., Nature, 388:190-195, 1997).
Table I provides an amino acid sequence of FLIP (also available in GenBank under accession number NP003870.3, GI:21361769).
BCL-XL is an anti-apoptotic protein related to BCL-2, which may be involved in chemoresistance (Boise et al., Cell, 74:597-608, 1993; Andreeffet al., Leukemia, 13:1881-92, 1999). Table I provides an amino acid sequence of BCL-XL (also available in GenBank under accession number NP 612815.1, GI:20336335). BxemplaryT cell epitopes of BCL-XL include Bcl-xLI 18-126(TAYQSFEQV; SEQ ID N4:92), Bcl-xL173-182 (YLNDFILBPWI; SEQ ID NO:93), and Bcl-xLl 69-178 (WMATYLNDHL;
SEQ ID NO:94) (Andersen et al., J. Immunol., 175:2709-14, 2005).
XIAP is a member of the inhibitor of apoptosis protein (IAP) family (Deveraux et al., Nature, 388:300-304, 1997). Table 1 provides an amino acid sequence of XIAP (also available in GenBank under accession number NP_001158.2, GI:32528299).
cIAPI is a meinber of the IAP family of apoptosis inhibitors (Rothe et al., Cell, 83:
1243-1252, 1995; Liston et al., Nature, 379:349-353, 1996). Table I provides an amino acid sequence of cIAPl (also available in GenBank under accession number NP
00i 157. I, GI:4502141).
cIAP2 is a member of the .IAP family of apoptosis inhibitors (Liston et al., Nature, 379:349-353, 1996). Table 1 provides an amino acid sequence of cIAP2 (also available in GenBank under accession number NP_031490.1, GI:6680696).
NAIP is a member of the TAP family of apoptosis inhibitors (Roy et al., Cell, 80:167-178, 1995). Table I provides an amino acid sequence of NAIP (also available in GenBank under accession number NP 004527.2, GI:119393878). An alternatively spliced isoform of NAIP is available in GenBank under accession number NP 075043.1, GI:119393876.
Survivin is a meinber of the IAP family of apoptosis inhibitors (Li et al., Nature, 396:580-584, 1998). Table 1 provides an amino acid sequence of NAIP (also avai!able in GenBank under accession number NP 001159.2, GI:59859878). Alternatively spliced isoforms of survivin have been identified (see Wheatley et al., Int. Rev.
Cytol., 247:35-88, 2005; Noton et al., J. Biol. Chem., 281:1286-95, 2006; and Taubertet al., Oncogene, 24:5258-61, 2005). Sequences of exemplary alternative isoforms are available in GenBank under accessionnunibers NP 001012270.1, GI:59859880, and NP_001012271.1, G1:59859882. Exemplary T cell epitopes of survivin include Sur2O-28 (STFKNWPFL; SEQ ID NO:95), Sur96-104. (LTLGEFLKL; SEQ ID NO:96), Sur133-141 (RAIEQLAAM; SEQ ID NO:97), and Surl26-135 (ETAKKVRftAI; SEQ ID NO:98) (Bachinsky etal., Cancer Immun., 5:6, 2005).. Other exemplary T cell epitopes of survivin include Sur92-101 (QFEELTLGEF; SEQ ID NO:99), Sur54-62 (LAQCFFCFK; SEQ ID
NO:100), Surl 12-120 (KIAKETNNK; SEQ ID NO:101), Sur53-62 (DLAQCFFCFK; SEQ
ID NO:102), Surl 12-121 (KIAKETNNKK; SEQ. ID NO:103), Sur.l'8-28 (RISTFKNWPFL; SEQ ID NO:104), Sur$6-96 (FLSVKKQFEEL; SEQ ID NO:; 105), and the modified peptides Sur92T2 (QTEELTLGEF; SEQ ID NO:106), Sur93T2 (FTELTLGEF; SEQ ID NO:107), Sur93S2 (FSELTLGEF; SEQ ID NO:108), Sur38Y9 (MAEAGFIHY; SEQ ID NO:109), Sur47Yl 0(PTENEPDLAY; SEQ ID NO:110), Sur5K9 (TLPPAWQPK; SEQ ID NO:111), Sur54L2 (LLQCFFCFK; SEQ ID NO:112), and SurT8K10 (RISTFKNWI'K; SEQ 1D. N(3:113) (Reker et al., Canccr Biol. Ther., 3:173-179, 2004): Other exemplary T cell epitopes of survivin include ELTLGEFLKL
(SEQ ID
NO:114) and TLPPAWQPFL (SEQ ID NO:115) (Schmitz et al., Cancer Res. 60:4845-4849, 2000). Additional survivin cpitopes are described in Siegel et al., Br.
J. Haernatol., 122:911-914,2003.
Table 1. Sequences of Hur,ian Antigens Antigen Amino acid sequence CD133 r1ALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATNYETQDSHKAGPIGILFELVHI
FLYWQPRDFPEDTLRKFLQKAYESKIDYDKPE'i'VILGLKIVYYEFIGIILCCVLGLLFIIL
MPLVG'1'FFCMCRCCNKCGGEMHQRQKENGPFLRKCFAISLLVICIIISIGIFYGFVANHQV
RTRIKRSRKLADSNFKDLRTLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGGILDR
LRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLHQQSTQLSSSLTSVKTSLRSSLNDP
I,CLVHPSSETCNSTRLSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQGYQSLND
IPDRVQRQTTTVt7AGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESYIHRNLPTL
EEYDSYWttrLGGLVICSLLTLIVIFYYLGLLCGVCGYDI2IIATPTTRGCVSNTGGVFLMVGVG
LSFLFCWILMIIVVLTFVFGANVEKLICEPYTSKELFRVLDTPYLLNEDWEYYLSGKLFNK
SKMKLTFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESLKVNLNIFLL
GAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKANSLPPGNLR[QSLK
RDAQTIKTIHQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASLDFAQNFITNNTS
SVIIEETKKYGRTIIGYFEHYLQWIEFSISEKVASCKPVATALDTAVDVFLCSYIIDPLNL
HNPVMTSPSQH (SEQ ID NO:53) CD9O MNLAISIALLLTVLQVSRGQKVTSLTACLVDQSLRLDCRHEN'1'SSSPIQYEFSLTRETKKH
VLFGTVGVPEHTYRSRTNFTSKYNMKVLYLSAFTSKDEGTYTCALHHSGHSPPISSQNVTV
LRDKLVKCEGISLLAQNTSWLLLLLLSLSLLQATDFMSL (SEQ ID NO:54) Antigen Anzino acid sequence CD44 rIDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTLP
TMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNAS
APPEEDCT'SVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNP'1'DDDVSSGSS
SERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRTPATTLMSTSATATETATKRQETWDW
FSWLFLPSESKNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDEDFIS
STISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTTRMTDVDRNGTTAYEGNWNPEAHPP
LIHHEHHEEEETPHSTSTIQATPSSTTEETA`1'QKEQWFGNRWHEGYRQTPKEDSHSTTGTA
AASAHTSHPMQGRTTPSPEDSSWTDFFNPISHPMGRGHQAGRRMDMDSSHSITLQPTANPN
TGLVEDLDRTGPLSMTTQQSNSQSFSTSHEGLEEDKDHPTTSTLTSSNRNDVTGGRRDPNH
SEGSTTLLEGYTSITYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNRSLSGDQDTFH
PSGGSHTTHGSESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIAVN
SRRRCGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRN
LQNVDMKIGV (SEQ ID NO:55) LVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNFLCKAVHVIYTV
NLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKWYVGVWIPALLLTIPDFIFANVSE
ADDRYICDRFYPNDLWVWFQFQHIMVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKT
TVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAFFHCCLNPIL
YAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHSS (SEQ ID
N0:56) Nestin MEGCMGEESFQMWELNRRLEAYLARVKALEEQNELLSAELGGLRAQSADTS6+TRAHADDELA
ALRALVDQRWREKHAAEVARDNLAEELEGVAGRCQQLRLARERTTEEVARNRRAVEAEKCA
RAWLSSQVAELERELEALRVAHEEERVGLNAQAACAPRCPAPPRGPPAPAPEVEELARRLG
EAWRGAVRGYQERVAHMETSLGQARERLGRAVQGAREGRLELQQLQAERGGLLERRAALEQ
RLEGRWQERLRATEKFQLAVEALEQEKQGLQSQIAQVLEGRQQLAHLKMSLSLEVA'I'YRTL
LEAENSRLQTPGGGSKTSLSFQDPKLELQF'PRTPEGRRLGSLLPVLSPTSLPSPLPATLET
PVPAFLKNQEFLQARTPTLASTPIPPTPQAPSPAVDAEIRAQDAPLSLLQTQGGRKQAPEP
LRAEARVAIPASVLPGPEEPGGQRQEASTGQSPEDHASLAPPLSPDHSSLEAKDGESGGSR
VFSICRGEGEGQIWGLVEKETAIEGKWSSLQQEIWEEEDLNRKEIQDSQVPLEKETLKSL
GEEIQESLKTLENQSHETLERENQECPRSLEEDLETLKSLEKENKELLKDVEWRPLEKEA
VGQLKPTGKEDTQTLQSLQKENQELMKSLEGNLETFLFPGTENQELVSSLQENLESLTALE
KENQEPLRSPEVGDEEALRPLTKENQEPLRSLEDENKEAFRSLEKENQEPLKTLEEEDQSI
VRPLETENHKSLRSLEEQDQETLRTLEKETQQRRRSLGEQDQMTLRPPEKVDLEPLKSLDQ
EIARPLENENQEFLKSLKEESVEAVKSLETEILESLKSAGQENLETLKSPETQAPLWTPEE
INQGAMNPLEKEIQEPLESVEVNQETFRLLEEENQESLRSLGAWNLENLRSPEEVDKESQR
NLEEEENLGKGEYQESLRSLEEEGQELPQSADVQRWEDTVEKDQELAQESPPGMAGVENED
EAELNLREQDGFTGKEEWEQGELNATEEVWIPGEGHPESPEPKEQRGLVEGASVKGGAEG
LQDPEGQSQQVGAPGLQAPQGLPEAIEPLVEDDVAPGGDQASPEVMLGSEPAMGESAAGAE
PGPGQGVGGLGDPGHLTREEVMEPPLEEESLEAKRVQGLEGPRKDLEEAGGLGTEFSELPG
KSRDPWEPPREGREESEAEAPRGAEEAFPAETLGHTGSDAPSPWPLGSEEAEEDVPPVLVS
PSPTYTPILEDAPGPQPQAEGSQEASWGVQGRAEALGKVESEQEELGSGEIPEGPQEEGEE
SREESEEDELGETLPDSTPLGFYLRSPTSPRWDPTGEQRPPPQGETGKEGWDPAVLASEGL
EAPPSEKEEGEEGEEECGRDSDLSEEFEDLGTEAPFLPGVPGEVAEPLGQVPQLLLDPAAW
DRDGESDGFADEEESGEEGEEDQEEGREPGAGRWGPGSSVGSLQALSSSQRGEFLESDSVS
VSVPWDDSLRGAVAGAPKTALETESQDSAEPSGSEEESDPVSLEREDKVPGPLEIPSGMED
AGPGADIIGVNGQGPNLEGKSQHVNGGVMNGLEQSEEVGQGMPLVSEGDRGSPFQEEEGSA
LKTSWAGAPVHLGQGQFLKFTQREGDRESWSSGED (SEQ ID N0:57) Antigen Amino acid sequence Msil METDAPQPGLASPDSPHDPCKMFIGGLSWQTTQEGLREYFGQFGEVKECLVMRDPLTKRSR
GFGFVTFMDQAGVDKVLAQSRHELDSKTIDPKVAFPRRAQPKMV'T'RTKKIFVGGLSVNTTV
EDVKQYFEQFGKVDDAMLMFDKTTNRHRGFGFVTFESEDIVEKVCEIHFHEINNKMVECKK
AQPKEVMSPTGSARGRSRVMPYGMDAFMLGIGMLGYPGFQATTYASRSYTGLAPGYTYQFP
EFRVERTPLPSAPVLPELTAIPLTAYGPMAAAAA.AAAVVRGTGSHPWTMAPPPGSTPSRTG
GFLGTTSPGPMAELYGAANQDSGVSSYISAASPAPSTGFGHSLGGPLIATAFTNGYH
(SEQ ID NO:58) MELK MKDYDELLKYYELHETIGTGGFAKVKI,ACHILTGEMVAIKxMDKNTLGSDLPRIKTEIEAL
KNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAY
VHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGK
SYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQML
QVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCV'I'ELSVHHRNNRQTMEDLI
SLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGQASATPFTDIKSNNWSLEDVTASDKN
YVAGL,IDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTPANKLKNKENVY
TPKSAVKNEEYFMI'PEPKTPVNKNQHKREILTTPNRYTTPSKARNQCLKETPIKIPVNSTG
'I'DKLMTGVISPERRCRSVELDLNQAHMEE'.PPKRKGAKVFGSLERGLDKVITVLTRSKRKGS
ARDGPRRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHVDFVQKGYTLKCQTQSDFGKVTMQ
FELEVCQLQKPDVVGIRRQRLKGDAWVYKRLVEDILSSCKV (SEQ ID NO:59) GLII MFNSMTPPPISSYGEPCCLRPLPSQGAPSVGTEGLSGPPFCHQANLMSGPHSYGPARETNS
CTEGPLFSSPRSAVKLTKKRALSISPLSDASLDLQTVIRTSPSSLVAFINSRCTSPGGSYG
HLSIGTMSPSLGFPAQMNHQKGPSPSFGVQPCGPHDSARGGMIPHPQSRGPFPTCQLKSEL
DMLVGKCREEPLEGDMSSPNSTGIQDPLLGMLDGREDLEREEKREPESVYETDCRWDGCSQ
EFDSQEQLVHHINSEHIHGERKEFVCHWGGCSRELRPFKAQYMLVVHMRRHTGEKPHKCTF
EGCRKSYSRLENLKTHLRSHTGEKPYMCEHEGCSKAFSNASDRAKHQNRTHSNEKPYVCKL
PGCTKRYTDPSSLRKHVKTVHGPDAHVTKRHRGDGPLPRAPSISTVEPKREREGGPIREES
RLTVPEGAMKPQPSPGAQSSCSSDHSPAGSAANTDSGVEMTGNAGGS'T'EDLSSLDEGPCIA
GTGLSTLRRLENLRLDQLHQLRPIGTRGLKLPSLSHTGTTVSRRVGPPVSLERRSSSSSSI
SSAYTVSRRSSLASPFPPGSPPENGASSLPGLMPAQHYLLRARYASARGGGTSPTAASSLD
RIGGLPMPPWRSRAEYPGYNPNAGVTRRASDPAQAADRPAPARVQRFKSLGCVHTPPTVAG
GGQNFDPYLPTSVYSPQPPSITENAAMDARGLQEEPEVGTSMVGSGLNPYMDFPPTDTLGY
GGPEGAAAEPYGARGPGSLPLGPGPPTNYGPNPCPQQASYPDPTQETWGEFPSHSGLYPGP
KALGGTYSQCPRLEHYGQVQVKPEQGCPVGSDSTGLAPCLNAHPSEGPPHPQPLFSITYPQP
SPPQYLQSGPYTQPPPDYLPSEPRPCLDFDSPTHSTGQLKAQLVCNYVQSQQELLWEGGGR
EDAPAQEPSYQSPKFLGGSQVSPSRAKAPVNTYGPGFGPNLPNHKSGSYPTPSPCHENFW
GANRASHRAAP:PPRLLPPLPTCYGPLKVGGTNPSCGHPEVGRLGGGPALYPPPEGQVCNPL
DSLDLDNTQLDFVAILDEPQGLSPPPSHDQRGSSGHTPPPSGPPNMAVGNMSVLLRSLPGE
TEFLNSSA (SEQ ID NO:60) Antigen Anvino acid sequence LEQISKGKATGRKAPLWLRAKFQRLLFKLGCYIQKNCGKFLWGLLIFGAFAVGLKAANLE
TNVEELWVEVGGRVSRELNYTRQKIGEEAMFNPQLMIQTPKEEGANVLTTEALLQHLDSAL
QASRVHVYMYNRQWKLEHLCYKSGELITETGYMDQIIEYLYPCLIITPLDCFWEGAKLQSG
TAYLLGKPPLRWTNFDPLEFLEELKKINYQVDSWEEMLNKA.EVGHGYMDRPCLNPADPDCP
ATAPNKNSTKPLDMALVLNGGCHGLSRKYMHWQEELIVGGTVKNSTGKLVSAHALQTMFQL
MTPKQMYEHFKGYEYVSHINWNEDKAAAILEAWQRTYVEVVHQSVAQNSTQKVLSFTTTTL
DDILKSFSDVSVIRVASGYLLMLAYACLTMLRWDCSKSQGAVGLAGVLLVALSVAAGLGLC
SLIGISFNAA`NPQVLPFLALGVGVDDVFLLAHAFSETGQNKRIPFEDRTGECLKRTGASVA
LTSISNVTAFFMAALIPIPALRAFSLQAAVVVVFNFAMVLLIFPAILSMDLYRREDRRLDI
FCCFTSPCVSRVIQVEPQAYTDTHDNTRYSPPPPYSSHSFAHETQITMQSTVQLRTEYDPH
THVYYTTAEPRSEISVQPVTVTQDTLSCQSPESTSSTRDLLSQFSDSSLHCLEPPCTKWTL
.SSFAEKHYAPFLLKPKAKVVVIFLFLGLLGVSLYGTTRVRDGLDLTDIVPRETREYDFIAA
QFKYFSFYNMYTV''rQKADYPNIQHLLYDLHRSFSNVKYVMLEENKQLPKMWLHYFRDWLQG
LQDAFDSDWETGKIMPNNYKNGSDDGVLAYKLLVQTGSRDKPIDISQLTKQRLVDADGIIN
PSAFYIYLTAWVSNDPVAYAASQANIRPHRPEWVHDKADYMPETRLRIPAAEPIEYAQFPF
YLNGLRDTSDFVEAIEKVRTICSNYTSLGLSSYPNGYPFLFWEQYIGLRHWLLLFISVVLA
CTFLVCAVFLLNPWTAGIIVMVLALMTVELFGMMGLIGIKLSAVPWILIASVGIGVEFTV
HVALAFLTAIGDKNRRAVLALEHMFAPVLDGAVSTLLGVLMLAGSEFDFIVRYFFAVLAIL
TILGVLNGLVLLPVLLSFFGPYPEVSPANGLNRLPTPSPEPPPSVVRFAMPPGHTHSGSDS
SDSEYSSQTTVSGLSEELRHYEAQQGAGGPAHQVIVEATENPVFAHSTVVH'PESRHHPPSN
PRQQPHLDSGSLPPGRQGQQPRRDPPREGLWPPPYRPRRDAFEISTEGHSGPSNRARWGPR
GARSHNPRNPASTAMGSSVPGYCQPITTVTASASVTVAVHPPPVPGPGRNPRGGLCPGYPE
TDHGLFEDPHVPFHVRCERRDSKVEVIELQDVECEERPRGSSSN (SEQ ID NO:61) Bmi-1 MHR`1".CRIKITELNPHLMCVLCGGYFIDATTIIECLHSFCKTCIVRYLETSKYCPICDVQVH
KTRPLLNIRSDKTLQDIVYKLVPGLFKNEMKRRRDFYAAHPSADAANGSNEDKGEVADEDK
RIITDDEIISLSIEFFDQNRLDRKVNKDKEKSKEEVNDKRYLRCPAAMTVMHLRKFLRSKM
DIPNTFQIDVMYEEEPLKDYYTLMDIAYIYTWRRNGPLPLKYRVRPTCKRMKISHQRDGLT
NAGELESDSGSDKANSPAGGIPSTSSCLPSPSTPVQSPHPQFPHISSTMNGTSNSPSGNHQ
SSFANRPRKSSVNGSSATSSG (SEQ ID NO:62) PSP MVSHSELRKLFYSADAVCF'DVDSTVIREEGIDELAKICGVEDAVSEMTRRAMGGAVPFKAA
LTERLALIQPSREQVQRLIAEQPPHLTPGIRELVSRLQERNVQVFLISGGFRSIVEHVASK
LNIPATNVFANRLKFYFNGEYAGFDETQP'I'AESGGKGKVIKLLKE,KFHFKKIIMIGDGATD
MEACPPADAFIGFGGNVIRQQVKDNAKWYITDFVELLGELEE (SEQ ID NO:63) Snail MPRSFLVRKPSDPNRKPNYSELQDSNPEFTFQQPYDQAHLLAAIPPPEILNPTASLPMLIW
DSVLAPQAQPIAWASLRLQESPRVAELTSLSDEDSGKGSQPPSPPSPAPSSFSSTSVSSLE
AEAYAAFPGLGQVPKQLAQLSEAKDLQARKAFNCKYCNKEYLSLGALKMHIRSHTLPCVCG
TCGKAFSRPWLLQGHVRTHTGEKPFSCPHCSRAFADRSNLRAHLQTHSDVKKYQCQACART
FSRMSLLHKHQESGCSGCPR (SEQ ID NO:64) PCPPPYEFCGGMAYCGPQVGVGLVPQGGLETSQPEGEAGVGVESNSDGASPEPCTVTPGAV
KLEKEKLEQNPEESQDIKALQKELEQFAKLLKQKRITLGYTQADVGL'I'LGVLFGKVFSQTT
ICRFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLVQARKRKRTSIENRVRGN
LENLFLQCPKPTLQQISHIAQQLGLEKDVVRVWFCNRRQKGKRSSSDYAQREDFEAAGSPF
SGGPVSFPLAPGPHFGTPGYGSPHFTALYSSVPFPEGEAFPPVSVTTLGSPMHSN (SEQ
ID NO:65) Antigen Aniino acid sequence j3CRP) MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVEK
EILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCNSG
YWQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVrQELGLDKVADSKVGTQFI
RGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIFSIHQ
PRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIINGDSTAV
ALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKKITVFKE
ISY'1'TSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTWLGLVIGAIYFGLKNDSTGIQNRA
GVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLPMRMLPSII
FTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSWSVATLLMTICFVFMM
IFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGNNPCNYATCTG
EEYI,VKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS (SEQ ID N0:66) MGMT MDKDCEMKR`PTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQ
CTAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKWKFGEVISYQQLAALAG
NPKAARAVGGAMRGNPVPILIPCHRWCSSGAVGNYSGGLAVKEWLLAHEGHRLGKPGLGG
SSGI,AGAWT,KGAGATSGSPPAGRN (SEQ ID NO:77) SRDPVARTSPLQTPAAPGAAAGPALSPVPPWHLTLRQAGDDFSRRYRRDFAEMSSQLHLT
PFTARGRFA`IWEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNR
HLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK (SEQ
ID NO:78) FLIP MSAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYR
VRRFDLLKRILKMDRKAVETHLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGR
GKISKEKSFLDLWELEKLNLVAPDQLDLLF.KCLKNIHRIDLKTKIQKYKQSVQGAGTSYR
NVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFLPQSIPEERY
KMKSKPLGICLIIDCIGNE'I'ELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMPEHRDY
DSFVCVLVSRGGSQSVYGVDQTHSGLPLHHIRRMFMGDSCPYLAGKPKMFFIQNYWSEGQ
LENSSLLEVDGPAMKNVEFKAQKRGLCTVHREADFFWSLCTADMSLLEQSHSSPSLYLQCL
SQKLRQERKRPLLDLHIELNGYMYDWNSRVSAKEKYYVWLQHTLRKKLILSYT (SEQ ID
N0:79) BCL-XL MSQSNRELWDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLAD
SPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQS
FEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQ
ENGGWDTFVELYGNNAAAESRKGQERFNRWFL`I'GMTVAGVV'LLGSLFSRK (SEQ ID
N0:80) XIAP MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTV
RCFSCtIAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLG
SRDHFALDRPSETHADYLLRTGQWDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRE
LASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAV
SSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGG
GLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRI
DDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESS
QTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVI
TFKQKIFMS (SEQ ID NO:81) Antigen Amino acid sequence cIAP 1 MHKTASQRLFPGPSYQNIKSIMEDSTILSDIqTNSNKQKMICYDFSCELYRMSTYSTFPAGVP
VSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKLGDSPIQKHKQLYPSCSFIQNLVSASLG
STSKNTSPMRNSFAHSLSPTLEHSSLFSGSYSSLSPNPLNSRAVEDISSSRTNPYSYAMST
EEARFLTYHMWPLTFLSPSELARAGFYYIGPGDRVACFACGGKLSNWEPKDDAMSEHRRHF
PNCPFLENSLETLRFSISNLSMQTHAARMRTFMYWPSSVPVQPEQLASAGFYYVGRNDDVK
CFCCDGGLRCWESGDDPWVEHAKWFPRCEFLIRMKGQEFVDEIQGRYPHLLEQLLSTSDTT
GEENADPPIIHFGPGESSSEDAVNMNTPVVKSALEMGFNRDLVKQTVQSKILTTGENYKTV
NDIVSALLNAEDEKREEEKEKQAEEMASDDLSLIRINRMALFQQLTCVLPILDNLLKANVI
NKQEHDIIKQKTQIPLQARELIDTILVKGNiAANIFKNCLKEIDSTLYKNLFVDKNNII{YIP
TEDVSGLSLEEQLRRLQEERTCKVCMDKEVSVVFIPCGHLWCQECAPSLRKCPICRGIIK
GTVRTFLS (SEQ ID NO:82) cjAP2 MVQDSAFLAKLMKSADTI'ELKYDFSCELYRLSTYSAFPRGVPVSERSLARAGFYYTGANDK
VKCFCCGLMLDNWKQGDSPMEKHRKLYPSCNFVQTLNPANSLEASPRPSLPSTAMSTMPLS
FASSENTGYFSGSYSSFPSDPVNFRANQDCPALSTSPYHFAMNTEKARLLTYETWPLSFLS
PAKI'.,AKAGFYYIGPGDRVACFACDGKLSNWERKDDAMSEHQRHFPSCPFLKDLGQSASRYT
VSNLSMQ"I'HAARIRTFSNWPSSALVHSQELASAGF`IYTGHSDDVKCFCCDGGLRCWESGDD
PWVEHAKWFPRCEYLLRIKGQEFVSQVQAGYPIiLLEQLLSTSDSPEDENADAAIVHFGPGE
SSEDVVMMSTPVVKAALEMGFSRSLVRQTVQRQILATGENYRTVSDLVIGLLDAEDEMREE
QMEQAAEEEESDDLALIRKNKMVLFQHLTCVTPMLYCLLSARAITEQECNAVKQKPHTLQA
STLIDTVLAKGNTAATSFRNSLREIDPALYRDIFVQQDIRSLPTDDIAALPMEEQLRKLQE
ERI+iCKVCMDREVSIVFIPCGHLWCKDCAPSLRKCPICRGTIKGTVRTFLS (SEQ ID
NO:83) NAIP MA`i'QQKASDERISQFDHNLLPELSALLGI:,DAVQLAKELEEEEQKERAKMQKGYNSQMRSEA
KRLKTFVTYEPYSSWIPQEMAAAGFYFTGVKSGIQCFCCSLILFGAGLTRLPIEDHKRFHP
DCGFLLNKDVGNIAKYDIRVKNLKSRLRGGKMRYQEEEARLASFRNWPFYVQGISPCVLSE
AGFVFTGKQIYIVQCFSCGGCLGNWEEGDDPWKEHAKWFPKCEFLRSKKSSEEITQYIQSYK
GFVDITGEHFVNSWVQRELPMASAYCNDSIFAYEELRLDSFKDWPRESAVGVAALAKAGLF
YTGIKDIVQCFSCGGCLEKWQEGDDPLDDHTRCFPNCPFLQNMKSSAEVTPDLQSRGELCE
LLETTSESNLEDSIAVGPIVPEMAQGEAQWFQEAKNLNEQLRAAYTSASFRHMSLLDISSD
LATDHLLGCDLSIASKI-TISKPVQEPLVLPEVFGNLNSVMCVEGEAGSGKTVLLKKIAFLWA
SGCCPLLNRFQLVFYLSLSSTRPDEGLASIICDQLLEKEGSVTEMCVRNIIQQLKNQVLFL
LDDYKEICSIPQVIGKLIQKNIiLSRTCLLIAVRTNRARDIRRYLETILEIKAFPFYNTVCI
LRKLFSHNMTRLRKFMVYFGKNQSLQKIQKTPLFVAAICAHWFQYPFDPSFDDVAVFKSYM
ERLSLRNKATAEILKATVSSCGELALKGFFSCCFEr`NDDDLAEAGVDEDEDLTMCLMSKFT
AQRLRPFYRFLSPAFQEFLAGMRLIELLDSDRQEHQDLGLYHLKQINSPMMTVSAYNNFLN
YVSSLPSTKAGPKIVSHLLHLVDNKESLENISENDDYLKHQPEISLQMQLLRGLWQICPQA
YF.SMVSEHLLVLALKTAYQSNITVAACSPFVLQFLQGRTLTLGALNLQYFFDHPESLSLLRS
IHFPIRGNKTSPRAHFSVLETCFDKSQVPTIDQDYASAFEPMNEWERNLAEKEDNVKSYMD
MQRRASPDLSTGYWKLSPKQYKIPCLEVDVNDIDWGQDMLEILMTVFSASQRIELHLNHS
RGFIESIRPALELSKASVI'KCSISKLELSAAEQELLLTLPSLESLEVSGTIQSQDQIFPNL
DKFLCLKELSVDLEGNINVFSVIPEEFPNFHHMEKLLIQISAEYDPSKLVKLIQNSPNLHV
FHLKCNFFSDFGSLMTMLVSCKKLTEIKFSDSFFQAVPFVASLPNFISLKILNLEGQQFPD
EETSEKFAYILGSLSNLEELILPTGDGIYRVAKLIIQQCQQLHCLRVLSFFKTLNDDSWE
IAKVAISGGFQKLENLKLSINHKITEEGYRNFFQALDNMPNLQELDISRHFTECIKAQATT
VKSLSQCVLRLPRLIRLNMLSWLLDADDIALLNVMKERHPQSKYLTILQKWILPFSPIIQK
(SEQ ID NO:84) Survivin MGAPTLPPAWQPFLKDHRISTFKN6dPF'LEGCACTPERMAEAGFIHCPTENEPDLAQCFFCF
KELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKK
EFEETAEKVRRAIEQLAAMD (SEQ ID NO:85) T cell epitopes can be identified by a number of different methods. Naturally processed MHC epitopes can be identified by mass spectrophotometric analysis ofpeptides cluted from antigen-loaded APC (e.g., APC that have taken up antigen, or that have been engineered to produce the protein intracellularly). After incubation at 37 C, cells are lysed. in detergent and the MHC protein is purified (e.g., by affinity chromatography). Treatment of the purified MHC with a suitable chemical medium (e.g., under acidic conditions) results in the elution of peptides from the MHC. This pool of peptides is separated and the profile compared with peptides from control APC
treated in the same way. The peaks -unique to the protein expressing/fed cells are analyzed (for example by mass spectrometry) and the peptide fragments identified. This protoco) identifies peptides generated from a particular antigen by antigen processing.
Alternatively, epitopes can be identified by screening a synthetic library of peptides that overlapand span the length of the antigen in an in vitro assay. For example, peptides that are 9 amino acids in length and which overlap by 5 amino acids may be used. The peptides are tested in an antigen presentation system that includes antigen presenting cells and T cells. T cell activation in the presence of APCs presenting the peptide can be measured (e.g., by measuring T cell proliferation or cytokine production) and compared to controls, to determine whether a particular cpitope is recognized by the T
cells:
T cell epitopes can be predicted in silico; e.g., usirig the methods described in Parker et al., J. Immuno1:,152:163, 1994 and Rammensee et al., Immunogenet., 50:213-219, 1999.
Antigenic peptides can be obtained by chemical synthesis using a commercially available automated peptide synthesizer. Synthetic peptides can be precipitated and further purified, for example by high perfonnance liquid chromatography (HPLC).
Alternatively, isolated peptides can be obtained by purification and/or recombinant methods using-host cell and.vector expression systems.
Preparation of Antijzen Presentinp, Cells Antigen presenting cells (APC), such as DCs, suitable for administration to subjects (e.g., glioma patients) can be isolated or obtained from any tissue in which such cells are found, or may be otherwise cultured and provided using standard techniques.
Methods of preparing antigen presenting cells are well-known to those of skill in the art.
Mature dendritic cells are typically idenfiified as having the following cell surface marker phenotype: MAC3", CD80t, CD86'-, CD40"', CD54+, MHC Class I and MHC Class II, and are capable of FITC-dextran uptake.
APCs (e.g., DCs) can be found, by way of example, in the bone marrow or PBMCs of a mammal, in the spleen of a mammal or in the skin of a mammal (i.e., Langerhan's cells, which possess certain qualities similar to that of DC, may be found in the skin). For instance, bone marrow can be harvested from a mammal and cultured in a medium that promotes the growth of DCs. GM-CSF, IL-4 and/or other cytokines (e.g., TNF-a), growth factors and supplements may be included in this medium.
After a suitable amount of time in culture in medium containing appropriate cytokines (e.g., time suitable to expand and differentiate the DCs into mature DCs, e.g., 2, 4, 6, 8, 10, 12, or 15 days), clusters of DCs are cultured in the presence of a sufficient number of antigens of interest (e.g., in the presence of eancer stem cell lysate, acid eluted peptides of cancer stem cells, peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1(Msi1), maternal embryonic leucine zipper kinase (MELK), GLII, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, clAP 1, c1AP2, NAIP, or survivin, or a combination of two or more of the above antigens) and harvested for use in a cancer vaccine. For example, peptide antigens can be added to the culture medium at a concentration of about 1.0 to 50, e.g., 5, 10, 15, 20, or 30 glml (per antigen).
Alternately, or in combination, antigens can be transgenically expressed in DCs, e.g., by transfection of nucleie acids encoding one or more of the antigens or portions of antigens.
In one exemplary method, APCs are isolated from a subject (e.g., a human) according to the following exemplary procedure. Mononuclear cells are isolated from blood using leukapheresis (e.g., using a COBE Spectra Apheresis System). The mononuclear cells are allowed to become adherent by incubation in tissue culture flasks for 2 hours at 37 C. Nonadherent cells are removed by washing. Adherent cells are cultured in medium supplemented with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4) for five days. On day five, TNF-a is added to the culture medium for another 3-4 days. On day 8 or 9, cells are harvested and washed, and incubated with peptide antigens for 16-20 hours on a tissue rotator. Peptide antigens are added to the cultures at a concentration of- 10 g/ml (per antigen).
Various other niethods can be used to isolate the APCs, as would be recognized by one of skill in the art. DCs occur in low numbers in all tissues in which they reside, making isolation and enrichment of DCs a requirement. Any of a number of procedures entailing repetitive density gradient separation, fluorescence activated.cell sorting techniques, positive selection, negative selection or a combination thereof are routinely used to obtain enriched populations or isolated DCs. Guidance on such methods for isolating DCs can be found in O'Doherty et al., J. Exp. Med., 178:1067-78, 1993; Young and Steinman, J. Exp. Med., 171:1315-32, 1990; Freudenthal and Steinman, Proc.
Nat.
Acad. Sci. USA, 57:7698-7702, 1990; Macatonia et al., 67:285-289, 1989;
Markowicz and Engleman, J. Clin. Invest., 85:955-961, 1990; Mehta-Damani et al., J.
Immunol., 153:996-1003, 1994; and Thomas et al., J. Immunol., 151:6840-6852, 1993. One method for isolating DCs from human peripheral blood is described in U.S. Patent No.
5,643,786.
Methods of producing DCs from embryonic stem cells are described in U.S.
Patent No.
7,247,480.
Administration of Cancer Vaccines The APC-based cancer vaccine may be delivered to a recipient by any suitable delivery route, which can include injection, infusion, inoculation, direct surgical delivery, or any combination thereof. In some embodiments, the cancer vaccine is administered to a human in the deltoid region or axillary region. In some embodimeiits, the vaccine is administered to a subject locally to the site of a tumor, within the tumor, or to an area from which a tumor has been surgically resected.
An appropriate carrier for administering the ceils may be selected by one of skill in the art by routine techniques. For example, the phartnaceutical carrier can be a buffered saline solution, e.g., cell culture media.
The quantity of APC appropriate for administration to a patient as a cancer vaccine to effc,~ct the methods of the present invention and the most convenient route of such administration may be based upon a variety of factors, as may the formulation of the vaccine itself. Some of these factors include the physical characteristics of the patient (e.g.., age, weight, and sex), the physical characteristics of the. tumor (e.g., location, size, rate of growth, and accessibility), and the extent to which other therapeutic methodologies (e.g., chemotherapy, and beam radiation therapy) are being implemented in connection with an overall treatment regimen. Notwithstanding the variety of factors one should consider in implementing the methods of the present invention to treat a disease condition, a mammal can be administered with from about 105 to about 109 APC (e.g., 107 APC) in from about 0.05 mL to about 5 mL solution (e.g., saline) in a single administration.
Additional administrations can be carried out, depending upon the above-described and other factors, such as the severity of tumor pathology. In one embodiment, from about_one to about five administrations of about 106 APC is performed at two-week intervals.
DC vaccination can be accompanied by other treatments. For example, a patient receiving DC vaccination may also be receiving chemotherapy, radiation, and/or surgical therapy concurrently. Methods of treating cancer using DC vaccination in conjunction with chemotherapy are described in Wheeler et al., U.S. Pat. Pub. No.
2007/0020297. In some embodiments, a patient receiving DC vaccination has already received chemotherapy, radiation, and/or surgical treatment for the cancer. In one embodiment, a patient receiving DC vaccination is treated with a COX-2 inhibitor, as described in Yu and Akasaki, WO 2005/037995.
Pharmaceutical Comgositions In various embodiments, the present invention provides pharmaceutical compositions including a pharmaceutically acceptable excipient along with a therapeutically effective amount of the inventive vaccine comprising dendritic cells pulsed with cancer stem cell antigens as described herein. " Pharmaceutieally acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous:
In various embodiments, the pharmaceutical compositions according to the invention may be formulated for delivery via any route of administration.
"Route of administration" may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, transmucosal, transdermal, or parenteral.
"Parenteral" refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac,,intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders.
The pharmaceutical compositions according to the.invention can also contain any pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof. Each component of the carrier must be "pharmaceutieally acceptable"
in that it must be compatible with the other ingredients of the forrnulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
The pharmaceutical compositions according to the invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration. One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, for instance, by monitoring a subject's response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed. 20th edition, Williams & Wilkins PA; USA) (2000).
Kits Kits to treat cancer are also contemplated. The kits are useful for practicing the inventive method of treating cancer with a vaccine comprising dendritic cells pulsed with cancer stem cell antigens as described herein. The kit is an assemblage of materials or components, including at least one of the inventive compositions. Thus, in some embodiments the kit contains a composition including a vaccine comprising dendritic cells pulsed with cancer stem cell antigens as described herein.
The exact nature of the components configured in the inventive kit depends on its intended purpose. For example, some embodiments are configured for the purpose of treating a particular cancer. In one embodiment, the kit is configured forthe purpose of treating brain tumors. In one particular embodiment, the brain tumor is a glioma. In another embodiment, the brain tumor is GBM. In one embodiment, the kit is configured particularly for the purpose of treating mammalian subjects. In another embodiment, the kit is configured particularly for the purpose of treating human subjects. In further embodiments, the kit is configured for veterinary applications, treating subjects such as, but not limited to, farm animals, domestic animals, and labaratory animals.
Instructions for use may be included in the kit. "Instructions for use"
typically include a tangible expression dcscribing the technique to be employed in using the components of the kit to effect a desired outcome, such as induction nf an immune response against a tumor, to treat a cancer. For example, the instructions may comprise instructions to administer a vaccine comprising dendritic cells pulsed with cancer stern cell antigens to the patient. ' Optionally, the kit also contains other useful components, such as, diluents, buffers, pharmaceutically acceptable carriers, syringes, catheters, applicators, pipetting or measuring tools, or other useful paraphernalia as will be readily recognized by those of skill in the art.
The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form;
they can be provided at room, refrigerated or frozen temperatures. 'I'he components are typically contained in suitable packaging material(s). As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as inventive compositions and the like. The packaging material is.
constructed by well known methods, preferably to provide a sterile, contaminant-free environment. The packaging materials employed in the kit are those customarily utilized in cancer treatments or in vaccinations. As used herein, the term "package"
refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the individual kit components. Thus, for example, a package can be a glass vial used to contain suitable quantities of an inventive composition containing for example, a vaccine comprising de,-ndritie cells pulsed with cancer stem cell antigens as described herein. The packaging material generally has an external label which indicates the contents and/or purpose of the kit and/or its components.
EXAMPLES
The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that spccific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One: skilled in the art.rnay develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.
Example 1. 'The 9L Gliosarcoma Cell Line Contains Self-Renewin ells To determine if a population of self-renewing stem cells exist within the phenotypically heterogeneous 9L gliosarcoma tumor, the cells were.grown as monolayers in the presence of 10% FBS and subsequently grew them in serum free media containing mitogens. A schematic diagram of culturing of tumorstem cells is presented in Fig. 2. 9L
gliosarcomas were resuspended in Dulbecco's modified Eagle's medium/F-12 medium containing 10% fetal bovine serum (FBS) and plated at a density of 1 x 106 live cells per 75 cm2 flask. The cells attached and grew as mondlayers and were passaged upon confluency. Spheres were derived by placing the 9L gliosarcomas cells grown as monolayers into a defined serum-free NSC medium (Reynolds et al., J.
Neurosci;, 12:
4565-74,1992; Reynolds et al., Science, 255:1707-10, 1992) consisting of Dulbecco's modified Eagle's rnediurn/F-12 medium supplemented with 20 ng/mL of both epidermal growth factor (EGF; Peprotech, Rock.y. Hill, NJ) and basic fibroblast growth factor (bFGF;
Peprotech, Rocky Hill, NJ). Cells were fed every 2 days by adding fresh NSC
media supplemented with growth factors. After primary spheres forined and reached 10-200 cells per sphere, the cells were harvested, dissociated into single cells using trypsin and EDTA
(GIBCO BRL) and mechanical pipetting, strained through a cell strainer, and plated at a clonal density of 1,000 cells/mL in neurosphere-conditioned medium to generate clonally dcrived subspheres (Geschwind et al., Neuron, 29:325-339, 2001; Groszer etal., Science, 294: 2186-89, 2001). The cells were fed every 2 days by adding fresh NSC media supplemented with mitogens. Cells and subsequent spheres were observed daily.for 18 days, and passaged into fresh media. Subspheres ranging from approximately 15 cells to cells were evident after 18 days and displayed the self-renewing and proliferative 35 capacity of the 9L spheres.
Subtle differences were observed in surface adhesion properties between the two cell populations when using different coating solutions. fit was found that poly-L-lysine proved less effective in binding toneurospheres than did.laminin. Even affter 2 days, only a small portion of the cells adhered (- 5%). However, when neurospheres were allowed to adhere to chamber slides coated with laminin, nearly all the cells (- 70%) adhered within the first 3 hours. As a consequence, poly-L-lysine was not used as an adhesive substrate in further studies. A similar trend was observed when comparing adhesion of monolayers to chamber slides coated with either poly-L-lysine or laminin-cellular morphology was more apparent in monolayers grown on laminin coated chamber slides within a 6 hour time period. Furthermore, a distinct morphololocal characteristic was apparent in the ditl'erentiated neurospheres, where arms of differentiated cells originating from one neurosphere homed to arms formed by another nearby neurosphere (FIG. 8A).
These examples of extracellular adhesion and cellular homing can be used to distinguish cancer stem-like cells (CSLCs) from non-CSLCs within a tumor.
Example 2. 9L Neurospheres Express NSC Markers and Can Generate Both Neuronal and Glial Cells in Culture To determine the expression of markers for stem cells, neurospheres were immunostained for NSC markers. nestin and Sox2. Neurospheres were.also stained for the lineage markers for astrocytes, OFAP, neurons, beta-tubulin III and MAP2, and oligodendrocytes, myclin/oligodendrocyte. Cells in the outer region of the neurosphere labeled for nestin, while cells throughout the neurospliere were labeled for Sox2. A large number of cells within the tumor spheres were also found to be positive for the lineage marker GFAP, while relatively few cells expressed the neuronal lineage markers 0-tubulin III, MAP2, and myelin/oligodendrocyte.
To test whether spheres have multipotent capabilities and produce progenies of different lineages, spheres were seeded into chamber slides (Lab-TekII, Nalge Nunc Internat7onal) for differentiation assay. The cells were grown for 14 days in medium devoid of growth factors bFGF and EGF but permissive for differentiation, and processed for immunocytochemistry as described below. The medium included Dulbecco's modified Eagle's medium/F-12 medium containing 10% fetal bovine serum (FBS).
To examine the expression ofNSC markers and lineage.markers,.immuncyto- and immunohistochemical staining was performed. For staining of differentiated spheres, spheres and 9L monolayers, cells growing in chamber slides were fixed with 4%
paraformaldehyde for 15 minutes at 4 C, treated with 5% NHS (normal horse serum)/0.1 % Triton-X, and then stained with the following antibodies: rabbit anti-riestin (1:200, Chemicon), rabbit anti-Sox2 (1:1,000, Chemicon), rabbit anti-MAP2 (I:I,000, Sigma), mouse anti-R-tubulin III (1:200, Chemicon), rabbit anti-GFAP (1:1000, Chemicon), mouse.anti-myelin/oligodendrocyte (1:1,000, Chemicon). The primary antibodies were detectcxi'with Cy3 or.:FITC-conjugated anti-mouse or anti-rabbit IgG
antibody (1:200, Jackson Immuno Research). 'I'he cells were counterstained with 4',6-diamidino-2-ph.enylindole (DAPI; Vector I:;aboiatoriess) to identifyall nuclei. The stained sections were examined and photographed using a QED cell scannerprograrn and Nikon Eclipse TE2000-E microscope, and analyzed using Image J(NIH). For iinmunostaining of spheres, the spheres where allowed to adhere to precoated (with laminin) chamber slides for 3 hours before fixation, while monolayers were allowed to adhere overnight in non-fixed chamber. slides.
Cells stained positive for the NSC markers.nestin and Sox2, as well as the lineage markers for astrocytes, GFAP, neurons, MAP2, and oligodendrocytes, myelin/oligodendrocyte. However, no cells were labeled with the neuronal marker beta-tubulin III. FACS analysis showed similar results to those derived via immunocytochemistry, which showed differentiated cells labeledfor nestin (88%;
FIG.
3C),Sox2 (24%), GFAP (96 /6; FIG. 3B), MAP2 (29%; FIG. 3D), and myelin/oligodendrocyte (6%; FIG. 3F), but not for (i-tubulin III (0%; FIG.
3E). For FACS
analysis, cells were fixed with 4% paraformaldehyde for 15 minutes at 4 C, treated with 5% NHS (normal horse serum)/0.1/o TritonT"'-X, and then stained with the following antibodies: rabbit anti-nestin (1:1,000, Chemicon), rabbit anti-Sox2 (1:1,000, Chemicon), rabbit anti-MAP2 (1:1,000, Sigma), mouse anti-p-tubulin IIi (1:500, Chemicon), rabbit anti-GFAP (1:1000, Chernicon), and mouse anti-myelin/oligoderxdrocyte (1:1,000, Chemicon). The primary antibodies were detected with FTI'C-conjugatcd atiti-mouse or anti-rabbit IgG antibody (1:200, Jackson Immuno Research) using 10d cells in a FACSVantageTM fluorescence activated cell. sorter (Becton Dickinson). "I'hese results indicate that these cancer stem-like cells (CSLCs), unlike normal stem cells, differentiate into aberrant cells that are positive for multiple differentiation markers, notably GFAP and MAP2. Such a dual nature is apparent in the majority of cells differentiated from neurospheres. Furthermore, many cells still remained highly positive for nestin and Sox2.
The expression pattern of the differentiated progeny was similar in profile to that of primary cultured tumor cells from which thespheres had originally been isolated and predominantly differentiated into GFAP and MAP2 positive cells that recapitulated the parental tumor phenotype. Additionally, the level of labeling for the NSC
markers nestin and Sox2 still remained high, even after 14 days of differentiation. The staining pattern for the monolayer population was similar to neurospheres differentiated for 14 days, except for the expression of Sox2, which was greater in neurospheres differentiated for 14 days.
These results reveal that 9L spheres are multipotent for the three neural cell types and differentiate into cells found in the original tumor from which they were obtained.
Example 3. The Aizuressiveness of 9L Cells in vivo is Reliant on the Neurosphere Cancer Stem-Like Cells To detennine if 9L cells grown as monolayer or neurospheres differ in their ability to grow as a tumor after implantation 5,000 cells from both populations of cells were injected into rats and survival and tumor volume were assayed.
Fisher F344 rats 6-8 weeks old (Harlan Sprague-Dawley, Indianapolis, IN) were anesthetized with i.p: ketamine and xylazine, and stereotactically implanted in the right striatum (from bregma in mm: anterior-posterior +1 mm; medial-lateral -3 mm;
dorsal-ventral -5 mm) with either isolated 9L sphere cells containing the luciferase gene (5,000 cells) or non-sphere-forming monolayer cells containing the luciferase gene (5,000 õells) in 4 L of 1.2% methylcellulose/PBS (Rehemtulla et al., Neoplasia, 2:491-495, 2000).
Rats were portioned to either the tumor volume group (n =10) or the survival group (n =
18), with control rats (n = 6) receiving 4 L of 1.2% methylcelluloselPBS only.
Because half of each group consisted of either animals implanted with spheres or monolayers, tumor aggression could be detennined. Animals in the tumor volume group were sacrificed 18 days after tumor implantation. Tumor volume was assessed by using the formula for an ellipsoid, (length x width x height)/2 (Advani et al., Cancer Res., 59:2055-58, 1999), with the height and the width of the tumor being approximately equal because of the well-defined circumference of the tumors generated by the 9L
gliosarcoma (see Sibenaller et al., Neurosurg. Focus, 19:E1, 2005). A significantly (P <
0.02) greater tumor volume was observed in the rats implanted with neurosphere cells as compared to rats implanted with monolayer cells (FIG. 4A).
Animals in the survival group were followed for survival and euthanized via asphyxiation when terminal neurological signs developed (e.g., inability to aeccss food, water, seizure activity, weakness, and paralysis) or if animals exceeded a survival period of 40 days. Following euthanization, brains were harvested and frozen in 2-methylbutane (Sigma), cooled to -20 C, and stored at -80 C until sectioning. For H&E
staining, 20 m coronal brain sections described above were mounted on slide and stained with Harris hematoxylin for 2 minutes and then counterstained with alcoholic eosin.
Reticulin stains were performed on 12 m coronal brain sections.
Similar to the results seen in the tumor size groups, rats implanted with neurospheres on average had shorter survival times than rats implanted with monolayer cells (FIG. 4B). Six rats in the neurosphere goup had large tumors that lead to terminal neurologcal symptoms, whereas 3 showed evidence of small tumors after 40 days of survival as seen by H&E staining of brain sections. In contrast, only 4 rats had tumors large enough to create terminal neurological symptoms in the monolayer group, whereas 5 showed evidence of small tumor or engraftment after 40 days of survival as determined by H&E staining. Furthermore, the rats in the monolayer group which developed terminal neurological signs of tumor did so at a later time (36 days compared to 29 days in the neurosphere group), which was significant when analyzed using the Kaplan-Meicr test (P
< 0.02).
To determine the establishment of tumor in vivo, 150 mg/kg of the luciferase substrate D-luciferin (Biosynth, International, Inc., Naperville, IL) was administered i.p. to animals in the survival group, and luciferase scans were taken 15 minutes later. Luciferase scans generated at 14 days post implantation demonstrated a greater proportion of animals with tumor burden in the neurosphere group compared to the monolayer group,.
even though a higher expression level of luciferase in vitro was observed in monolayer cells as compared to neurosphere cells.
'To determine if the 9L neurospheres could recapitulate the 9L sarcoma in vivo, histological analysis of the tumors was performed. The tumor-cell-implanted rat brains were cut with a cryostat into 20 m coronal sections and fixed in 4%
paraformaldehyde, washed with PBS, and air dried. To characterize the brain tissue by immunohistochemistry, free-floating sections were blocked with 5% NHS (normal horse serum) for 30 minutes at room temperature and then stained with the following antibodies:
rabbit anti-nestin (1:200, Chemicon), rabbit anti-Sox2 (1:1,000, Chemicon), rabbit anti-MAP2 (1:1,000, Sigma), mouse anti-(3-tubulin 111 (1:200, Chemicon), rabbit anti-GFAP
(1:1000, Chemicon), mouse anti-myelin/oligodendrocyte (1:1000; Chemicon). The primary antibodies were detected as in Example 1. The cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories) to identify all nuclei. The stained sections were examined and photographed using the Zeiss Axiovision 3.1 program in conjunction with Zeiss AxioskopT"" 2 microscope, and analyzed using Image J
(NIH).
Tumors from the neurosphere cell population were large and well-circumferential, and showed cells positive for the NSC marker nestin, as well as cells positive for the lineage markers GFAP, 0-tubulin III, and myelin/oligodendrocytes. Most of the labeling within the tumor volume was directed against GFAP, and a lesser degrce of labeling was observed for (i-tubulin III, myelin/oligodendrocyte, and nestin. A significant portion (>
75%) of the tumor volume stained positive for reticulin, consistent with a sarcomatous component. Additionally, H&E staining revealed a high grade glioma with necrosis consistent with a glioblastoma, displaying the dual naturc of the gliosarcoma.
Neurospheres formed high grade gliomas with necrosis as seen on H&E (FIG. 5A).
The tumors were large and well circwnferential as evidenced in non-stained sections (FIG. 5B) and stained for the nuclear marker DAPI (FIG. 5D). A comparison of non-tumor area (FIG. 5D) with tumor area (FIG. 5E) stained for reticulin revealed high levels of reticulin in tumor engulfed regions, showing the histological sarcomatous component of the gliosarcoma. The staining pattems suggest that 9L neurospheres recapitulated the original tumor by differentiating into both neural and glial lineages in vivo.
Example 4. Proliferation Rate and Drug Sensitivityof 9L Neurospheres To compare the differential proliferation rates and resistance to chemotherapeutic agents, 2,000 healthy 9L sphere and monolayer cells were exposed to either Dulbecco's modified Eagle's medium/F-12 medium containing 10% fetal bovine serum (FBS), or 100 M stock solution of Temozolamide or Carboplatin dissolved in PBS at concentrations of 1,000 M, 500 M, 250 M, and 125 M for 2 days. The viability of the cells was scored by measurement of the absorption of formazan dye (the amount of formazan dye formed directly correlates to the number of metabolically active cells) using the cellular proliferation assay WST-1 (Roche Molecular Biochemicals, Mannheim, Germany).
Formazan was measured with the use of a microplate reader (Tecan) and spectrophotometer set at a wavelength of 440 nm and a reference wavelength of 890 nm.
Cellular viability was determined by exposing cells to WST-] for 4 hours, and calculating the percentage of viable cells. Proliferation was also assessed by using manual cell counting after 7 days in culture, with an initial cellular concentration of 100,000 cells/mL
in a 25 mmZ flask.
The neurospheres demonstrated significantly (P < 0.05) greater resistance to temozolamide (FIG. 6B) and carboplatin (FIG. 6A) when compared to the 9L cells grown as a monolayer under the same conditions. When the celis were not treated with the chemotherapeutic agents and simply grown in medium, there was a significantly (P < 0.05) greater increase in cell number in the monolayer group by a factor of 1.48 when using the WST-1 proliferation assay when the cells were not treated with the chemotherapeutic agents. The results of the proliferation assays are depicted in FIG. 7, which is a bar graph that shows a greater increase in cells in the monolayer group. A similar trend in the untreated cells was also observed using the manual cell count metliod, which showed a greater increase in monolayers by a factor of 1.35. This example demonstrates that neurosphere cells have a.greater resistance to chemotherapeutic agents.
Example 5. Isolation of Human CD133-Positive Cancer Stem Cells Glioblastoina specimens were obtained froin patients (with inforned consent) via the Brain Tumor Registry and were reviewed and released by a pathologist in the operating room. Independent pathologists classified the tumors by type and grade in accordance with the WHO histological grading of central nervous system tumors. IRB
certified technicians processed the glioma tissues under sterile conditions in a laminar flow hood.
Tumor cells were cultured in the following complete medium:.I3am's F-12/DMEM
with high glucose (Irvine scientific, Santa Ana, CA), 10 mM HEPES (Invitrogen, Carlsbad, CA), 0.1 mg/ml Gentamicin (Invitrogen) and 10% heat-inactivated FBS (Irvine Scientific, Santa Ana, CA). The cultured cells were maintained for 3-4 passages. Floating neurosphere-like cells wcre obtained that were capable of forming new spheres.
in medium containing FBS for 3-4 passages.
Three adult glioblastoma primary tumor cell lines (Nos. 1049, 377, and 66) were derived by the above method and analyzed by FACS for CD133 expression. Tumor cells were collected and stained with anti-CD133 antibody (mouse monoclonal IgG1; 1:
10;
Milteny Biotec) or IgG I isotype control antibody(BD Pharmingen, San Diego, CA).
After PE-anti-mouse IgGI (BD Pharmingen) staining for 30 minutes, CD133 staining was analyzed by flow cytometry using a FACSCaliburTm fluorescence activated cell sorter (Becton Dickinson, San Jose, CA). CD133 expression was observed in 10:2% (No.
66;
FIG. 9C), 27% (No. 1049, FIG. 9A) and 69.7% (No. 377; FIG. 9B) of the total population examined.
To investigate the capacity of self-renewal and clonogenic potential of CD133+
cell, a single isolated CD133 positive cancer stem cell was isolated by DAKOcytomationT'" (DAKO, Carpinteria, CA) sorting and cultured in a defined serum-free NSC medium (Kabos et al., Exp. Neurol., 178:288-293, 2002) containing 20 ng/ml of basic fibroblast growth factor (bFGF, Peprotcch, Rocky Hill, NJ), 20 ng/ml of epidermal growth factor (EGF, Peprotech) and 20 ng/ml leukemia inhibitory factor (LIF, Chemicon, Temecula, CA). Single isolated CD133 positive cancer stem cells were able to form neurospheres (FIG. 8A), and were demonstrated to have the capacity for self-renewal and clonogenic potential (FIG. $B), and sustained expression of CD133 in serum-free medium containing EGF/FGF (FIG. $C).
Example b Human CD133 Positive Tumor Cells Express Markers Associated With Neural Precursors To determine the expression of other genes in CD 133 positive cells, CD 133 positive cells and CD133 negative cells were obtained by FACS sorting as described in Example 5 and real-time PCR was used to analyze some markers associated with neural precursors in.these two populations. 'Total RNA was extracted from the isolated CD133 positive and CD133 negative cells using an RNA4PCRTM kit (Ambion, Austin, TX) according to the manufacturer's protocol. For eDNA synthesis, -l g total RNA
was reverse-transcribed into cDNA using Oligo dT primer and iScriptT'" cDNA
synthesis kit reverse transcriptase. cDNA was stored at -20 C. Gene expression was quantified by real-time quantitative RT-PCR using QuantiTect''"' SYBR Green dye (Qiagen, Valencia, CA). DNA amplification was carried out using IcyclerT"" (BIO-RAD, Hercules, CA), and the detection was perfonned by measuring the binding of the fluorescence dye SYBR
Green I to double-stranded DNA. All the primer sets were obtained from Qiagen (see Table l).
Table 2. Oiieonucleotide primers sequences used for SYBR Green real=time PCR
Gene Fortivard Reverse Beta- 5'-TTCTACAATGAGCTGCGTGTG-3' 5'-GGGGTG'1"I'GAAGG'I'CTCAAA-3' actin (SEQ ID NO:1) (SEQ ID NO:2) CD133 5'-GCATTGGCATCTI'CTATGGTT-3' 5'-CGCCTTGTCCTI'GGTAG'fGT-3' (SEQ ID NO:3) (SEQ ID NO:4) MSIl 5'-GAGACTGACGCGCCCCAGCC-3' 5'-CGCCTGGTCCAT'GAAAGTGACG-3' (SEQ ID NO:5) (SEQ IDNO:6) MELK 51-CTI'GGATCAGAGGCAGATGI'T"TGGAG-3' 5'-GTTG"rAATCTTGCATGATCCAGG-3' (SEQ ID NO:7) (SEQ ID NO:8) PSP 3-GGCGGGGCAGTGCCITTCAAA-3' 5'=TG'ITGGCTGCGTCTCATCAAAACC-3' (SEQ ID NO:9) (SEQ ID N0:10) CD90 5'=CGC1'CTCCTGCTAACAGTCTT-3' 5'-CAGGCTGAACTCGTACTGGA-3' .(SEQ IDNO:11) (SEQ,ID NO:12) NESTIN 5-ATCGCT'CAGGTCCTGGAA-3' 5'-AAGCTGAGGGAAGTCTTGGA-3' (SEQ ID NO:13) (SEQ ID NO:14) CD44 5'-AGAAGG'TGTGGGCAGAAGAA-3' S'-AAATGCACCA'I'TTCCTGAGA-3' (SEQ ID NO: 15) (SEQ ID NO: 16) GLII 5'-AGGGAGGAAAGCAGACTGAC-3' 5'-CCAGTCATTTCCACACCACf-3' (SEQ ID NO: 17) (SEQ ID NO: 18) CXCR4 5'-GATCAGCATCGACTCCTTCA-3' 5'-GGCfCCAAGGAAAGCATAGA-3' (SEQ ID N0:19) (SEQ ID NO:20) Bmi-1 5'-GGAGACCAGCAAGTATTGTCCTT'I'TG-3' 5'-CATTGCI'GCTGGGCATCGTAAG-3' (SEQ ID NO:21) (SEQ ID NO:22) PTCHI 5'-CGCCTATGCCTGTCTAACCATGC=3' 5'-AAATGGCAAAACCTGAGTTG-3' (SEQ ID NO:23) (SEQ ID NO:24) Snail 5'-ACCACTATGCCGCGCTCTT-3' 5'-GGTCGTAGGGCTGCI'GGAA-3' (SEQ ID NO:25) (SEQ ID NO:26) SIRT1 5'-ACTTGTACGACGAAGACGAC-3' 5'-CAGAAGGTTATC'I'CGGTACC-3' (SEQ ID N0:27) (SEQ ID NO:28) Survivin 5'-TGCCTGGCAGCCCTITC-3' 5'-CCTCCAAGAAGGGCCAGTI'C-3' (SEQ ID NO:29) (SEQ ID NO:30) CIAP1 5'-CAGCCTGAGCAGCTTGCAA-3' 5'-CAAGCCACCA'I'CACAACAAAA-3' (SEQ ID NO:31) (SEQ ID NO:32) CIAP2 5'-TCCGTCAAGTI'CAAGCCAGTT-3' 5'-TCTCCTGGGCTGTCTGATGTG-3' (SEQ ID NO:33) (SEQ ID NO:34) NAIP 5'-GCITCACAGCGCATCGAA-3' 5'-GCTGGGCGGATGCITfC-3' (SF..Q ID NO:35) (SEQ ID NO:36) XIAP 5'-AGTGGTAGTCCfG'I'TTCAGCATCA-3' 5'-CCGCACGGTATCTCCfTCA-3' (SEQ ID N0:37) (SEQ ID NO:38) BCL-2 5'-CATGCTGGGGCCGTACAG-3' 5'-GAACCGGCACCTGCACAC-3' (SEQ ID N0:39) (SEQ ID N0:40) BCL-XL 5'= CGCATI`GTTCCCATAGAGTfCCA-3' 5'-CCTGA:A'I'GACCACCTAGAGCCTT-3' (SEQ ID NO:41) (SEQ ID NO:42) FLIP 5'-CATCCACAGAATAGACCTGAAGACAA-3' 5'-(SEQ ID NO:43) GCTTGGAGAACA CfCCI'GTAACTfG-3' (SEQ ID NO:44) BAX 5'-TGG AGCTGCAGAGGATGATTG-3' 5'-GAAGTI'GCCGTCAGAAAACATG-3' (SEQ ID NO:45) (SEQ ID NO:46) BCRP-1 5' TGGCTGTCATGGCTFCAGTA-3' 51-GCCACGTGA'C'TCITCCACAA-3' (SEQ ID NO:47) (SEQ ID NO:48) MGMT 5'-C'I'.GGCI'GAATGCCTACTI CC=3' 5'- CAACC1TCAGCAGCITCCAT-3' (SEQ Il) NO:49) (SEQ ID NO:50) OCT4 5'-CCTGAAGCAGAAGAGGATCA-3' 5'-CCGCAGCT'I'ACACATGITCT-3' (SEQ ID NO:51) (SEQ ID NO:52) Quantification of target genemRNA as compared to an internal control (beta-actin) was performed by following a. C=1= method. An amplification plot that had been the plot of tluorescence signal vs. cyele number was drawn. The difference (ACT) between the mean values in the duplicated samples of target gene and those of beta-actin were calculated by Microsoft Excel and the relative quantified value (RQV) was expressed as 2-cT. The relative expression of each gene was compared to autologous CD133 negative cells. The.results ofthe QT-PCT analysis are presented in Table 3.
Table 3. Relative Expression of Genes in CD133+ Cancer Stem Cells No. 66 No. 377 No. 1049 Gene name CD133- CD133+ CD133- CD133+ CD133- CD133+
CD90 1 15.6 0.66 1 12.8~0.94 1 13.5:E 0.75 CD44 1 5.70.48 1 2.5~0:22 1 2:8+0.19 337,8t 251.53= 264.9t CXCR4 1 l 1 29.2 22.1 22.9 Nestin 1 21:4 1.25 1 23.2 1.65 1 22.1 + 1.54 MSI . 1 84 t 7.6 1 75.4 + 7.03 1 53.5 f 6:2 467.7 ~ 514.6 MELK 1 1351195.8 1 ~~ 1 40:5 45.6 GLI-1 .1 46 3.8 1 4314.5 1 49~5.9 PTCH 1 164:1.48 1 13.5 0.85 1 14.3t1:24 MGMT 1 32.4t2:5 1 34.7 2.9 1 56.3+4:2 BCRPI 1 .6:5 0.43 1 4r3 0.25 1 4.8 Ø24 SIRTl 1 4:9 034 1 4.2 0.26 1 5.4 0.29 FLIP 1 294 25.5 1 157.6t 1 145.6 14.2 13.7 BCL-2 1 13.9 0.95 1 4.9 0.54 1 3.8t0.54 BCL-XL 1 5.6~0.39 1 3.2 0.16 1 2.5t0.14 cIAPl 1 39.0 4- 3.5 1 4.3 0.53 1 5.6 0.65 cIAP2 1 3 0.25 1 1.9t0.12 1 1.7 0.14 XIAP 1 21.9 2:2 1 9.7 0.68 1 10.3 0.91 NAIP 1 12.1 0.75 1 6.4 0.43 1 4.5 f 0.62 Survivin 1 1.6-10.08 1 2.3 0.18 1 2.4~0.18 BAX 1 0.33 0.03 1 0.49 0.06 1 0.21 ~ 0.05 CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi 1), and maternal embryonic leucine zipper kinase (MELK) mRNA expression on CD 133 positive cancer stem cells was upregulated by an average of 15.6, 5.7, 337.8, 2.14, 84, and 1351 fold, respectively, compared to the levels found on autologous CD133 negative tumor cells. mRNA
levels for GLI1 and PTCH1 were upregulated an average of 46 and 16 times, respectively, in CD133 positive cells, as compared to CD133 negative cells. Furthermore, Bmi-1, phosphoserine phosphatasc (PSP), SI-IH, OCT4 and Snail mRNA were expressed in CD133 positive cells derived from the three cell lines; none of the five genes were detectable on CD133 negative cells. Additionally, anti-apoptotic genes were also upregulated (see Example 8).
Example 7. CD133 Positive Cancer Stem Cells Are Resistant to Chemotherapeutic Aeents To detennine whether CD133 positive cancer stem cells were resistant to chemotherapeutic agents, the WST-1 Cell Proliferation Assay was used to examine the drug sensitivity of CD 133 positive cells and CD 133 negative cells (both collected by FACS sorting from the three glioblastoma patients' primary cultured tumor cells as described above). CD133 positive and negative cells were exposed to conventional chemotherapeutic agents, temozolomide, carboplatin, VP- 16 or taxol at various concentrations, for up to 48 hours in 10% FBS/F-12/DMEM culture medium.
Temozolomide was supplied by the Schering-Plough Research Institute (Kenilworth, NJ) and was dissolved in DMSO (Sigma Chemical Co., St Louis, MO) at 100 mM stock solution. Carboplatin, etoposide (VP-16) and paclitaxel (Taxol) were obtained from Sigma-Aldrich (St. Louis, MO). CD133 positive cells isolated from No. 66 showed dramatic drug resistance to the above four agents including temozolomide (FIG.
I OC), carboplatin (FIG. lOD), VP- 16 (FIG. l0A), and Taxol (FIG, lOB) as compared to autologous CD133:negative cells. CD133 positive cells isolated from No. 377 showed significant resistance to carboplatin at all concentrations tested (FIG. 11A) and. to V'P-1.6 at 200 M (FIG.11B). CD133 positive cells isolated from No. 1049 showed significant resistance to carboplatin at 200 M compared to autologous CD.133 negative cells (FIG.
1 i C). This example demonstrates increased drug resistance of CD 133 positive cancer stem cells as compared to autologous CD133 negative cells.
Example $ Anti-Apontotic Genes Are Upregulated in CD133 Positive Cancer Stem Cells Real-time PCR of FACs-sorted CD139 positive and CD133 negative cells was used to investigate the relative expression of multi-drug resistance genes and genes related to inhibiting cell apoptosis between these two populations. BCRP1 has been demonstrated to play an important role in the drug resistance of normal stem cells and tumor stem cells (Zhou et al., Nat. Med., 7:1028-34, 2001; Hirschmann-Jax et al., Proc. Natl.
Acad. Sci.
USA, 101: 14228-33, 2004). Higher expression of BCRP 1(6.5 fold) was found in positive cells as compared to that of autologous CD133 negative cells.
Furthermore, anti-apoptotic genes, such as FLIP, BCL-2, and BCL-XL, were found at significantly higtier levels (294,139and:5.6 times higher) in CD133 positive cells than in CD133 negative cells. Also, inhibitorof apoptosis protein (IAPs) familymernbers; XIAP, cIAPl, cIAP2, NACP, and survivin were found at higher expression levels on CD133 positive cells 21.9, 39.04, 3.03, 12.1, 6.73, and 1.6 times higher, respectively, than in CD133 negative cells. It has been demonstrated that SIRT1 deacetylates the DNA repair factor Ku70, causing it to sequester the pro-apoptotic factor, Bax, away.from mitochondria, thereby inhibiting stress-induced apoptotic cell death (Cohen et al., Science, 305:390-392, 2004). SIRT1 deacetylase mRNA.expression was increased 4.92 times in CD133 positive cells.
The pro-apoptotic gene BAX was decreased 3 times in CD133 positive cells as compared to autologous CD 133 negative cells. 'Ifius, gene cxpression differences were observed in CD133 positive cells as compared to CD133 negative cells.
Example 9. Recurrent.Glioblastomas Express.Hig_her LevelsofCD133 Malignant glioma is a highly recurrent tumor even after surgery, chemotherapy, radiation and immunotherapy. To address the potential role of CD133 positive tumor cells in glioblastoma recurrence, the CD133 expression upon first and second resection of tumor tissue from the same patient were compared. We obtained primary tumor tissue from five pathological confirmed grade IV astrocytoma (GBM) patients, and thenre-operated following radiation, chemotherapy, and/or immunotherapy to obtain rccurrent tumor tissue. RNA extraction and RT-PCR was performed for CD133 as described above.
For all tested patients, CD133 expression was significantly higher in recurrent tumor tissue (relative expression -2.5-19.1) than that in autologous primary tumor tissue (relative expression -l)(FIG. 12). This example implicates a resistant CD133 positive tumor population in tumor recurrence.
Example 10lmmuni7.ation With Cancer Stem Cell Antigens Increased Survival A dendritic cell vaccine was.generated using antigens from neurospheres, daughter cells, and monolayer cells. Immature dendritic cells were generated from the bone marrow of 6-12-week-old Fisher F344 rats as previously described (Talmor et al., Eur.
J.
Immunol., 28:811-817, 1998). Briefly, bone marrow was harvested from the femoral and tibial marrow cavities and cultured in RPMI 1640 media supplemented with.10%
fetal bovine serum (Gemini Biotechnologies, Calabasas, CA), 1%
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 50 ng/ml recombinant rat GM-CSF and 100 ng/ml recombinant rat IL-4 (R & D Systems, Minneapolis, MN). Cultures were fed every 2 days by removing 75% of the media and replacing it with fresh media containing cytokines (this washed away most of the lymphocytes and granulocytes). To determine the percentage of immature dendritic cells generated and cultured from the bone marrow of Fisher rats after 1 week of exposure to GM-CSF and IL-4, FACS analysis was run on cells immunostained with antibodies for CD86 (costimulatory marker B7-1; DC marker), CD80 (costimulatory marker B7-2; DC marker), CD3 (T cell marker), or MHC II (DC marker). The dendritic cell populations obtained were positive for CD86, CD80, and MHC II, while negative for CD3.
Soluble peptides were generated for dendritic cell pulsing by cell lysis. 9L
neurospheres, daughter cells, and monolayer (adherent) cells were processed in the laboratory to produce a single cell suspension. The cells were then lysed by 4 to 5 freeze cycles (on liquid nitrogen) and thaw cycles (room temperature). Lysis was monitored by tight microscopy, and larger particles were removed by centrifugation (10 minutes at 600x g). The supernatants were passed through a 0.2 m filter, and protein concentrafion was determined by BioRad protein assay and aliquots frozen at -80 C until use.
To establish intracranial tumors, adult Fisher F344 rats were stereotactically inoculated in the right corpus striatum (from bregma in mm: anterior-posterior +1 mm;
medial-lateral -3 mm; dorsal-ventral -5 mm) with 25,000 9L-luciferase tumor cells as described above. For vaccination of the rats, freshly cultured immature dendritic cells were cocultured overnight for 24 hours with 80-100 g of cell lysate one day prior to the vaccination at days 7, 14, and 21 post-operatively. Vaccinations were given subcutaneously in the flanks on days 7, 14, and 21 with 50,000 DCs pulsed with antigens from either 9L neurospheres (NS), daughter cells (DtC), monolayer (adherent) cells (AC), or saline control. The animals were followed for survival and euthanized when terminal neurological signs developed, for example, inability to access food, water, seizure activity, weakness, and paralysis.
Tumor bearing rats injected with three successive vaccines (once per week) of dendritic cells pulsed with control, AC , DtC, or NS antigens, had median survival dates of 26.5, 32, 29 and 50 days, respcctively (FIG. 13). Kaplan-Meier analysis showed that rats treated with 9L neurosphere lysate-pulsed DC had significantly longer survival time than each of the other groups (p = 0.0015).
Example 11. DCs Pulsed With Cancer Stem Cell Antip-ens Induced a Strong Cvtotoxic T
Cell Resnonse Against 9L Tumor Cells To determine whether the relative protective effect of NS-DC vaccination on survival. is due to tumor-specific immuriity, a cytotoxic T lymphocyte (CTL) assay was performed. Spleens were removed on day 28 post-intracranial 9L-luciferase tumor cells implantation from groups of rats treated with either control or 9L peptide-pulsed dendritic cells. Splenocytes were isolated and re-stimulated in vitro, as described (Wunderlich et al., "Assays for T-cell function," In: Coligan et al., eds., Current Protocols in Immunology, New York, NY, John Wiley & Sons, Inc;1997:3.11.1-3.11.20; Ehtesham et al., J.
Immunother., 26:107-116, 2003) with either irradiated (10,000 rads) 9L
adherent cells (AC), daughter cells (DtC) or neurospheres (NS). The effector: target (E:T) ratio was 6:1.
Re-stimulated cells were cultured in RPMI-1640 with 10% fetal bovine serum, 1%
penicillin-streptomycin, and 1% HEPES in 6-Well flat-bottom plates in a humidified 37 C, 5% COz incubator. Cells were incubated for 11 days with addition of IL-2 (300 units/mL) every 3 days. After 11 days of re-stimulation, the.cells were re-exposed to their initial target (i.e., irradiated 9L AC, DtC, or NS). 24 hours later, culture media was harvested from the remaining cells and used for IFNy protein quantification by ELISA
(Ehtesham et al., J. Immunother., 26:107-116, 2003). Re-stimulated splenocytes from rats treated with NS pulsed DCs showed significantly higher IFNy release in response to exposure to tumor cell targets than re-stimulated splenocytes from rats treated with AC or DtC
(FIG. 14), indicating that a higher cytotoxic T cell response was obtained in the NS-DC
vaccinated rats. These data were also confirmed by PCR for IFNy levels (dat:a not shown).
The higher IFNy response in the NS-DC vaccinated group corresponds to the higher survival rate observed in the same group. These data show that a cancer stem cell antigen vaccine targets tumor cells more potently than vaccines based on tumor antigens from daughter cells, or cell populations that are not.enriched for cancer stem cells.
Example 12. Intracranial T-Cell Infiltration Is Associated With .Prolonged Survival A representative number of brains from DC-DtC and DC-NS vaccinated rats were carefully removed and post-fixed in 4% paraformaldehyde. Coronal sections of 20 m were cut on a cryostat and blocked with normal horse serum for I hour. Slides were then incubated with anti-CD4 (clone OX-38 monoclonal antibody diluted in 1:200 in PBS) for 2 hours at room temperature, followed by. a 20 minute incubation at room temperature with the linking antibody (BioGenex biotinylated anti-mouse immunoglobulin). After washing in PBS, the labeled moiety (BioGenex Horse Radish Peroxidase-conjugated streptavidin) was added for 20 minutes at room temperature. DAB (3,3'-diaminobenzidine) was used as the chromogen. For analysis of CD8 expression, slides were incubated overnight with Anti-CD8 alpha Chain, clone OX-8 antibody (Chemicon).
Immunohistochemical assessment of brain sections from rats vaccinated with dendritic cells pulsed with NS vaccinated showed that there was a robust infiltration of CD4+ (FIG. 15B) and CD8 + lymphocytes that was not observed in the brain sections obtained from rats vaccinated with dendritic cells pulsed with daughter cell antigens (FIG.
15A). This infiltration of T cells correlates with increased survival of rats vaccinated with NS pulsed DCs.
Example 13. Cancer Stem Cells Express MHC. Unlike Normal Stem Cells Five glioblastoma multiforme (GBM) cancer stem cells (CSC) were generated by the methods described in Yuan et al. (Oncogene, 23:9392-9400, 2004). Briefly, tumor specimens were obtained within half an hour of surgical resection from five adult GBM
patients, as approved by the Institutional Review Boards at the Cedars-Sinai Medical Center. Tumor tissue was washed, minced, and enTymatically dissociated (Reynolds et al., Science,.255:1707-10,1992). Tumor cells were.resuspended in DMEM/F12 medium containing 10% fetal bovine serum (FBS) as growth medium and plated at a density of 2x 106 live cells per 75 emZ flask. The cells attached and grew as a monolayer in flasks.
All the five monolayer growing adult GBM cells were switched into a defined serum-free NSC medium (Reynolds et al., Science, 255:1707-10,1992) containing 20 ng/ml of basic fibroblast growth factor (bFGF, Peprotech, Rocky Hill, NJ) and 20 ng/ml of epidermal growth factor (EGF, Peprotech). Normal human fetal neural stem cells (NSC) were cultured in the same defined serum-free medium as for cancer stem celis. CSC
and NSC
cells were stained by FITC-HLA-A,B,C antibody and isotype control antibody (BD
Bioscience, San Diego, CA) and analy-ced by flow cytometry. Representative CSC
and NSC results were shown in the FIGs. 17A-17B and 18A-18B, respectively.
HLA expression was seen in 5 of 5 cancer stem cells from different patients.
CSCs expressed high levels of HLA-A,B,C, however, NSC did not expression MHC class I
(HLA-A,B,C) antigens on the surface. This unexpected result indicates that specific cancer stem cell antigens on cancer stem cells can be targeted using vaccines that generate T cells that recognize and kill cancer stem cell antigens in the context of MHC. Therefore cancer stem cells will be targeted, whereas normal stem cells will not.
Example 14. Isolation of CD133 T Cell Epitopes A nucleic acid encoding a portion of CD133 extracellular domain 1(amino acid residues 116-270 of SEQ ID NO:53) is used in cloning and expression on the surface of DC. DC are transfected with CD133-1 cDNA constract or empty vector (mock) for hours. The successful transfection of DC-CD133 cells is identified either by anti-CD133 monoclonal antibody using flow cytometry. or by EGFP cloned vector under fluorescent microscopy.
Antigen presenting cells with CD133 receptor are stimulated by CD133 T cell epitopes. Overlapping peptides ofS-10 amino acids of residues 325-350 of SEQ
ID
NO:53 are produced as.MHC class I epitopes. Similarly, overlapping peptides of.13-20 amino acid of residues 325-350 are produced as .MHC class 11 epitopes.
Stimulated APC
using the peptide epitopes lead to enhanced production of CD8 T celis targetcd to CD133 molecular on stem/progenitor cells in brain tumors.
OTHER EMBODIMENTS
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the. scope of the following claims.
Claims (20)
1. A method of treating neural cancer in a patient, the method comprising:
obtaining a population of dendritic cells;
contacting the dendritic cells with a neural cancer stem cell antigen composition under conditions such that the dendritic cells present neural cancer stem cell antigens; and administering to a patient a composition comprising the dendritic cells.
obtaining a population of dendritic cells;
contacting the dendritic cells with a neural cancer stem cell antigen composition under conditions such that the dendritic cells present neural cancer stem cell antigens; and administering to a patient a composition comprising the dendritic cells.
2. The method of claim 1, wherein the dendritic cells are autologous.
3. The method of claim 1, wherein the dendritic cells are allogeneic.
4. The method of claim 1, wherein the neural cancer stem cell antigen composition is obtained from a brain tumor.
5. The method of claim 4, wherein the brain tumor is a glioma.
6. The method of claim 1, wherein the neural cancer stem cell antigen composition comprises a lysate of neural cancer stem cells.
7. The method of claim 1, wherein the neural cancer stem cell antigen composition comprises an acid eluate of neural cancer stem cells.
8. The method of claim 6, wherein the neural cancer stem cells express CD133.
9. The method of claim 1, wherein the neural cancer stem cell antigen composition comprises one or more isolated peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi1), maternal embryonic.leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
10. The method of claim 9, wherein the one or more isolated peptides are synthetic.
11. A method of preparing a neural cancer vaccine, the method comprising:
obtaining a population of dendritic cells; and contacting the dendritic cells with a neural cancer stem cell antigen composition under conditions such that the dendritic cells present neural cancer stem cell antigens, thus preparing a neural cancer vaccine.
obtaining a population of dendritic cells; and contacting the dendritic cells with a neural cancer stem cell antigen composition under conditions such that the dendritic cells present neural cancer stem cell antigens, thus preparing a neural cancer vaccine.
12. A method of preparing a cell vaccine for treating a neural cancer, the method comprising:
obtaining mononuclear cells from a subject;
culturing the mononuclear cells in vitro under conditions in which mononuclear cells differentiate into antigen presenting cells;
isolating neural cancer stem cells from the subject;
obtaining a neural cancer stem cell antigen composition from the neural cancer stem cells; and culturing the antigen presenting cells in the presence of the neural cancer stem cell antigen composition, thus preparing a cell vaccine.
obtaining mononuclear cells from a subject;
culturing the mononuclear cells in vitro under conditions in which mononuclear cells differentiate into antigen presenting cells;
isolating neural cancer stem cells from the subject;
obtaining a neural cancer stem cell antigen composition from the neural cancer stem cells; and culturing the antigen presenting cells in the presence of the neural cancer stem cell antigen composition, thus preparing a cell vaccine.
13. The method of claim 12, further comprising administering the cell vaccine to the subject.
14. A kit for preparing a cell vaccine for treating a brain cancer, the kit comprising:
one or more isolated peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi1), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
one or more isolated peptides of CD133, CD90, CD44, CXCR4, Nestin, Musashi-1 (Msi1), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, cIAP1, cIAP2, NAIP, or survivin.
15. A composition consisting essentially of dendritic cells comprising one type or one or more different types of neural cancer stem cell antigens.
16. The composition of claim 15, wherein the neural cancer stem cell antigens include peptides of one or more of CD 133, CD90, CD44, CXCR4, Nestin, Musashi-I
(Msi1), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, clAP1, clAP2, NAIP, or survivin.
(Msi1), maternal embryonic leucine zipper kinase (MELK), GLI1, PTCH1, Bmi-1, phosphoserine phosphatase (PSP), Snail, OCT4, BCRP1, MGMT, Bcl-2, FLIP, BCL-XL, XIAP, clAP1, clAP2, NAIP, or survivin.
17. A method of treating cancer in a patient, the method comprising:
obtaining a population of dendritic cells;
contacting the dendritic cells with a cancer stem cell antigen composition under conditions such that the dendritic cells present cancer stem cell antigens;
and administering to a patient a composition comprising the dendritic cells.
obtaining a population of dendritic cells;
contacting the dendritic cells with a cancer stem cell antigen composition under conditions such that the dendritic cells present cancer stem cell antigens;
and administering to a patient a composition comprising the dendritic cells.
18. A method of preparing a cancer vaccine, the method comprising:
obtaining a population of dendritic cells; and contacting the dendritic cells with a cancer stem cell antigen composition under conditions such that the dendritic cells present cancer stem cell antigens, thus preparing a cancer vaccine.
obtaining a population of dendritic cells; and contacting the dendritic cells with a cancer stem cell antigen composition under conditions such that the dendritic cells present cancer stem cell antigens, thus preparing a cancer vaccine.
19. A method of preparing a cell vaccine for treating a cancer, the method comprising:
obtaining mononuclear cells from a subject;
culturing the mononuclear cells in vitro under conditions in which mononuclear cells differentiate into antigen presenting cells;
isolating cancer stem cells from the subject;
obtaining a cancer stem cell antigen composition from the cancer stem cells;
and culturing the antigen presenting cells in the presence of the cancer stem cell antigen composition, thus preparing a cell vaccine.
obtaining mononuclear cells from a subject;
culturing the mononuclear cells in vitro under conditions in which mononuclear cells differentiate into antigen presenting cells;
isolating cancer stem cells from the subject;
obtaining a cancer stem cell antigen composition from the cancer stem cells;
and culturing the antigen presenting cells in the presence of the cancer stem cell antigen composition, thus preparing a cell vaccine.
20. A method.of treating cancer in a patient, the method comprising:
administering to a patient a composition consisting essentially of dendritic cells that present cancer stem cell antigens.
administering to a patient a composition consisting essentially of dendritic cells that present cancer stem cell antigens.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82695506P | 2006-09-26 | 2006-09-26 | |
US60/826,955 | 2006-09-26 | ||
PCT/US2007/079600 WO2008039874A2 (en) | 2006-09-26 | 2007-09-26 | Cancer stem cell antigen vaccines and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2700573A1 true CA2700573A1 (en) | 2008-04-03 |
CA2700573C CA2700573C (en) | 2016-11-22 |
Family
ID=39230952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2700573A Active CA2700573C (en) | 2006-09-26 | 2007-09-26 | Cancer stem cell antigen vaccines and methods |
Country Status (4)
Country | Link |
---|---|
US (2) | US8129184B2 (en) |
EP (1) | EP2084267B1 (en) |
CA (1) | CA2700573C (en) |
WO (1) | WO2008039874A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080199484A1 (en) * | 2003-10-06 | 2008-08-21 | Cedars-Sinai Medical Center | Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy |
JP5015601B2 (en) * | 2003-10-21 | 2012-08-29 | セダーズ−シナイ メディカル センター | Systems and methods for the treatment of cancer, including cancer of the central nervous system |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
US8097256B2 (en) | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
US20100068142A1 (en) * | 2006-10-03 | 2010-03-18 | Craig Gedye | Melanoma repopulating cells |
ITMI20062100A1 (en) * | 2006-10-31 | 2008-05-01 | Fondazione I R C C S Istituto Neurologico | METHOD FOR THE STIMULATION OF DENDRITIC CELLS AND CELL PRODUCT SO OBTAINED FOR AUTOLOGOUS IMMUNOTHERAPY OF HUMAN SOLID TUMORS |
CA2675521C (en) | 2007-01-22 | 2016-04-26 | Raven Biotechnologies | Human cancer stem cells |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US20100285465A1 (en) * | 2007-08-02 | 2010-11-11 | Glaxosmithkline Biologicals S.A. | Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis |
CN110075113A (en) | 2008-04-17 | 2019-08-02 | Pds生物科技公司 | Immune response is stimulated by the enantiomer of cation lipid |
EP2318040A4 (en) * | 2008-07-24 | 2013-05-01 | Univ Central Florida Res Found | Therapy targeting cancer stem cells |
EP2328923B1 (en) * | 2008-09-02 | 2016-01-13 | Cedars-Sinai Medical Center | Cd133 epitopes |
AU2016204709B2 (en) * | 2008-10-01 | 2018-02-22 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
ES2536465T3 (en) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composition of tumor-associated and cancer-related peptides for the treatment of glioblastoma (GBM) and other cancers |
CA2761389A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
WO2010124498A1 (en) * | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
PL2427485T3 (en) * | 2009-05-07 | 2017-10-31 | Immunocellular Therapeutics Ltd | Cd133 epitopes |
CA2767970C (en) | 2009-07-13 | 2019-10-08 | Biogencell, Ltd. | Method for using directing cells for specific stem/progenitor cell activation and differentiation |
JP2011135864A (en) | 2009-12-30 | 2011-07-14 | Korea Univ Research & Business Foundation | Composition for retrodifferentiating somatic cell to embryonic stem cell-like cell, by using oct4 in combination with bmi1 or upstream regulator thereof, and method for generating embryonic stem cell-like cell using the same |
CN102692506A (en) * | 2011-03-21 | 2012-09-26 | 复旦大学 | Use of CD133 in preparation of tumor marker and kit of CD133 |
WO2013016675A1 (en) * | 2011-07-27 | 2013-01-31 | Baylor Research Institute | Dendritic cell (dc)-vaccine therapy for pancreatic cancer |
US8956870B2 (en) | 2012-01-19 | 2015-02-17 | Biogencell, Ltd. | Method for using directing cells for specific stem/progenitor cell activation and differentiation |
JP2015526087A (en) * | 2012-08-15 | 2015-09-10 | ネオステム オンコロジー リミテッド ライビリティ カンパニー | Rapid preparation of high purity cancer stem cells and high purity cancer stem cell populations |
EP2897639A4 (en) | 2012-09-21 | 2016-05-04 | Frank Bedu-Addo | Improved vaccine compositions and methods of use |
EP2911748B1 (en) * | 2012-10-24 | 2018-03-14 | The Regents Of The University Of Michigan | Cancer stem cell vaccination and treatment |
US20140234350A1 (en) * | 2013-02-14 | 2014-08-21 | Cedars-Sinai Medical Center | Ovarian cancer vaccines and vaccination methods |
ES2662333T3 (en) | 2013-02-14 | 2018-04-06 | Immunocellular Therapeutics Ltd. | Cancer vaccines and vaccination methods |
US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
JP2016510756A (en) * | 2013-03-07 | 2016-04-11 | ネオステム オンコロジー リミテッド ライビリティ カンパニー | Individual high-purity hepatocellular carcinoma stem cells, preparation method thereof and use thereof |
US20160030537A1 (en) * | 2013-03-12 | 2016-02-04 | Neostem Oncology, Llc | Individualized High Purity Glioblastoma Multiforme Stem Cells and Methods for Stimulating Immune Response |
JP2016512423A (en) * | 2013-03-12 | 2016-04-28 | ネオステム オンコロジー リミテッド ライビリティ カンパニー | High purity ovarian cancer stem cells for active autoimmune therapy |
EP2968407A4 (en) * | 2013-03-13 | 2017-01-04 | Neostem Oncology, LLC | Individualized high purity colon carcinoma stem cells, methods and use of the same |
AU2014236135A1 (en) | 2013-03-14 | 2015-09-10 | Thomas Jefferson University | Androgen receptor down-regulating agents and uses thereof |
US9808472B2 (en) | 2013-08-12 | 2017-11-07 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
WO2015143074A1 (en) * | 2014-03-20 | 2015-09-24 | University Of Southern California | Brain cancer immunotherapy |
US20170216419A1 (en) * | 2014-07-22 | 2017-08-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cancer immunotherapy |
TWI563085B (en) * | 2014-08-29 | 2016-12-21 | China Medidal University Hospital | Dendritic cell tumor vaccine and preparation method thereof |
WO2016161309A1 (en) * | 2015-04-01 | 2016-10-06 | Colorado State University Research Foundation | Optimized cancer stem cell vaccines |
WO2017081686A1 (en) | 2015-11-10 | 2017-05-18 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
AU2016354590B2 (en) | 2015-11-13 | 2023-11-23 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
CA3054871A1 (en) | 2017-03-03 | 2018-09-07 | Treos Bio Zrt | Population-based immunogenic peptide identification platform |
KR20210086612A (en) | 2018-09-04 | 2021-07-08 | 트레오스 바이오 리미티드 | peptide vaccine |
CN109620952A (en) * | 2019-01-04 | 2019-04-16 | 北京中台恒基生物技术有限公司 | A kind of tumor vaccine and preparation method thereof |
AU2020267768A1 (en) * | 2019-05-09 | 2021-12-23 | Figene, Llc | Fibroblast generated patient-specific vaccines |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US710903A (en) | 1902-06-21 | 1902-10-07 | Louis J Sticklin | Lid-controlling device. |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
EP0474727B1 (en) | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5541104A (en) | 1991-05-23 | 1996-07-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5925729A (en) | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
ATE260971T1 (en) | 1992-04-01 | 2004-03-15 | Univ Rockefeller | METHOD FOR THE IN VITRO CULTIVATION OF DENDRITIC PRECURSOR CELLS AND THEIR USE FOR IMMUNOGENIC PRODUCTION |
US5672499A (en) | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
NZ256154A (en) | 1992-07-27 | 1997-02-24 | California Inst Of Techn | Production of mammalian multipotent neural stem cells, antibodies |
US6077519A (en) | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
IL111181A0 (en) | 1993-10-06 | 1994-12-29 | Univ Florida | Stem cell proliferation factor, its preparation, purification and uses |
US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
CA2188432C (en) | 1994-04-22 | 2011-02-01 | Yutaka Kawakami | Melanoma antigens |
US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
WO1996018409A1 (en) | 1994-12-14 | 1996-06-20 | The Scripps Research Institute | In vivo activation of tumor-specific cytotoxic t cells |
US6010905A (en) | 1995-01-27 | 2000-01-04 | The United States Of America As Represented By The Department Of Health & Human Services | Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells |
US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
US6514942B1 (en) | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US5861483A (en) | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
US6455678B1 (en) | 1996-04-26 | 2002-09-24 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen |
US6458585B1 (en) | 1996-08-14 | 2002-10-01 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
WO1998044142A1 (en) | 1997-04-01 | 1998-10-08 | The General Hospital Corporation | Molecular marker for muscle stem cells |
WO1998053048A1 (en) | 1997-05-21 | 1998-11-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells |
JP2002508167A (en) | 1997-12-18 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 110 human secreted proteins |
US20020034819A1 (en) | 1998-02-23 | 2002-03-21 | Alan K. Smith | Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses |
US20020192211A1 (en) | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
EP1100872A1 (en) | 1998-07-24 | 2001-05-23 | Carnegie Institution Of Washington | Method for maintenance and propagation of germline stem cells using members of the tgf-beta family of growth factors |
US7186409B2 (en) | 1998-08-14 | 2007-03-06 | The Children's Medical Center Corporation | Neural stem cells and use thereof for brain tumor therapy |
US20020115213A1 (en) | 1998-08-14 | 2002-08-22 | Northeastern Ohio Universities Of Medicine | Engraftable neural progenitor & stem cells for brain tumor therapy |
CN1330557A (en) | 1998-09-15 | 2002-01-09 | 匹兹堡大学联邦系统高等教育 | In situ injection of antigen-presenting cells with generatically enhanced cytokine expression cell factor |
US7504490B1 (en) | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
WO2000024778A1 (en) | 1998-10-26 | 2000-05-04 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2 |
GB9824306D0 (en) | 1998-11-05 | 1998-12-30 | Isis Innovation | Method for producing dendritic dells |
JP2002529070A (en) | 1998-11-09 | 2002-09-10 | モナシュ・ユニヴァーシティ | Embryonic stem cells |
BR9916536A (en) | 1998-12-23 | 2002-01-02 | Searle & Co | Method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and, combination |
JP2003529319A (en) | 1999-01-08 | 2003-10-07 | キャロル ディ. ウエイス, | Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 |
WO2000066713A2 (en) | 1999-05-03 | 2000-11-09 | Karolinska Innovations Ab | Materials and methods relating to neuronal development |
US6566395B1 (en) | 1999-05-25 | 2003-05-20 | Biomedicines, Inc. | Methods of treating proliferative disorders |
US20030204052A1 (en) | 2000-10-04 | 2003-10-30 | Herrmann John L. | Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
US7060284B1 (en) | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
US20070098776A1 (en) | 1999-12-13 | 2007-05-03 | Fikes John D | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
EP1242049A4 (en) | 1999-12-13 | 2005-01-05 | Epimmune Inc | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US20060003323A1 (en) | 2000-03-01 | 2006-01-05 | John Alsobrook | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
JP4800544B2 (en) | 2000-03-15 | 2011-10-26 | チルドレンズ メディカル センター コーポレーション | Systemic gene delivery vehicle for tumor therapy |
US20020076707A1 (en) | 2000-06-30 | 2002-06-20 | David Mack | Novel methods of diagnosing cancer, compositions, and methods of screening for cancer modulators |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
CA2422454A1 (en) | 2000-09-15 | 2002-03-21 | Ortho-Mcneil Pharmaceutical, Inc. | Compositions and methods for inducing specific cytolytic t cell responses |
US20030202963A1 (en) | 2000-10-12 | 2003-10-30 | Cornell Research Foundation, Inc. | Method of treating cancer |
US6632459B2 (en) | 2000-12-11 | 2003-10-14 | Nutricia N.V. | Chlorogenic acid and an analog thereof for immune system stimulation |
US20040121946A9 (en) | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
ATE396691T1 (en) | 2001-02-20 | 2008-06-15 | Ortho Mcneil Pharm Inc | CELL THERAPY PROCESS FOR THE TREATMENT OF TUMORS |
ES2394293T3 (en) | 2001-02-28 | 2013-01-30 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Vaccine against cancers that are associated with the HER-2 / neu oncogene |
CN1168740C (en) | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | Cell factor gene modified antigen presentation cell/tumor cell conjugate, its preparatino and use |
DE10132502A1 (en) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Attack on tumor cells with missing, low or abnormal MHC expression by combining non-MHC-restricted T cells / NK cells and MHC-restricted cells |
CA2454734A1 (en) | 2001-07-25 | 2003-02-06 | I.D.M. Immuno-Designed Molecules | New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions |
GB0119346D0 (en) | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
WO2003015705A2 (en) | 2001-08-17 | 2003-02-27 | Roger Williams Hospital | In situ immunization |
CA2459713C (en) | 2001-09-06 | 2015-08-18 | Northwest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
US20040072246A1 (en) | 2001-09-11 | 2004-04-15 | Roland Martin | System and method for identifying t cell and other epitopes and the like |
US6645763B2 (en) | 2001-10-12 | 2003-11-11 | Naoya Kobayashi | Immortalized bone marrow mesenchymal stem cell |
EP1446159A4 (en) | 2001-10-26 | 2005-06-01 | Irx Therapeutics Inc | Immunotherapy for reversing immune suppression |
EP1474450A2 (en) | 2002-02-08 | 2004-11-10 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | A novel target to inhibit angiogenesis |
CA2480008C (en) | 2002-03-22 | 2015-10-06 | The Penn State Research Foundation | Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine |
US7413869B2 (en) | 2002-04-05 | 2008-08-19 | Dendreon Corporation | Method for determining potency of antigenic presenting cell based vaccines |
US7204982B2 (en) | 2002-07-02 | 2007-04-17 | The Regents Of The University Of California | Compositions and methods for treatment and detection of multiple cancers |
US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
US20040057935A1 (en) | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
US20040197903A1 (en) | 2003-01-31 | 2004-10-07 | Northwest Biotherapeutics, Inc. | Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15 |
RU2364625C2 (en) | 2003-02-27 | 2009-08-20 | Норсуэст Байотерапьютикс, Инк. | Dendritic cell generation from monocytic dendritic cell pre-cursors by means of gm-csf in absence of additional cytokines |
US20080199484A1 (en) | 2003-10-06 | 2008-08-21 | Cedars-Sinai Medical Center | Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy |
JP5015601B2 (en) | 2003-10-21 | 2012-08-29 | セダーズ−シナイ メディカル センター | Systems and methods for the treatment of cancer, including cancer of the central nervous system |
EP1705992A1 (en) | 2004-01-20 | 2006-10-04 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
WO2006099448A2 (en) | 2005-03-14 | 2006-09-21 | University Of Iowa Research Foundation | Accelerated cd8+ t-cell memory after dendritic cell vaccination |
US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
WO2007062138A2 (en) | 2005-11-23 | 2007-05-31 | Applera Corporation | Methods and compositions for treating diseases targeting human prominin-1(cd133) |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
US8097256B2 (en) | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
CA2668223A1 (en) | 2006-10-31 | 2008-05-08 | National Stem Cell Holding Inc. | Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata |
ITMI20062100A1 (en) | 2006-10-31 | 2008-05-01 | Fondazione I R C C S Istituto Neurologico | METHOD FOR THE STIMULATION OF DENDRITIC CELLS AND CELL PRODUCT SO OBTAINED FOR AUTOLOGOUS IMMUNOTHERAPY OF HUMAN SOLID TUMORS |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
US8168586B1 (en) | 2007-11-21 | 2012-05-01 | Celera Corporation | Cancer targets and uses thereof |
EP2328923B1 (en) | 2008-09-02 | 2016-01-13 | Cedars-Sinai Medical Center | Cd133 epitopes |
PL2427485T3 (en) | 2009-05-07 | 2017-10-31 | Immunocellular Therapeutics Ltd | Cd133 epitopes |
WO2012027379A2 (en) | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
AP2013006918A0 (en) | 2010-12-09 | 2013-06-30 | Univ Pennsylvania | Use of chimeric antigen receptormodified T-cells to treat cancer |
US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
US20140234350A1 (en) | 2013-02-14 | 2014-08-21 | Cedars-Sinai Medical Center | Ovarian cancer vaccines and vaccination methods |
ES2662333T3 (en) | 2013-02-14 | 2018-04-06 | Immunocellular Therapeutics Ltd. | Cancer vaccines and vaccination methods |
-
2007
- 2007-09-26 CA CA2700573A patent/CA2700573C/en active Active
- 2007-09-26 WO PCT/US2007/079600 patent/WO2008039874A2/en active Application Filing
- 2007-09-26 US US11/862,135 patent/US8129184B2/en active Active
- 2007-09-26 EP EP07843269.7A patent/EP2084267B1/en active Active
-
2012
- 2012-02-03 US US13/365,666 patent/US9023338B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2084267B1 (en) | 2018-04-11 |
EP2084267A2 (en) | 2009-08-05 |
WO2008039874A2 (en) | 2008-04-03 |
WO2008039874A3 (en) | 2008-07-10 |
US9023338B2 (en) | 2015-05-05 |
US20080206286A1 (en) | 2008-08-28 |
US8129184B2 (en) | 2012-03-06 |
US20120189664A1 (en) | 2012-07-26 |
EP2084267A4 (en) | 2011-03-02 |
CA2700573C (en) | 2016-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2084267B1 (en) | Cancer stem cell antigen vaccines and methods | |
Waeckerle-Men et al. | Encapsulation of proteins and peptides into biodegradable poly (D, L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells | |
EP2956544B1 (en) | Cancer vaccines and vaccination methods | |
Davis et al. | Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients | |
KR20100033471A (en) | Human cancer stem cells | |
US20220000930A1 (en) | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same | |
AU2002307243A1 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | |
JP2005523277A (en) | Cancer treatment | |
JP2016510756A (en) | Individual high-purity hepatocellular carcinoma stem cells, preparation method thereof and use thereof | |
JP2010523141A (en) | Cell lines, compositions containing them for the treatment of melanoma, compositions manufacturing procedures and methods of treatment | |
US20160030537A1 (en) | Individualized High Purity Glioblastoma Multiforme Stem Cells and Methods for Stimulating Immune Response | |
Tan et al. | Induction of CTLs by DCs pulsed with K-ras mutant peptide on the surface of nanoparticles in the treatment of pancreatic cancer | |
Pellegatta et al. | Dendritic cell vaccines for cancer stem cells | |
US9149515B2 (en) | Interferon-alpha-producing bone marrow dendritic cells | |
Zhou et al. | Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses | |
RU2395572C1 (en) | Human melanoma cell line ig which secretes recombinant granulocytic-macrophagal colony-stimulating factor | |
EP1178822B1 (en) | Whole cell cancer vaccine comprising co-cultured malignant and non-malignant cells | |
A Chistiakov et al. | Approaches to improve efficiency of dendritic cell-based therapy of high grade gliomas | |
Yu et al. | Immunization with Embryonic Stem Cells/Induced Pluripotent Stem Cells Induces Effective Immunity against Ovarian Tumor-Initiating Cells in Mice | |
EP2195650B1 (en) | Methods of treating tumors in immune-privileged sites | |
US8128923B2 (en) | Renal carcinoma cell line and uses thereof | |
RU2395574C1 (en) | Human melanoma cell line ilg which secretes recombinant granulocytic-macrophagal colony-stimulating factor | |
CN115778984A (en) | Method and application for inducing transplantation immune tolerance and transplantation tolerance animal model | |
RU2395573C1 (en) | Human melanoma cell line 31g which secretes recombinant granulocytic-macrophagal colony-stimulating factor | |
AU2008200315B2 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |